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FOREWORD
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein. Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is 
also presented, but is described in less detail than the key studies. The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance's relevant 
toxicological properties. Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects. The adequacy of information to 
determine a substance's health effects is described in a health effects summary. Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the federal, state, and 
local levels; interested private sector organizations and groups; and members of the public. We plan to 
revise these documents in response to public comments and as additional data become available. 
Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Comments should be sent to:
The Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Environmental Medicine 
Applied Toxicology Branch
Regular Mailing Address: Physical Mailing Address:
1600 Clifton Road, N.E. 4770 Buford Highway
Mail Stop F-62 Building 106, 8,b floor, MS F-62
Atlanta, Georgia 30333 Chamblee, Georgia 30341
Electronic Comments should be sent to: TPPublicComments@cdc.gov
vi
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 
104(i)(l) directs the Administrator of ATSDR to “...effectuate and implement the health-related 
authorities” of the statute. This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the 
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile 
for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for 
substances not found at sites on the National Priorities List, in an effort to “...establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA 
Section 104(i)(l)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise 
necessary to support the site-specific response actions conducted by ATSDR.
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other federal scientists have 
also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel 
and is being made available for public review. Final responsibility for the contents and views expressed 
in this toxicological profile resides with ATSDR.
Thomas R. Frieden, M.D., M.P.H.
Administrator 
Agency for Toxic Substances and 
Disease Registry
TOXAPHENE
QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance. Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions.
Primary Chapters/Sections o f Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance. It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure.
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are 
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: I-8OO-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies.
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials. Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998
• Phone: 800-35-NIOSH.
The National Institute o f Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association o f Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues. Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.
The American College o f Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.
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PEER REVIEW
A peer review panel was assembled for toxaphene. The panel consisted of the following members:
1. Dr. Laurie H.M. Chan, Professor, Aboriginal Environmental Health, University of Northern
British Columbia, Prince George BC V2N 4Z9, Canada;
2. Dr. Lucio G. Costa, Professor, Department of Environmental and Occupational Health Sciences,
University of Washington, Seattle, Washington; and
3. Dr. Mark Robson, Professor and Dean of Agricultural and Urban Programs, Rutgers University,
New Brunswick, New Jersey.
These experts collectively have knowledge of toxaphene’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile. A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR.
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1 .  P U B L I C  H E A L T H  S T A T E M E N T
This public health statement tells you about toxaphene and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. Toxaphene has been found in at least 68 of the 1,699 current or former NPL 
sites. Although the total number of NPL sites evaluated for this substance is not known, the possibility 
exists that the number of sites at which toxaphene is found may increase in the future as more sites are 
evaluated. This information is important because these sites may be sources of exposure and exposure to 
this substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You 
can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If you are exposed to toxaphene, many factors will determine whether you will be harmed. These factors 
include the dose (how much), the duration (how long), and how you come in contact with it. You must 
also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and 
state of health.
1.1 WHAT IS TOXAPHENE?
Chlorinated camphene Toxaphene is made by reacting chlorine gas with a substance 
called camphene. The resulting product (toxaphene) is a 
mixture of hundreds of different chlorinated camphenes and 
related chemicals.
Manufactured insecticide Toxaphene was one of the most heavily used pesticides in the 
United States in the 1970s and early 1980s. It was used 
primarily to control insect pests on cotton and other crops in the 
southern United States. Other uses included controlling insect 
pests on livestock and killing unwanted fish in lakes.
Banned for all registered uses 
in the United States
Toxaphene was banned for all registered uses by 1990.
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Form Toxaphene is usually found as a solid or gas. In its original
form, toxaphene is a yellow to amber waxy solid that has a
piney odor.
1.2 WHAT HAPPENS TO TOXAPHENE WHEN IT ENTERS THE ENVIRONMENT?
Movement between air, water, 
soil, and sediment
When toxaphene is released to the environment, it can enter 
the air (by evaporation), the soil (by sticking to soil particles), 
and the water (from runoff after rains). Toxaphene does not 
dissolve well in water, so it is more likely to be found in air, soil, 
or the sediment at the bottom of lakes and streams.
Breaks down slowly Once toxaphene is in the environment, it can last for many 
years because it breaks down very slowly.
Transported by air over long 
distances
Toxaphene has been found in water, soil, sediment, air, and 
animals in places far from where it has been used. This shows 
that toxaphene can be carried long distances by the air.
Bioaccumulates Toxaphene levels may be high in some predatory fish and 
mammals because toxaphene accumulates in fatty tissues. 
Even when levels are low or confined to a certain area, they 
could be high in individual animals.
1.3 HOW MIGHT I BE EXPOSED TO TOXAPHENE?
Hazardous waste sites People living near a location with heavy toxaphene 
contamination, such as a hazardous waste sites, may be 
exposed to higher levels through breathing contaminated air or 
through direct skin contact with contaminated soil or water.
Eating contaminated soil Infants and toddlers, who are likely to put things in their mouth, 
may be exposed to toxaphene by eating contaminated soil.
Eating fish, shellfish, and wild 
game
People who eat large quantities of fish, shellfish, or wild game 
animals from areas contaminated by toxaphene may have 
higher exposure to this substance since these animals tend 
concentrate toxaphene in their fatty tissues.
Drinking water Individuals may be exposed to toxaphene through drinking 
water contaminated with toxaphene runoff from contaminated 
soils.
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May enter your body 
through food, drinking 
water, breathing, and 
skin contact
Toxaphene can enter your body if you eat food contaminated with 
toxaphene, such as fish caught from water where toxaphene is 
present. Toxaphene in drinking water can similarly enter your body, 
although when toxaphene has been detected in drinking water, levels 
have been generally more than 1,000 times lower than levels 
measured in toxaphene-contaminated food. Toxaphene could enter 
your body if it were to come into contact with your skin (for example, 
by bathing or showering in water contaminated with the chemical) or if 
you were to breathe air containing toxaphene.
Leaves through bodily 
fluids
Toxaphene is quickly broken down into other substances in your body. 
Toxaphene and its breakdown products leave your body mostly in 
urine and feces. Small amounts may leave through breast milk and 
exhaled air.
1.5 HOW CAN TOXAPHENE AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in animal and human studies.
Nervous system Convulsions were experienced by some people who accidentally or 
intentionally swallowed large amounts of toxaphene, including three 
women who ate collard greens contaminated with toxaphene. 
However, since toxaphene is no longer used as a pesticide, you would 
not likely eat enough toxaphene-contaminated food to affect your 
nervous system in this way.
Immune system Effects on the immune system have been observed in laboratory 
studies of animals that were given toxaphene by mouth in amounts 
that you would not likely get by eating food or drinking water containing 
toxaphene.
Liver Toxaphene temporarily damaged the liver of a man who attempted 
suicide by drinking a large amount of an insecticide that contained 
toxaphene. Liver damage was seen in laboratory studies of animals 
that were given toxaphene by mouth in amounts that you would not 
likely get by eating food or drinking water containing toxaphene.
Kidneys Toxaphene temporarily damaged the kidneys of a man who attempted 
suicide by drinking a large amount of an insecticide that contained 
toxaphene. Swollen kidneys were seen in a small boy who died after 
drinking a large amount of toxaphene. Kidney damage was seen in 
laboratory studies of animals that were given toxaphene by mouth in 
amounts that you would not likely get by eating food or drinking water 
containing toxaphene.
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1. PUBLIC HEALTH STATEMENT
Cancer Toxaphene caused liver cancer in mice and possibly thyroid cancer in
rats that were given toxaphene by mouth in large amounts that you
would not likely get by eating food or drinking water containing
toxaphene. We do not know whether toxaphene would cause cancer
in humans. However, based on animal studies, the Department of
Health and Human Services has determined that toxaphene may
reasonably be anticipated to be a carcinogen. The International
Agency for Research on Cancer has determined that toxaphene is
possibly carcinogenic to humans. Also, the EPA has determined that
toxaphene is a probable human carcinogen.
1.6 HOW CAN TOXAPHENE AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.
Effects in children Toxaphene would be expected to affect children in the same manner 
as adults. It is not known whether children are more susceptible than 
adults to the effects of toxaphene.
Developmental effects A few studies in animals have shown minor changes in fetal 
development. We do not know if toxaphene would cause 
developmental effects in humans.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO TOXAPHENE?
Reduce consumption 
of foods and drinking 
water that contain 
toxaphene
For people who live in areas where surface waters (lakes) have been 
contaminated with toxaphene, consumption of toxaphene- 
contaminated foods such as fish may need to be reduced. Also, do 
not drink water that has been contaminated with toxaphene.
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
TOXAPHENE?
Can be measured in 
blood and urine
Toxaphene and some of its breakdown products can be measured in 
blood and urine. However, it is not likely that you would be exposed to 
enough toxaphene to make such measurements that would be 
meaningful to your health.
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1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. Regulations 
can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances. Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans. Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available. 
For the most current information, check with the federal agency or organization that provides it.
Some regulations and recommendations for toxaphene include the following:
1. PUBLIC HEALTH STATEMENT
Levels in drinking The EPA has determined that exposure to toxaphene in drinking water at 
water set by EPA concentrations of 0.004 mg/L for up to 10 days is not expected to cause any 
adverse effects in a child.
The EPA has determined that lifetime exposure to 0.01 mg/L toxaphene in 
the drinking water is not expected to cause any adverse noncancer effects 
if the only source of exposure to toxaphene is the drinking water.
EPA established a maximum contaminant level (MCL) of 0.003 mg/L for 
toxaphene in drinking water.
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1. PUBLIC HEALTH STATEMENT
Bottled water The FDA has determined that the toxaphene concentration in bottled 
drinking water should not exceed 0.003 mg/L.
Levels in 
workplace air set 
by OSHA
OSHA set a legal limit of 0.5 mg/m for toxaphene in air averaged over an 
8-hour work day.
1.10 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may 
request a copy of the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information and technical 
assistance number at I-8OO-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
1600 Clifton Road NE
Mailstop F-62
Atlanta, GA 30333
Fax: 1-770-488-4178
Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/
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2. RELEVANCE TO PUBLIC HEALTH
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TOXAPHENE IN THE 
UNITED STATES
Toxaphene is a manufactured pesticide comprising a complex mixture of hundreds of chlorinated 
terpenes. After DDT was banned from use in the United States in 1972, toxaphene became the most 
popular substitute. Control of pests on cotton crops was the principal use of toxaphene in the United 
States, although the pesticide was used to control a variety of insects on a range of crops and to eradicate 
undesirable fish species in some aquatic environments. In November of 1982, EPA canceled the 
registration of toxaphene for most uses as a pesticide or pesticide ingredient. All registered uses of 
toxaphene mixtures in the United States and its territories were canceled in 1990.
Toxaphene was widely released to the environment mainly as a result of its past use as an insecticide. 
Toxaphene has been transported over long distances in the atmosphere. The presence of toxaphene in 
surface waters of the Great Lakes has been attributed to aerial transport of the mixture from application 
sites in the southern United States. Atmospheric toxaphene is transported back to soil and water surfaces 
by wet and dry deposition processes. Toxaphene strongly adsorbs to particles and is relatively immobile 
in soils. In water, toxaphene is strongly adsorbed to suspended particulates and sediments and is 
bioconcentrated by aquatic organisms to fairly high levels, with bioconcentration factors (BCFs) on the 
order of 4,200-60,000. Toxaphene also appears to be biomagnified in aquatic food chains.
The composition of technical toxaphene released to the environment has changed over time since 
toxaphene congeners degrade at different rates, resulting in what is commonly termed weathered 
toxaphene. Degradation proceeds mainly through dechlorination and dehydrochlorination resulting in a 
shift in composition toward lower chlorinated homologs. Presently, exposure to persistent toxaphene 
congeners and degradation products is the primary health concern for the general population. Toxaphene 
congeners that have been found to persist in fish, marine mammals, and human serum and breast milk 
include those identified as Parlars p-26, p-40/41, p-44, p-50, and p-62. Pooled results of studies that 
assessed levels of these congeners in human serum and/or breast milk indicate that p-26, p-50, and p-62 
comprise most of the total toxaphene body burden.
The major source of exposure for the general population appears to be ingestion of low concentrations of 
persistent toxaphene congeners in food, particularly fish, and toxaphene-contaminated drinking water. 
Subpopulations with increased potential for significant exposure to persistent toxaphene congeners
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include northern Native American groups that eat toxaphene-contaminated aquatic mammals, recreational 
or subsistence hunters in the southern United States that consume significant amounts of game animals 
(especially species like raccoons), and people who consume certain types of sport-caught fish (such as 
trout, salmon, herring, smelt, and walleye) from the Great Lakes.
2.2 SUMMARY OF HEALTH EFFECTS
This toxicological profile for toxaphene summarizes health effects information for toxaphene based on 
exposure to technical toxaphene that was formerly widely used as a pesticide in the United States. Since 
being banned for use as a pesticide in the United States in 1990, the greatest present concern for the 
general population would be exposure to persistent toxaphene congeners and degradation products of 
technical toxaphene formerly released to the environment.
Limited information is available regarding noncancer health effects in humans or laboratory animals 
following inhalation exposure to toxaphene. Pulmonary hypersensitivity and hematological alterations 
were indicated in two Egyptian agricultural pesticide workers involved in spraying a pesticide 
formulation (68% toxaphene, 35% kerosene, 3% xylol, and 2% emulsifier). One controlled study found 
no signs of toxicity in a group of 25 volunteers exposed to an aerosol containing a maximum of 500 mg 
toxaphene/m3 30 minutes/day for 30 days. The nervous system and the liver have been identified as 
targets of toxaphene toxicity in limited animal studies that employed the inhalation exposure route.
Ingestion of toxaphene has resulted in death in some cases of acute poisoning. Mortalities have also been 
observed in animals following single- and repeated-dose oral exposure.
Clinical signs of central nervous system stimulation including convulsions have been reported in humans 
following accidental or intentional ingestion of toxaphene. Similar effects have been observed in animals 
following oral exposure to toxaphene. Dogs appear to be particularly sensitive to the neurological effects 
of toxaphene; convulsions were elicited at oral doses as low as 10 mg/kg/day.
Animal studies provide evidence that toxaphene can also affect the liver, kidney, endocrine system, 
immunological system, and body weight, as well as the nervous system. Morphological and degenerative 
changes were observed in the livers of dogs, rats, and mice following repeated oral exposure to 
toxaphene; doses as low as 1.8 mg/kg/day caused nuclear changes in hepatocytes of rats. Renal tubular 
injury was reported in the kidneys of rats receiving toxaphene at 8.6 mg/kg/day for 13 weeks.
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Histopathological evidence of effects on the thyroid gland of male rats was observed following 13 weeks 
of oral administration of toxaphene at 1.8 mg/kg/day. Significant reductions in IgM responses (indicative 
of depressed humoral immunity) were reported in female cynomolgus monkeys administered toxaphene 
by oral capsule at a dose level of 0.4 mg/kg/day during a 75-week treatment period. Pregnant animals 
may be particularly sensitive to toxaphene-induced effects on body weight; for example, average body 
weight gain of rat dams administered toxaphene by gavage at 15 mg/kg/day during pregnancy was 22% 
lower than that of pregnant control rat dams.
Toxaphene-induced reproductive effects have not been demonstrated in animal studies. Effects such as 
decreased early postnatal body weight and increased incidences of supernumary ribs were observed in 
offspring of rat dams that were fed toxic doses of toxaphene. Decreased renal protein was noted in the 
kidneys of 21-day-old rat fetuses whose mothers had been administered toxaphene by gavage at
12.5 mg/kg/day during gestation. Suppression of macrophage phagocytic function was reported in
8-week-old offspring of mouse dams administered toxaphene at doses >2 mg/kg/day during premating 
and throughout mating, gestation, and lactation. In one developmental toxicity study, slight delays in 
successful responses to a righting reflex test were observed in nursing pups from rat dams administered 
toxaphene by gavage at 6 mg/kg/day during mating and throughout gestation. Retarded swimming ability 
and righting reflex were reported in young pups of rat dams administered toxaphene at 0.05 mg/kg/day 
during gestation and lactation; however, the effect was transient, observed only during postpartum days 
10-12 and of uncertain toxicological significance.
Limited animal data indicate that dermal exposure to high levels of toxaphene can cause clinical signs of 
neurotoxicity, liver effects, and death at very high doses.
Statistically significant associations between exposure to toxaphene and risk of cancers such as leukemia 
and certain types of non-Hodgkin’s lymphoma have been reported in case-control studies of groups of 
farm workers. It should be noted that all uses of toxaphene in the United States were canceled in 1990. 
Increased incidences of thyroid tumors were observed in rats administered toxaphene at approximately 
80 mg/kg/day for 80 weeks; in similarly-treated mice, increased incidences of hepatocellular tumors were 
noted at toxaphene doses of 17 and 34 mg/kg/day. One unpublished study reported increased incidences 
of hepatocellular tumors in male mice administered toxaphene orally at approximately 8.6 mg/kg/day for 
18 months. Available in vivo studies and in vitro assays provide equivocal evidence for toxaphene- 
induced genotoxicity. The International Agency for Research on Cancer (IARC) has classified toxaphene 
as Group 2B (possibly carcinogenic to humans). The National Toxicology Program (NTP) considers
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toxaphene as “reasonably anticipated to be a human carcinogen”. EPA has given toxaphene a 
classification of B2 (probable human carcinogen). The cancer classifications are based on the findings of 
hepatocellular tumors in toxaphene-treated mice, thyroid tumors in toxaphene-treated rats, and evidence 
of mutagenicity in in vitro bacterial assays.
2.3 MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for toxaphene. An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate 
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990a), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
No inhalation MRLs were derived for toxaphene due to the lack of reliable human and animal data. One 
controlled human study found no evidence of adverse effects among 25 human subjects exposed to an 
aerosol containing a maximum of 500 mg toxaphene/m3 for 30 minutes/day for 10 days (Keplinger 1963). 
However, exposures were brief, air concentrations were not measured, and assessments were limited to 
clinical examinations and incomplete blood and urinalysis testing. Acute pulmonary insufficiency was 
noted in two agricultural workers involved in spraying a formulation consisting of (60% toxaphene, 35% 
kerosene, 3% xylol, and 2% emulsifier) for 2 months. No other information was located regarding health 
effects in humans exposed to toxaphene in the air.
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Available animal data are limited to summaries of unpublished data cited in a secondary unpublished 
bulletin and a report of clinical signs of neurotoxicity in several animal species following repeated 
inhalation exposure to toxaphene dust (Industrial Biotest 1965). Some studies conducted by Industrial 
Biotest have been shown to be less than reliable.
Oral MRLs
• An MRL of 0.05 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) to 
toxaphene.
Information on effects of acute-duration oral exposure to toxaphene in humans is limited to reports of 
cardiac dilatation and swelling of the kidneys in a 2-year-old boy who ingested an unspecified lethal 
amount of toxaphene (McGee et al. 1952), temporarily-compromised hepatic and renal function in a 
26-year-old male who attempted suicide by ingesting an insecticide containing toxaphene as the active 
ingredient (Wells and Milhorn 1983), and signs of neurotoxicity (convulsive seizures, temporary memory 
loss, nausea) in several females who had ingested collard greens coated with toxaphene (McGee et al. 
1952).
Available acute-duration oral toxicity animal studies include single-dose studies in rats (Garcia and 
Mourelle 1984; Peakall 1976), guinea pigs (Chandra and Durairaj 1992, 1995), and dogs (Chu et al. 1986; 
Lackey 1949); and multiple-dose studies in rats (Chernoff and Carver 1976; Chernoff et al. 1990;
Kavlock et al. 1982; Mehendale 1978; Rao et al. 1986; Trottman and Desaiah 1980; Waritz et al. 1996), 
mice (Chernoff and Carver 1976; Hedli et al. 1998), and dogs (Chu et al. 1986; Lackey 1949). Targets of 
acute oral toxaphene toxicity include the nervous system, liver, body weight, immunological system, 
endocrine system, and development.
Several animal studies include reports of treatment-related liver weight changes following acute-duration 
oral exposure to toxaphene. Chernoff and Carver (1976) reported 23, 25, and 32% increased mean 
relative liver weight in mouse dams administered toxaphene by gavage at 15, 25, and 35 mg/kg/day 
during gestation days 7-16; the 35 mg/kg/day dose level represented a no-observed-adverse-effect level 
(NOAEL) for liver weight in similarly-treated rat dams. Trottman and Desaiah (1980) reported 20% 
increased mean liver weight in rats receiving toxaphene from the diet at 18 mg/kg/day for 14 days; the 
NOAEL for effects on liver weight was 13.5 mg/kg/day. Hedli et al. (1998) reported 48 and 78% 
increased mean relative liver weights in mice gavaged at 50 and 100 mg/kg/day, respectively, for 7 days;
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the NOAEL for effects on liver weight was 25 mg/kg/day. Peakall (1976) reported a 9% increase in 
relative liver weight and significantly increased microsomal enzyme activity in rats at 5 days following 
administration of a single 120 mg/kg oral dose of toxaphene. Mehendale (1978) reported decreased 
biliary excretion of imipramine metabolites from perfused livers of rats that had received toxaphene from 
the diet at an estimated dose of 10 mg/kg/day for 8 days.
Chu et al. (1986) observed convulsions in dogs following oral administration of toxaphene at 
10 mg/kg/day for 2 days; convulsions were not elicited after the dose was reduced to 5 mg/kg/day for the 
remainder of a 13-week treatment period. Lackey (1949) reported convulsions in dogs administered a 
single 10 mg/kg dose of toxaphene. Mild tremors and nervousness were noted in rats receiving toxaphene 
by gavage at 25 mg/kg/day for 3 days (Rao et al. 1986).
Toxaphene-induced effects on maternal body weight were observed in rat and mouse dams administered 
toxaphene via gavage during organogenesis (Chernoff and Carver 1976; Chernoff et al. 1990). The 
mouse study identified a NOAEL of 15 mg/kg/day and a serious lowest-observed-adverse-effect level 
(serious LOAEL) of 25 mg/kg/day for 22% decreased maternal body weight gain (Chernoff and Carver 
1976). The rat studies identified serious LOAELs of 32 mg/kg/day (the only dose tested by Chernoff et 
al. 1990) and 15 mg/kg/day (the lowest dose tested by Chernoff and Carver 1976) for the effect.
Trottman and Desaiah (1980) reported a 36% decrease in mean thymus weight in rats receiving toxaphene 
from the diet at an estimated dose of 13.5 mg/kg/day for 14 days; this effect was not observed at the lower 
dose (9 mg/kg/day). The study report made no mention of histopathological evaluations.
A greater than 2-fold increase in serum TSH and histopathologic thyroid lesions were reported in rats 
administered toxaphene by gavage at 75 mg/kg/day (the only dose tested) for 14 days (Waritz et al. 1996).
Significantly increased incidence of supernumerary ribs (17% greater than controls) was reported in 
fetuses of rat dams administered toxaphene by gavage at 32 mg/kg/day (the only dose tested) during 
gestation days 6-15 (Chernoff et al. 1990). Significantly decreased fetal renal protein and slight, but 
statistically significant retardation in kidney development were reported in fetuses of rat dams 
administered toxaphene by gavage at 12.5 or 25 mg/kg/day during gestation days 7-16; lower dose levels 
were not tested (Kavlock et al. 1982).
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The most sensitive effects of acute oral toxaphene toxicity were observed at doses in the range of 10­
15 mg/kg/day and include increased liver weights, clinical signs of neurotoxicity, depressed maternal 
body weight gain, and indicators of treatment-related effects on developmental end points. There is some 
degree of uncertainty regarding the toxicological significance of the reported effects on liver weight, fetal 
renal protein, thymus weight, and biliary excretion of imipramine metabolites. The reported 22% 
decreased maternal body weight gain in the toxaphene-treated rat dams of the Chernoff and Carver (1976) 
study is clearly a serious adverse effect. However, this effect was observed at the lowest dose tested, and 
the study did not identify a NOAEL. ATSDR does not derive MRLs based on a serious LOAEL in the 
absence of an identified NOAEL. The dog study of Chu et al. (1986) identified a NOAEL (5 mg/kg/day) 
and a LOAEL (10 mg/kg/day) for clinical signs of toxaphene-induced neurotoxicity, but did not include 
histopathological investigations. To derive an acute-duration oral MRL for toxaphene, the dog study of 
Chu et al. (1986) is selected as the principal study, and the NOAEL of 5 mg/kg/day is selected as the 
critical effect and point of departure (POD) for MRL derivation. An acute-duration oral MRL derived in 
this manner is expected to be protective of toxaphene-induced effects on the nervous system, liver, 
endocrine system, and developmental end points.
In the principal study (Chu et al. 1986), groups of male and female beagle dogs (6/sex/group) were given 
gelatin capsules containing toxaphene at 0, 0.2, 2.0, or 5.0 mg/kg daily for 13 weeks. During the first 
2 treatment days, the high-dose group received toxaphene at 10 mg/kg/day. This dose was reduced to 
5 mg/kg/day on treatment day 3 because the 10 mg/kg/day dose level elicited convulsions, salivation, and 
vomiting in 1/6 males and 2/6 females. These clinical signs were not observed in any of the toxaphene- 
treated dogs throughout the remainder of the scheduled 13-week treatment period. This study identified a 
serious LOAEL of 10 mg/kg/day for neurological effects elicited during the first 2 days of oral treatment 
and a NOAEL of 5 mg/kg/day. Using the NOAEL of 5 mg/kg/day as the POD, application of a total 
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability) 
yields an acute-duration oral MRL of 0.05 mg/kg/day for toxaphene.
• An MRL of 0.002 mg/kg/day has been derived for intermediate-duration oral exposure (15­
364 days) to toxaphene.
No human studies were located regarding the effects of intermediate-duration oral exposure to toxaphene.
Intermediate-duration oral toxicity studies are available for rats (Chu et al. 1986, 1988; Crowder et al. 
1980; Garcia and Mourelle 1984; Kennedy et al. 1973; Koller et al. 1983; NCI 1979; Olson et al. 1980; 
Ortega et al. 1957; Peakall 1976; Waritz et al. 1996), mice (Allen et al. 1983; NCI 1979), dogs (Chu et al.
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1986; Lackey 1949), and cynomolgus monkeys (Bryce et al. 2001; Tryphonas et al. 2000, 2001). The 
animal studies identified the nervous system, liver, kidney, thyroid gland, and immunological system as 
targets of toxaphene toxicity from intermediate-duration oral exposure. Lackey (1949) reported 
occasional convulsions in groups of dogs (2/group) administered toxaphene by capsule at 4 mg/kg/day for
44 or 106 days, but did not include more specific details. Study limitations preclude the usefulness of this 
study for quantitative risk assessment. One developmental toxicity study reported inferior swimming 
ability at postnatal days 10-12 in pups of rat dams receiving toxaphene from the diet at 0.05 mg/kg/day 
throughout gestation and for 30 days postpartum; however, swimming behavior appeared normal by 
postnatal day 16 (Olson et al. 1980). No additional studies were located to support the finding of 
toxaphene-related effects on postnatal development at such low dose levels.
Identified LOAELs for liver, kidney, and thyroid effects range from 0.5 to 45 mg/kg/day. A 13-week 
dietary study of male and female rats (Chu et al. 1986) identified the lowest LOAELs for these effects. 
Significantly increased incidences of histopathologic lesions of the liver (anisokaryosis) and kidney (renal 
tubular injury) were observed in the females at a 0.5 mg/kg/day dose level in the absence of an identified 
NOAEL. Similar effects were observed in the males at the dose level of 1.8 mg/kg/day; the lowest dose 
tested in the male rats (0.35 mg/kg/day) represented a NOAEL for liver and kidney effects. The same 
study identified NOAELs of 0.35 and 12.6 mg/kg/day and LOAELs of 1.8 and 63 mg/kg/day for 
morphologic lesions in the thyroid (angular collapse of follicles, increased epithelial height with 
multifocal papillary proliferation, and reduced colloid density) of the males and females, respectively.
Chu et al. (1986) also observed hepatomegaly in dogs administered toxaphene by capsule at 5 mg/kg/day 
for 13 weeks, but no evidence of treatment-related liver effects at a daily 2 mg/kg dose level.
Depressed humoral immune responses have been observed in rats, mice, and cynomolgus monkeys 
administered toxaphene orally for periods ranging from 8 to 52 weeks. In an enzyme-linked 
immunosorbent assay (ELISA) performed on female mice that received toxaphene from the diet at doses 
>19 mg/kg/day for up to 8 weeks, Allen et al (1983) reported suppressed antibody production, indicating 
depressed humoral immunity; the study identified a NOAEL of 2 mg/kg/day for the effect. Koller et al. 
(1983) reported a 46% decrease in the IgG primary antibody response in male rats receiving toxaphene 
from the diet at 2.6 mg/kg/day for up to 9 weeks and challenged twice (after 8 and 15 days on test) with 
keyhole limpet hemocyanin (KLH).
Tryphonas et al. (2001) reported a NOAEL of 0.1 mg/kg/day and a LOAEL of 0.4 mg/kg/day for 
toxaphene-induced decreased anti-SRBC (IgM) titers as an indicator of depressed humoral immunity. In
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the study, groups of 10 female cynomolgus monkeys/dose group received toxaphene via oral capsules at 
0, 0.1, 0.4, or 0.8 mg toxaphene/kg/day for up to 75 weeks. Groups of 5 males dosed at 0 or 
0.8 mg/kg/day were included in the study. Testing for immune effects was initiated on week 33 and 
included flow cytometry, lymphocyte transformation, natural killer cell activity and determination of 
serum cortisol during weeks 33-46 and immunizations with sheep red blood cells (SRBC) treatment at 
week 44 for a primary response and week 48 for a secondary response (observations made through 
treatment week 52). Treatment with toxaphene at 0.4 mg/kg/day resulted in significant (p<0.05) 
reductions in mean primary anti-SRBC IgM responses at weeks 1 and 4 following primary immunization 
(27 and 35% lower than that of controls) and secondary anti-SRBC IgM responses at week 1 following 
secondary immunization (10% lower than that of controls). The dose level of 0.8 mg/kg/day resulted in 
significantly reduced mean primary anti-SRBC IgM responses at weeks 1-4 following primary 
immunization, significantly reduced mean secondary anti SRBC IgM response at weeks 1 and 4 following 
secondary immunization, and significantly reduced primary anti-SRBC IgG responses at weeks 2 and 3 
following primary immunization (51 and 43% lower than that of controls). In males, 0.8 mg/kg/day 
toxaphene induced a significant reduction in mean primary anti-SRBC IgM response at weeks 1-3 
following primary immunization. Flow cytometry tests showed that the only effect on leukocyte and 
lymphocyte subsets was a reduction in absolute B lymphocytes (CD20) in 0.8 mg/kg/day females (62% 
lower than controls). There were no detectable treatment-related effects on natural killer cell activity, 
lymphoproliferative response to mitogens, or serum cortisol levels. This study identified the lowest 
LOAEL (0.4 mg/kg/day for depressed humoral immunity) among reliable LOAELs for intermediate- 
duration oral exposure to toxaphene, and is selected as the critical effect for deriving an intermediate- 
duration oral MRL for toxaphene.
To derive a POD for MRL derivation, BMD modeling was conducted using data for depressed humoral 
immunity from the female cynomolgus monkeys (Tryphonas et al. 2001). All continuous variable models 
in the EPA Benchmark Dose Software (Version 2.1.1) were fit to the mean anti-SRBC (IgM) titre data at 
week 1 post-immunization at treatment week 44; the modeled data are presented in Table A-3 of 
Appendix A. A default benchmark response (BMR) of 1 standard deviation (1SD) from the control mean 
was selected in the absence of a toxicological rationale for selecting an alternative BMR. As discussed in 
detail in Appendix A, the polynomial and power models converged on the linear model and provided 
identical fit to the data. These models predicted BMD1SD and BMDL1SD values of 0.34 and
0.22 mg/kg/day, respectively. The BMDL1SD of 0.22 mg/kg/day was divided by an uncertainty factor of 
100 (10 for interspecies extrapolation and 10 for human variability). The resulting intermediate-duration 
oral MRL is 0.002 mg/kg/day.
2. RELEVANCE TO PUBLIC HEALTH
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2. RELEVANCE TO PUBLIC HEALTH
A chronic-duration oral MRL was not derived for toxaphene for the following reasons:
1. No human studies were located regarding the effects of chronic-duration oral exposure to 
toxaphene.
2. A study designed to assess the effect of toxaphene on the immune system of cynomolgus 
monkeys identified a LOAEL of 0.4 mg/kg/day for decreased anti-SRBC IgM response during 
intermediate-duration oral exposure (<52 weeks) that is lower than the LOAEL of 0.8 mg/kg/day 
for decreased anti-TT response to chronic-duration oral exposure (testing initiated after 53 weeks 
of treatment).
3. Toxaphene doses used in chronic duration oral toxicity studies in rats and mice (NCI 1979) were 
2 orders of magnitude higher than doses eliciting immunological effects in cynomolgus monkeys 
treated for intermediate and chronic durations.
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3. HEALTH EFFECTS
3.1 INTRODUCTION
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of toxaphene. It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
Toxaphene is a manufactured pesticide composed of over 670 different constituents; the relative 
proportions of the major components of the pesticide are essentially the same in different formulations. 
The production and use of toxaphene have been banned in the United States and all of its territories since 
1990 (EPA 1990b). Nevertheless, because of its earlier widespread use, persistence in the environment, 
and storage in waste sites, exposure to toxaphene and its persistent congeners is still possible.
Following its release to the environment, technical toxaphene undergoes biotic and abiotic “weathering” 
processes, resulting in congener mixtures that differ from those of technical toxaphene (EPA 2010e; 
Ruppe et al. 2003, 2004; Simon and Manning 2006). Because toxaphene has not been used as a pesticide 
in the United States since 1990, exposure to persistent toxaphene congeners from weathered toxaphene is 
of primary health concern. Major congeners of toxaphene that have been found to persist in fish, marine 
mammals, and human serum and breast milk include Parlars p-26, p-40/41, p-44, p-50, and p-62 (Simon 
and Manning 2006). Pooled results of studies that assessed levels of these congeners in human serum 
and/or breast milk (Gill et al. 1996; Polder et al. 2003; Sandanger et al. 2003; Skopp et al. 2002b; Walker 
et al. 2003) indicate that p-26, p-50, and p-62 comprise approximately 33, 55, and 6%, respectively, of the 
total toxaphene body burden (Simon and Manning 2006).
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more).
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Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest- 
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction. However, the 
Agency has established guidelines and policies that are used to classify these end points. ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective. Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of toxaphene are 
indicated in Table 3-2 and Figure 3-2. Because cancer effects could occur at lower exposure levels,
Figure 3-2 also shows a range for the upper bound of estimated excess risks, ranging from a risk of 1 in 
10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA.
A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
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3.2.1 Inhalation Exposure
Very little information is available regarding the health effects of toxaphene following inhalation 
exposure in humans. Most of the existing data come from case reports and long-term studies of pesticide 
workers and are of limited value. In such studies, precise levels of exposure are usually not provided, and 
concurrent exposure to several pesticides confounds the interpretation of the results.
Limited information is available regarding health effects in animals following inhalation exposure to 
toxaphene. Secondary sources have cited unpublished results of studies for Hercules Incorporated, a 
major U.S. producer while toxaphene was registered for use as a pesticide in the United States. Although 
the primary study reports have not been made available to ATSDR, the results are presented in 
Section 3.2.1 as summarized in the Drinking Water Criteria Document for Toxaphene (EPA 1985c).
3.2.1.1 Death
No studies were located regarding death in humans following inhalation exposure to toxaphene.
A 40% toxaphene dust (3,000-4,000 mg/m3) caused death in about one-half of an exposed group of rats 
after 1 hour of exposure (EPA 1985c). Unpublished results of repeated inhalation exposure studies cited 
by EPA (1985c) include the death of all rats (number unspecified) exposed to toxaphene dust at 
250 mg/m3 for up to 1 week, unspecified numbers of deaths among rats, dogs, and guinea pigs exposed at 
12 mg/m3 for up to 3 months (but no deaths at 4 mg/m3), and no mortality in rats and rabbits exposed at 
500 mg/m3 for 3 weeks.
3.2.1.2 System ic Effects
No studies were available regarding cardiovascular, gastrointestinal, musculoskeletal, endocrine, or ocular 
effects in humans or animals following inhalation exposure to toxaphene.
One controlled human study investigated the general effects of inhaled toxaphene. Keplinger (1963) 
reported that no toxic effects were seen in 25 human subjects (15 males, 10 females) exposed to an 
aerosol containing a maximum of 500 mg toxaphene/m3 for 30 minutes/day for 10 days. The author 
estimated the absorbed dose to be as much as 60 mg/person/day. After a 3-week period, these same 
subjects were exposed for three more 30-minute periods. Examinations of these subjects by a 
dermatologist and an internist (some of them using blood tests and urinalysis) indicated no effects. Due
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to the limited information reported in this study and the unusual exposure conditions, it is difficult to 
assess the adequacy of these data. Nevertheless, the study is referenced below for the appropriate 
systemic end points.
The highest NOAEL values for humans for each effect are recorded in Table 3-1 and plotted in 
Figure 3-1.
Respiratory Effects. Pulmonary hypersensitivity reactions to toxaphene were suspected in two 
Egyptian agricultural pesticide workers in 1958. In these cases, men involved in the spraying of 
toxaphene (formulated as 60% toxaphene, 35% kerosene, 3% xylol, and 2% emulsifier) for approximately 
2 months suffered from acute pulmonary insufficiency (Warraki 1963). Chest x-rays revealed extensive 
miliary shadows, and one man exhibited marked bilateral hilar lymphadenopathy. The diagnosis in both 
cases was extensive bilateral allergic bronchopneumonia as a result of insecticide exposure. Both patients 
recovered quickly and completely with cortisone, streptomycin, and isoniazid treatment. Although the 
clinical sequelae observed in these two patients could be associated with toxaphene exposure, the effects 
could have been caused by other components of the spray. No similar cases have been reported since 
1958.
No studies were located regarding respiratory effects in animals following inhalation exposure to 
toxaphene.
Hematological Effects. No blood abnormalities were observed in a group of volunteers exposed to 
toxaphene spray 30 minutes/day for 10 days at a maximum nominal concentration of 500 mg/m3 
(Keplinger 1963). Clinical findings in two male Egyptian agricultural pesticide workers involved in the 
spraying of toxaphene (formulated as 60% toxaphene, 35% kerosene, 3% xylol, and 2% emulsifier) for 
approximately 2 months included elevated sedimentation rates, the presence of blood eosinophilia, and 
high serum globulin (Warraki 1963).
Hepatic Effects. No studies were available regarding hepatic effects in humans following inhalation 
exposure to toxaphene.
Slight hepatocellular necrosis was reported in some female rats that survived inhalation exposure to 
toxaphene dust (4 or 12 mg/m3) for 3 months (EPA 1985c).
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Table 3-1 Levels of Significant Exposure to Toxaphene - Inhalation
Key to Species
Figure (Strain)
Exposure/
Duration/
Frequency
(Route)
LOAEL
System
NOAEL
(mg/m3)
Less Serious 
(mg/m3)
Serious
(mg/m3)
Reference 
Chemical Form Comments
ACUTE EXPOSURE
Systemic
1 Human 10 d 30 min/d Resp 500 Keplinger 1963
Hemato 500
Renal 500
Dermal 500
a The number corresponds to entries in Figure 3-1.
d = day(s); Hemato = hematological; LOAEL = lowest-observed-adverse-effect level; min = minute(s); NOAEL = no-observed-adverse-effect level; Resp = respiratory
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Figure 3-1 Levels of Significant Exposure to Toxaphene - Inhalation
Acute (<14 days)
1000
m g/m3
.os?
dr
& <<(r- ,0V
100
1 1 1 1
c-Catd-Dogr-Ratp-Pigq-Cow
-Humansk-Monkeym-Mouseh-Rabbita-Sheep
f-Ferret j-Pigeon e-Gerbil s-Hamster g-Guinea Pig
n-Mink Cancer Effect Level-Animalso-Other LOAEL, More Serious-AnimalsLOAEL, Less Serious-Animals NOAEL - Animals
Cancer Effect Level-Humans LOAEL, More Serious-Humans LOAEL, Less Serious-Humans NOAEL - Humans
LD50/LC50 Minimal Risk Level for effects other than Cancer
—OXAPHENE 
22
3. 
HEAL—H 
EFFEC—S
TOXAPHENE 23
Renal Effects. Urinalyses were normal for a group of volunteers exposed to toxaphene spray 
30 minutes/day for 10 days at a maximum nominal concentration of 500 mg/m3 (Keplinger 1963).
No studies were located regarding renal toxicity in animals following inhalation exposure to toxaphene.
Dermal Effects. There were no signs of exposure-related dermal effects in a group of 25 volunteers 
exposed to an aerosol containing a maximum nominal concentration of 500 mg/m3 toxaphene for 
30 minutes/day for 10 days (Keplinger 1963).
No studies were located regarding dermal effects in animals following inhalation exposure to toxaphene.
Body W eight Effects. No studies were available regarding body weight effects in humans or animals 
following inhalation exposure to toxaphene.
No studies were located regarding the following effects in humans or animals following inhalation 
exposure to toxaphene:
3.2.1.3 Im m unological and Lym phoreticu lar Effects
3.2.1.4 Neurological Effects
3.2.1.5 Reproductive Effects
3.2.1.6 Developmental Effects
3.2.1.7 Cancer
Mills et al. (2005) reported a significant association (odds ratio [0R]=2.20, 95% confidence interval [CI] 
1.04-4.65) between risk of leukemia and exposure to toxaphene in a nested case-control study of 
131 lymphohematopoietic cancer cases (leukemia, multiple myeloma, non-Hodgkin’s lymphoma [NHL]) 
diagnosed between 1988 and 2001 among members of the United Farm Workers (UFW) labor union in 
California (cohort of 139,000 workers). For each case, five gender- and age-matched members of the 
UFW without any cancer diagnoses were selected as controls. Crop and pesticide exposures were 
estimated by linking job history information from union records with California Department of Pesticide 
Regulation pesticide use reports during the 20-year period prior to cancer diagnosis. There was no 
significant association between exposure to toxaphene and risk of multiple myeloma or NHL.
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Schroeder et al. (2001) reported a significant association (OR=3.7, 95% CI 1.9-7.0) between 
t(14;18)-positive NHL cases (n=5) and toxaphene exposure. The FARM (Factors Affecting Rural Men) 
case-control study included 182 NHL cases assayed for the t(14;18) translocation. This translocation is a 
common somatic mutation associated with B cell CLL/lymphoma-2 gene expression. Controls consisted 
of 30 participants who did not report use of toxaphene on farms where they worked. The study authors 
mentioned that chromosomal damage has been reported to be higher in peripheral blood lymphocytes 
during the peak spraying season (Schroeder et al. 2001). This study is limited by the small numbers of 
cases and controls.
In an agricultural health study of 22,409 subjects assessed by interview and/or questionnaire for total 
lifetime exposure days to various pesticides, a statistically significant increased risk for rectal cancer 
(RR=2.0, 95% CI=1.1-3.5) was noted among those with self-reported exposure to toxaphene; the risk was 
independent of age (Purdue et al. 2006). However, no statistically significant association was found 
between toxaphene exposure and risk of leukemia or NHL within this study group.
No studies were located regarding cancer effects in animals following inhalation exposure to toxaphene.
3.2.2 Oral Exposure
Toxaphene is toxic following short-term, high-dose oral exposure. Several cases of fatal and nonfatal 
poisoning have been reported in humans following the accidental or intentional ingestion of toxaphene or 
food contaminated with large amounts (gram quantities) of toxaphene. In such instances of acute 
poisoning, toxaphene stimulates the central nervous system like other chlorinated hydrocarbon pesticides. 
Long-term animal studies indicate that toxaphene causes central nervous system toxicosis and hepatic 
hypertrophy accompanied by increased microsomal enzyme activity and histological changes in liver 
cells. The kidneys, spleen, immunological system, and adrenal gland have also been identified as targets 
of toxaphene toxicity.
3.2.2.1 Death
Ingestion of large doses of toxaphene by humans can be fatal. Six case studies of acute poisoning were 
reported, three of which (all children) were fatal (McGee et al. 1952). In all cases, an unknown quantity 
of toxaphene was ingested, either alone or as a residue of spray on food. Symptoms were usually abruptly 
manifested by 7 hours post-ingestion and consisted of intermittent convulsions, generally without
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abdominal pain, vomiting, or diarrhea. Death was attributed to respiratory failure resulting from the 
seizures. An approximate minimum lethal dose in humans was estimated to be 2-7 g (CDC 1963); 
however, the available report did not provide a basis for the estimate.
In animals, single-dose gavage administration of toxaphene resulted in estimated oral LD50 values of 80­
293 mg/kg for rats (Boyd and Taylor 1971; Gaines 1969; Jones et al. 1968) and 25 mg/kg for dogs 
(Lackey 1949). A 300 mg/kg dose was reported to be lethal to male guinea pigs within 72 hours 
postdosing; the study authors indicated that the 300 mg/kg dose represented an LD50 dose level, but did 
not provide more detailed dosing information (Chandra and Durairaj 1995). Gavage administration of 
toxaphene to heifers (136-232 kg) at 50, 100, or 150 mg/kg resulted in 2/8, 6/7, and 5/6 deaths, 
respectively (Steele et al. 1980).
Mortality was also reported in animals following repeated gavage dosing. Epstein et al. (1972) observed 
the death of 2/12 and 9/12 male mice administered toxaphene by daily gavage on 5 consecutive days at 
40 and 80 mg/kg, respectively. Chernoff and Carver (1976) administered toxaphene to rat and mouse 
dams on gestation days 7-16 at gavage doses of 0 (vehicle controls), 15, 25, or 35 mg/kg/day. Mortality 
was noted in 0/33, 2/39, 3/39, and 5/16 of the rat dams (0, 15, 25, and 35 mg/kg/day dose levels, 
respectively) and 1/75, 0/26, 0/45, and 07/90 of the mouse dams. In a separate study, Chernoff et al. 
(1990) observed mortality in 50% of the rat dams (n~25) administered toxaphene at 32 mg/kg/day during 
gestation days 6-15. In a 28-day oral toxicity study, Waritz et al. (1996) administered toxaphene (in corn 
oil) by daily gavage to a group of 40 male rats. An initial dose level of 100 mg/kg/day was reduced to 
75 mg/kg/day after 2/40 of the treated rats died after three doses; no additional unscheduled deaths were 
observed. No treatment-related deaths were observed in pregnant rats administered 6 mg/kg/day by 
gavage from gestational day 7 to parturition (Crowder et al. 1980).
The vehicle used to deliver toxaphene may influence its toxicity (Lackey 1949). Among groups of dogs 
administered toxaphene once via gavage in corn oil at 15, 20, 25, 30, 40, or 50 mg/kg, mortalities were 
noted in 2/8, 1/5, 6/7, 4/7, 3/7, and 5/5 animals, respectively. However, when toxaphene was 
administered in kerosene (a poorly absorbed solvent) at 25-250 mg/kg, mortalities were observed only at 
doses >200 mg/kg.
The nutritional status of an animal influences its susceptibility to the lethal effects of ingested toxaphene. 
Boyd and Taylor (1971) found that the oral LD50 for rats fed a protein-deficient diet was 80 mg/kg/day, 
whereas the oral LD50 for rats fed a control diet was 220 mg/kg/day. This has important implications for
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the possible increased susceptibility of humans who ingest a protein-deficient diet and live in areas of 
potential exposure to toxaphene.
No treatment-related deaths were observed in a one-generational two-litter study of rats administered 
toxaphene in the diet for 48 weeks at estimated doses up to 46 mg/kg/day (Chu et al. 1988). The lack of 
lethality at a dietary dose within the range of LD50 doses noted previously is likely a reflection of 
differences in dose rate (i.e., bolus gavage dosing versus a slower dose rate from feeding). Treatment- 
related mortality was not observed in rats following gavage administration of 6 mg/kg/day for 21 days 
(Crowder et al. 1980). In a 6-week range-finding study that employed groups of male and female 
B6C3F1 mice (5/sex/group), estimated toxaphene doses of 58 and 115 mg/kg/day to males resulted in 
1/5 and 2/5 deaths, respectively; estimated toxaphene doses of 62 and 125 mg/kg/day to females resulted 
in 1/5 and 4/5 mortalities, respectively (NCI 1979). In similarly-treated Osborne-Mendel rats, estimated 
doses of 112 and 224 mg/kg/day to males resulted in 0/5 and 1/5 deaths, respectively; estimated doses of 
121 and 242 mg/kg/day to females caused 0/5 and 2/5 deaths, respectively. In a subsequent cancer 
bioassay in which toxaphene was administered in the diet to Osborne-Mendel rats and B6C3F1 mice for 
80 weeks, estimated TWA doses as high as 83 and 34 mg/kg/day, respectively, did not appear to 
significantly affect survival (NCI 1979). No treatment-related mortality was observed in parental male or 
female Sprague-Dawley rats administered toxaphene in the diet for up to 42 weeks at estimated doses up 
to 8.6 mg/kg/day (males) or 9.8 mg/kg/day (females) (Kennedy et al. 1973).
The LD50 values and doses associated with death in each species following acute and intermediate oral 
exposure are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.2 System ic Effects
No studies were located regarding musculoskeletal effects following oral exposure of humans or animals 
to toxaphene. The systemic effects of oral toxaphene exposure are described below.
The highest NOAEL values and all reliable LOAEL values for each species and duration of exposure for 
each systemic effect are recorded in Table 3-2 and plotted in Figure 3-2.
Respiratory Effects. Available information regarding respiratory effects in humans following oral 
exposure to toxaphene is limited to an account of congestion and edema of the lungs at autopsy of a 
2-year-old boy who ingested an unspecified but lethal amount of toxaphene (McGee et al. 1952).
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral
Key to Species
Figure (Strain)
Exposure/
Duration/
Frequency
(Route)
LOAEL
NOAEL Less Serious 
System (mg/kg/day) (mg/kg/day)
Serious
(mg/kg/day)
Reference 
Chemical Form Comments
ACUTE EXPOSURE
Death
1 Rat
(Wistar)
once
(GO)
220 M (LD50 for standard 
laboratory chow diet)
Boyd and Taylor 1971
2 Rat once
(Wistar) (GO)
3 Rat once
(Wistar) (GO)
4 Rat Gd 7-16 1x/d
(CD) (GO)
5 Rat Gd 6-15 1x/d
(Sprague- (GO)
Dawley)
6 Rat once
(Sherman) (GO)
7 Rat 
(NS)
once
(G)
8 Mouse Gd 7-16 1x/d
(CD-1) (GO)
9 Mouse 5 d 1x/d
(ICR/Ha (G) 
Swiss)
80 M (LD50 low protein diet) Boyd and Taylor 1971
293 M (LD50 for normal-protein Boyd and Taylor 1971 
diet)
35 F (5/16 maternal deaths) Chernoff and Carver 1976
32 F (50% maternal lethality) Chernoff et al. 1990
90 M (LD50) 
80 F (LD50)
Gaines 1969
283 (LD50) Jones et al. 1968
35 F (7/90 maternal deaths) Chernoff and Carver 1976
40 M (death; 2/12) Epstein et al. 1972
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
Duration/
Frequency
(Route)
NOAEL Less Serious 
System (mg/kg/day) (mg/kg/day)
LOAEL
Serious
(mg/kg/day)
Reference 
Chemical Form Comments
10 Gn Pig 
(NS)
once
(GO)
300 M (death) Chandra and Durairaj 1995
11 Dog
(NS)
once
(GO)
15 (death of 2/8 dogs) Lackey 1949
12 Dog
(NS)
Systemic
13 Rat
(CD)
once
(GO)
Gd 7-16 1x/d 
(GO) Hepatic 35 F
200 (death in 1/5 dogs) Lackey 1949
Chernoff and Carver 1976
Bd Wt 15 F (22% reduced maternal 
weight gain)
14 Rat
(Sprague-
Dawley)
Gd 6-15 1x/d 
(GO) Bd Wt
32 F (up to 50% depressed Chernoff et al. 1990 
maternal weight gain)
15 Rat
(Sprague-
Dawley)
8 d ad lib
(F)
Hepatic 10 M (23% decline in biliary 
excretion of imipramine 
metabolites)
Mehendale 1978
16 Rat
(Osborne-
Mendel)
80 wk ad lib 
(F) Bd Wt 147 F 130 M (14% lower mean bodyweight)
NCI 1979 Body weight results 
during the first 2 weeks 
of an 80-week dietary 
exposure period
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________System (mg/kg/day) (mg/kg/day)__________________ (mg/kg/day)________________Chemical Form__________________ Comments
17 Rat 0nce Hepatic 120 M (9% increased relative Peakall 1976
(NS) (C) liver weight)
18 Rat
(Sprague-
Dawley)
14 d ad lib 
(F)
Hepatic 13.5 M 18 M (20% increased relative
liver weight)
Trottman and Desaiah 1980 No effects on body,
heart, or kidney 
weights
Bd Wt 18 M
19 Rat
(Sprague-
Dawley)
14 d 
1 x/d 
(GO)
Endocr 75 M (increased TSH; thyroid 
histopathology)
Waritz et al. 1996
20 Mouse 
(CD-1)
Gd 7-16 1x/d 
(GO)
Hepatic 15 F (23% increased relative 
liver weight)
Chernoff and Carver 1976
Bd Wt 15 F 25 F (22% depressed body 
weight gain)
21 M°use 7 d/d Hepatic 25 M 50 M (48% increased relative Hedli et al. 1998
(CD-1) (GO) liver Weight) toxaphene
Bd Wt 100 M
22 Gn Pig once Hepatic 300 M Chandra and Durairaj 1992
(NS) (GO) K
Renal 300 M
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
Duration/
Frequency
(Route)
LOAEL
NOAEL Less Serious 
System (mg/kg/day) (mg/kg/day)
Serious
(mg/kg/day)
Reference 
Chemical Form Comments
Immuno/ Lymphoret
23 Rat
(Sprague- 
Dawley)
14 d ad lib
(F)
9 M 13.5 M (36% decreased relative 
thymus weight)
Trottman and Desaiah 1980
Neurological
24 Rat
(Sprague-
Dawley)
3 d 1x/d 
(GO) 25 M (mild tremors, nervousness)
Rao et al. 1986
25 Gn Pig 
(NS)
once
(GO)
300 M (sedation, convulsions) Chandra and Durairaj 1995
26 Dog
(Beagle)
13 wk 
(C)
b
5 10 (convulsions, salivation, Chu et al. 1986 
and vomiting in 1/6 males 
and 2/6 females)
Neurological effects 
observed during the 
first 2 treatment days at 
10 mg/kg/day, but not 5 
mg/kg/day from 
treatment day 3 onward
27 Dog
(NS)
once
(GO) 10 (convulsions)
Lackey 1949
2s Bovine
(Mixed- 
breed)
Developmental
2s Rat
(Sprague-
Dawley)
once
(GW)
Gd 6-15 1x/d 
(GO)
50 (convulsions)
32 (significantly increased 
incidence of fetal 
supernumerary ribs)
Steele et al. 1980
Chernoff et al. 1990
5
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________System (mg/kg/day) (mg/kg/day)__________________ (mg/kg/day)________________Chemical Form__________________ Comments
30 Rat
(CD)
Gd 7-16 1x/d 
(GO)
12.5 F (decreased fetal renal 
protein)
Kavlock et al. 1982 Decreased fetal renal 
protein may indicate 
retardation in fetal 
growth
31 Mouse 
(CD-1)
Gd 7-16 1x/d 
(GO) 35 F
INTERMEDIATE EXPOSURE
Death
32 Rat 6 wk ad lib
(Osborne- (F)
Mendel)
Chernoff and Carver 1976
224 M (death in 1/5 males) NC| 1979
242 F (death of 2/5 females)
33 Mouse 6 wk ad lib
(B6C3F1) (F)
Systemic
34 Monkey
(Cynomolgus)
52 wk 
1 x/d 
(C)
Ocular 1 (inflammation and/or 
enlargement of tarsal 
glands during treatment 
weeks 8-13; impacted 
diverticulae of eyelids 
during treatment weeks 
10-41)
57.7 M (death of 1/5 males) 
31.2 F (death of 1/5 females)
NCI 1979
Bryce et al. 2001
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments
35 Rat 13 wk ad lib ,,  ^ ^,,„*.,1 moc35 Hemato 45.9 M Chu et al. 1986
(Sprague- (F)
Dawley) 63 F
Hepatic 0.35 M 
0.5 F
1.8 M (nuclear necrosis, 
anisokaryosis)
2.6 F (nuclear necrosis, 
anisokaryosis)
Renal 0.35 M 1.8 M (tubular injury)
0.5 F (tubular necrosis, 
anisokaryosis)
8.6 M (focally severe tubular 
injury)
45.9 M (multiple and relatively 
severe kidney lesions)
Bd Wt 45.9 M 
63 F
12.6 F (focally severe tubular 
injury)
Endocr 0.35 M 
12.6 F
1.8 M (moderate morphological 
changes in thyroid)
63 F (moderate morphological 
changes in thyroid)
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________System (mg/kg/day) (mg/kg/day)__________________ (mg/kg/day)________________Chemical Form__________________ Comments
36 Rat 26 wk ad lib
(Sprague- (F) 
Dawley)
Hemato 45 M
46 F
Chu et al. 1988
Hepatic
Renal
45 M
46 F 
9.2 M 
8.5 F
45 M (18% increased kidney 
weight, increased 
incidence of tubular 
injury)
Endocr 9.2 M 
8.5 F
46 F (increased incidence of 
renal tubular injury)
45 M (cytoplasmic vacuolation 
in thyroid)
46 F (cytoplasmic vacuolation 
in thyroid)
Bd Wt 45 M
46 F
37 Rat 21 d 1x/d
(Sprague- (GO) 
Dawley)
Bd Wt Crowder et al. 19806
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/
Duration/
Key to Species Fr(Rque" cy
Figure (Strain) (Route)
NOAEL Less Serious 
System (mg/kg/day) (mg/kg/day)
LOAEL
Serious
(mg/kg/day)
Reference 
Chemical Form Comments
38 Rat 39-42 wk ad lib
(Sprague- (F) 
Dawley)
Cardio 8.6 M 
9.8 F
Kennedy et al. 1973
Hepatic
Renal
Endocr
Bd Wt
2.2 M
2.5 F
8.6 M
9.8 F
8.6 M
9.8 F
8.6 M
9.8 F
8.6 M (cytoplasmic vacuolation) 
9.8 F (cytoplasmic vacuolation)
39 Rat
(Sprague-
Dawley)
6-9 wk ad lib 
(F)
Hepatic 2.6 M 26 M (24% liver weight
increase and hepatic 
degeneration)
Koller et al. 1983
Endocr 
Bd Wt
26 M 
26 M
40 Rat
(Osborne-
Mendel)
6 wk ad lib 
(F)
Bd Wt 224 M 
242 F
NCI 1979
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
Duration/
Frequency
(Route)
LOAEL
NOAEL Less Serious 
System (mg/kg/day) (mg/kg/day)
Serious
(mg/kg/day)
Reference 
Chemical Form
0 X A ~01
Comments
41 Rat up to 9 mo ad41 nu Renal 20 M Ortega et al. 1957
(Sherman) lib
(F) 22.6 F
Bd Wt 20 M 
22.6 F
0 
P cD1
C
CO
42
43
Rat
(Sprague-
Dawley)
Mouse
(Swiss
Webster)
28 d 
1 x/d 
(GO)
8 wk ad lib 
(F)
Endocr
Resp
Cardio
Gastro
Hepatic
39 F
39 F 
39 F 
2 F
75 M (increased TSH; thyroid 
histopathology)
Waritz et al. 1996
Allen et al. 1983
.
Hm
A
19.5 F (increased relative liver 
weight, variation in cell 
size with some fatty 
infiltration)
Renal 
Endocr 
Bd Wt
39 F 
39 F 
39 F
44 Mouse 6 wk ad lib
(B6C3F1) (F) Bd Wt 57.7 M
NCI 1979
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________System (mg/kg/day) (mg/kg/day)__________________ (mg/kg/day)________________Chemical Form__________________ Comments
45 Dog
(Beagle)
13 wk 7 d/wk
1x/d
(C)
Hemato Chu et al. 1986
Hepatic (increased liver weight, 
increased serum alkaline 
phosphatase, 
hepatomegaly)
5
2 5
Renal 
Bd Wt
Immuno/ Lymphoret
46 Monkey 52 wk 
(Cynomolgus) 1 x/d 
(C)
Tryphonas et al. 2000 Antibody response 
testing was performed 
during treatment weeks 
36-51
47 Monkey Up to 75 wk 
(Cynomolgus) 1 x/d 
(C)
0.1 F 0.4 F (depressed humoral 
immunity)
Tryphonas et al. 2001 27-35% depressed 
humoral immunity 
expressed as reduced 
anti-SRBC IgM 
response during 
treatment weeks 45-49
48 Rat 39-42 wk ad lib 8 6 M Kennedy et al. 1973
(Sprague- (F)
Dawley) 9.8 F
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________System (mg/kg/day) (mg/kg/day)__________________ (mg/kg/day)________________Chemical Form__________________ Comments
49 Rat
(Sprague-
Dawley)
9 wk ad lib 
(F)
2.6 M (46% decreased IgG 
primary antibody 
response at day 15 
postimmunization)
Koller et al. 1983
50 Mouse 
(Swiss 
Webster)
8 wk ad lib 
(F)
2 F 19.5 F (depressed humoral 
immunity)
Allen et al. 1983
Neurological
51 Rat
(Sprague-
Dawley)
21 d 1x/d 
(GO)
Crowder et al. 1980
52 Dog
(NS)
Reproductive
53 Rat
(Sprague-
Dawley)
44 or 106 d
1x/d
(C)
48 wk ad lib 
(F)
4 (convulsions)
46
Lackey 1949
Chu et al. 1988
54 Rat
(Sprague-
Dawley)
39-42 wk ad lib 
(F) 8.6 M 
9.8 F
Kennedy et al. 1973
6
55 Mouse multigen 4.9 F Keplinger et al. 1970
(Swiss) (F)
TOXAPHENE 
37
3. 
HEALTH 
EFFECTS
***DRAFT 
FOR 
PUBLIC 
COM
M
ENT***
Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
Duration/
Frequency
(Route)
LOAEL
System
NOAEL
(mg/kg/day)
Less Serious 
(mg/kg/day)
Serious
(mg/kg/day)
Reference 
Chemical Form Comments
Developmental
56 Rat
(Sprague-
Dawley)
Gd 7-21 1x/d 
(GO)
(transiently delay in 
development of righting 
reflex)
Crowder et al. 1980
57 Mouse
(Swiss
Webster)
9.5 wk ad lib 
(F)
19.5 (suppression of
macrophage phagocytic 
function)
Allen et al. 1983 Immune function was 
tested in 8-week-old 
mice from dams that 
had been administered 
toxaphene in the diet 
during gestation and 
lactation
CHRONIC EXPOSURE
Systemic
58 Monkey 75 wk 
(Cynomolgus) 1 x/d 
(C)
Hemato 0.8 F Arnold et al. 2001
Bd Wt 0.8 F
59 Monkey 52 wk 
(Cynomolgus) 1 x/d 
(C)
Resp Bryce et al. 2001
Cardio
Gastro
Hemato
Hepatic
Renal
Endocr
6
2
Bd Wt
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________System (mg/kg/day) (mg/kg/day)__________________ (mg/kg/day)________________Chemical Form__________________ Comments
60 Rat 80 wk ad lib „  > n,.,,Resp 39 M (dyspnea, epistaxis) NCI 1979
(Osborne- (F) K w  K K '
Mendel)
Gastro 39 M (abdominal distension,
diarrhea)
Hepatic
Renal
Dermal
77.9 M 
83.3 F
39 M (hematuria)
39 M (alopecia, dermatitis, 
rough hair coats)
Bd Wt 77.9 M 41.6 F (up to 15% lower mean
body weight)
61 Mouse 80 wk ad lib
(B6C3F1) (F)
Resp 17 (dyspnea) NCI 1979
Gastro 17 (abdominal distension, 
diarrhea)
Dermal 17 (alopecia, rough hair 
coat)
Bd Wt 34
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
Duration/
Frequency
(Route)
System
NOAEL
(mg/kg/day)
Less Serious 
(mg/kg/day)
LOAEL
Serious
(mg/kg/day)
Reference 
Chemical Form Comments
Immuno/ Lymphoret
62 Monkey Up to 75 wk 
(Cynomolgus) 1 x/d 
(C)
0.4 F 0.8 F (depressed humoral 
immunity)
Tryphonas et al. 2001 Depressed humoral 
immunity expressed as 
reduced anti-TT titers 
during treatment weeks 
53-63
Neurological
63 Monkey 52 wk 
(Cynomolgus) 1 x/d 
(C)
Bryce et al. 2001
64 Rat 80 wk ad lib
(Osborne- (F) 
Mendel)
39 M (leg paralysis, ataxia, 
epistaxis)
NCI 1979
41.6 F (leg paralysis, ataxia, 
epistaxis)
65 Mouse 80 wk ad lib
(B6C3F1) (F)
Reproductive
66 Monkey 75 wk
(Cynomolgus) 1 x/d
(C)
34 F 17 M (hyperexcitability)
0.8 F
NCI 1979
Arnold et al. 2001 NOAEL is for menstrual 
status
67 Monkey 52 wk 
(Cynomolgus) 1 x/d 
(C)
Bryce et al. 2001
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Table 3-2 Levels of Significant Exposure to Toxaphene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________System (mg/kg/day) (mg/kg/day)__________________ (mg/kg/day)________________Chemical Form__________________ Comments
68 Rat 
(Osborne- 
Mendel)
Cancer
69 Rat 
(Osborne- 
Mendel)
80 wk ad lib 
(F)
80 wk ad lib 
(F)
41.6 F (vaginal bleeding)
77.9 M (CEL: follicular -cell 
carcinomas, thyroid 
adenomas)
NCI 1979
NCI 1979
83.3 F (CEL: thyroid adenomas)
70 Mouse 80 wk ad lib 
(B6C3F1) (F)
17 M (CEL: hepatocellular 
carcinoma)
NCI 1979
17 F (CEL: hepatocellular 
carcinoma or neoplastic 
nodule)
a The number corresponds to entries in Figure 3-2.
b Used to derive an acute-duration oral minimal risk level (MRL) of 0.05 mg/kg/day; dose divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 
for human variability).
c Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.002 mg/kg/day; the BMDL1SD of 0.22 mg/kg/day, based on benchmark dose analysis of anti-SRBC (IgM) 
titers as an indicator of humoral immunity, was divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).
ad lib = ad libitum; Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F)= feed; F = Female; (G) = gavage; 
Gastro = gastrointestinal; Gd = gestation day; (GO) = gavage in oil; (GW) = gavage in water; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; LD50 = 
lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); NOAEL = no-observed-adverse-effect level; NS = not specified; x = time(s); wk = 
week(s)
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Figure 3-2 Levels o f S ignificant Exposure to Toxaphene - Oral
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Figure 3-2 Levels o f S ignificant Exposure to Toxaphene - Oral (Continued)
Intermediate (15-364 days)
Systemic
1000
mg/kg/day
/  /  S  <?$> ____
&
>f-
100
10
0.1
0.01
0.001
•3 2 r  *32r
33m
33m 43m 43m
38r 38r
35r
43m 35r 36r 36r
45d
36r 036r 43m 35r (Ï36r ®36r
Cl43m
Cl45d
045d É Â  (J35r
35r
35r
C»38r 
38r 38r
*39r
*38r
39r
41r 41r
45d
•3 5 r
•3 5 r  36r 36r 38r 38r
(Ï35r
35r
35r
c-Catd-Dogr-Rat
p-Pigq-Cow
-Humansk-Monkeym-Mouseh-Rabbita-Sheep
f-Ferret j-Pigeon e-Gerbil s-Hamster g-Guinea Pig
n-Mink Cancer Effect Level-Animalso-Other LOAEL, More Serious-AnimalsLOAEL, Less Serious-Animals NOAEL - Animals
Cancer Effect Level-Humans LOAEL, More Serious-Humans LOAEL, Less Serious-Humans NOAEL - Humans
LD50/LC50 Minimal Risk Level for effects other than Cancer
TOXAPHENE 
43
3. 
HEALTH 
EFFECTS
***DRAFT 
FOR 
PUBLIC 
COM
M
ENT***
Figure 3-2 Levels o f S ignificant Exposure to Toxaphene - Oral (Continued)
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Figure 3-2 Levels o f S ignificant Exposure to Toxaphene - Oral (Continued)
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In rats, the acute oral administration of toxaphene has been shown to cause congestion and parenchymal 
hemorrhage, indicative of a generalized inflammatory response (Boyd and Taylor 1971). The study was 
limited by the fact that the dose was not specified. The chronic administration of toxaphene in feed to rats 
or mice at doses of 27 and 12.9 mg/kg/day, respectively, has been shown to cause dyspnea (NCI 1979). 
Bryce et al. (2001) noted no remarkable histopathology following examination of tissues (including lung 
tissue) from cynomolgus monkeys administered toxaphene by oral capsule at 1 mg/kg/day for 52 weeks.
Cardiovascular Effects. Available information regarding cardiovascular effects in humans 
following oral exposure to toxaphene is limited to a report of dilatation of the heart at autopsy of a 
2-year-old boy who ingested an unspecified but lethal amount of toxaphene (McGee et al. 1952).
Available information in animals is limited. Congestion and hemorrhage of cardiac capillaries were 
observed in rats that died following single gavage administration of an unspecified dose of toxaphene 
(Boyd and Taylor 1971). These effects are indicative of a generalized inflammatory response. Increased 
heart rate, in the absence of apparent effects on the vascular system, was noted in dogs following 
administration of a 10 mg/kg dose of toxaphene (Lackey 1949). Progressive neural degeneration was 
noted in the hearts of pregnant rats following daily gavage administration of toxaphene at 12 mg/kg/day 
during pregnancy (Badaeva 1976). However, the methods used to identify the lesions in this study are not 
well described and the effects were not quantitatively evaluated.
No treatment-related effects on heart weight were observed in rats fed toxaphene in the diet for 14 days at 
10 mg/kg/day (Trottman and Desaiah 1980) or up to 42 days at 8.6 mg/kg/day (males) or 9.8 mg/kg/day 
(females) (Kennedy et al. 1973). Bryce et al. (2001) noted no remarkable histopathology following 
examination of tissues (including heart tissue) from cynomolgus monkeys administered toxaphene by oral 
capsule at 1 mg/kg/day for 52 weeks.
G astro intestinal Effects. No studies were located regarding gastrointestinal effects in humans 
following oral exposure to toxaphene.
Gastric ulcers and local gastroenteritis (an inflammatory reaction) were observed in rats administered a 
single unspecified oral dose of toxaphene (Boyd and Taylor 1971). In this study, animals fed a low 
protein (3.5%) diet had a greater incidence of toxaphene-induced gastritis than rats fed normal chow or a 
test diet with normal protein content, in keeping with the apparent “diet-dependency” of toxaphene 
toxicity. Abdominal distension and diarrhea were observed in rats and mice receiving toxaphene from the
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diet during 80 weeks at doses >39 mg/kg/day (rats) or >17 mg/kg/day (mice) (NCI 1979). These effects 
were most prominent in the high-dose (78 mg/kg/day) male rats. Bryce et al. (2001) noted no remarkable 
histopathology following examination of tissues (including esophagus, stomach, and small and large 
intestine) from cynomolgus monkeys administered toxaphene by oral capsule at 1 mg/kg/day for 
52 weeks.
Hematological Effects. No studies were located regarding hematologic effects in humans following 
oral exposure to toxaphene.
No adverse effects on standard hematological parameters were noted in dogs dosed with up to 
5 mg/kg/day by capsule for 13 weeks (Chu et al. 1986); dogs dosed with 4 mg/kg/day by capsule for 44 or 
106 days (Lackey 1949); male and female rats receiving toxaphene from the diet for 13 weeks at 
estimated doses of 45.9 or 63 mg/kg/day, respectively (Chu et al. 1986); or male rats receiving
45 mg/kg/day from the diet for 26 weeks (Chu et al. 1988). There was no evidence of treatment-related 
hematological effects in cynomolgus monkeys administered toxaphene in oral capsules at 1 mg/kg/day for 
52 weeks (Bryce et al. 2001) or 0.1-0.8 mg/kg/day for up to 75 weeks (Arnold et al. 2001).
Abnormalities in the blood-forming elements were observed in the spleens of rats that died following the 
oral administration of a single unspecified dose of toxaphene; the study authors attributed this to a 
generalized stress reaction (Boyd and Taylor 1971).
Hepatic Effects. Little information was located regarding hepatic effects in humans following oral 
exposure to toxaphene. Transiently-elevated liver lactate dehydrogenase and serum glutamic oxaloacetic 
transaminase indicative of reversible liver injury were observed in a 26-year-old man who attempted 
suicide by ingesting the insecticide Tox-Sol, which contains toxaphene as the active ingredient (Wells and 
Milhorn 1983).
Oral administration of toxaphene has been shown to result in increased liver weight in some studies of 
rats and mice (Allen et al. 1983; Chernoff and Carver 1976; Chu et al. 1986, 1988; Hedli et al. 1998; 
Koller et al. 1983; Peakall 1976).
Chandra and Durairaj (1992) reported 13% increased absolute (but not relative) liver weight in guinea 
pigs administered a single gavage dose of toxaphene at 300 mg/kg (in groundnut oil) in the absence of 
indications of treatment-related histopathologic liver lesions. In a subsequent study by the same 
investigators (Chandra and Durairaj 1995), a similar exposure scenario resulted in significantly decreased
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hepatic phospholipid content and significantly increased hepatic neutral lipid content. Similar effects 
were noted in other guinea pigs receiving toxaphene by gavage at 5 mg/kg/day for 60 days (Chandra and 
Durairaj 1995).
Inhibition of hepatobiliary function was reported in perfused livers from male rats exposed to
5 mg/kg/day toxaphene in feed for 8 days (Mehendale 1978). Induction of hepatic microsomal enzymes 
and increased liver weights were noted in male rats given 120 mg/kg/day by capsule or 10 mg/kg/day in 
feed for 14 days (Peakall 1976; Trottman and Desaiah 1980). Increased gamma-glutamyl transpeptidase 
(GGTP) activity was observed in male rat liver plasma membranes and blood serum after a single gavage 
exposure to 110 mg/kg toxaphene (Garcia and Mourelle 1984). Increased hepatic microsomal activity 
(aminopyrene, ethoxyresorufin, and methoxyresorufin) was noted in male and female cynomolgus 
monkeys (two per sex) administered toxaphene in glycerol/corn oil via gelatin capsule at 1 mg/kg/day for 
52 weeks compared to vehicle controls (Bryce et al. 2001). However, the majority of these studies did 
not report any other evidence of hepatic toxicity. Therefore, enzyme induction in the absence of other 
signs of liver toxicity is not generally considered adverse, but enzyme induction may precede the onset of 
more serious hepatic effects.
Morphological and degenerative changes were observed in the livers of dogs (Chu et al. 1986; Lackey 
1949), rats (Chu et al. 1988; Kennedy et al. 1973; Koller et al. 1983; Ortega et al. 1957), and mice (Allen 
et al. 1983) following intermediate-duration exposure to 4, 5-45, and 13 mg/kg toxaphene, respectively. 
These changes included generalized hydropic degenerative changes, cytoplasmic vacuolization, 
centrilobular cell hypertrophy, peripheral migration of basophilic cytoplasmic granules, and the presence 
of lipospheres. Hepatic enzyme induction was also observed in rats following intermediate exposure to 
toxaphene at 2.4 mg/kg/day (Peakall 1976) or 16.5 mg/kg/day (Garcia and Mourelle 1984). The study of 
Peakall (1976) did not include a concurrent control group. Toxaphene may also induce hypoxia and alter 
hepatic energy metabolism because it has been shown to decrease lactate dehydrogenase activity (Gertig 
and Nowaczyk 1975; Kuz'minskaya and Alekhina 1976). The intermediate-duration oral administration 
of 2 mg/kg/day toxaphene to dogs caused increased relative liver weight, hepatomegaly, and hepato­
cellular cytoplasmic vacuolation (Chu et al. 1986). This study is limited by the fact that the high-dose 
dogs were inadvertently fed the wrong dose for part of the study period. In rats, biochemical and 
histological evidence of toxaphene-induced liver toxicosis was observed in F0 male and female rats fed 
toxaphene at 45 mg/kg/day for at least 26 weeks (Chu et al. 1988).
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Liver necrosis was observed in dogs chronically administered 5 mg/kg/day toxaphene in the feed (EPA 
1985c; summary of an unpublished report for Boots Hercules Agrochemicals). The unpublished report 
was not available to ATSDR. Histopathologic examinations of livers from male and female rats and mice 
receiving toxaphene from the diet for up to 80 weeks at estimated time-weighted average (TWA) doses as 
high as 78-83 mg/kg/day (rats) and 34 mg/kg/day (mice) revealed no evidence of treatment-related 
nonneoplastic lesions (NCI 1979). See Section 3.2.2.7 for discussion of cancer results from the NCI 
(1979) study. Bryce et al. (2001) noted no remarkable histopathology following examination of tissues 
(including liver) from cynomolgus monkeys administered 1 mg/kg/day of toxaphene by oral capsule for 
52 weeks.
Renal Effects. Little information was available regarding renal effects in humans following oral 
exposure to toxaphene. Renal function was temporarily compromised in a 26-year-old man who 
attempted suicide by ingesting an unknown quantity of a toxaphene-containing pesticide (Wells and 
Milhorn 1983). Swelling of the kidney was observed in a 2-year-old boy following acute exposure to a 
lethal amount of toxaphene (McGee et al. 1952).
Toxaphene has been shown to be nephrotoxic in laboratory animals. A single unspecified, but lethal, oral 
dose of toxaphene induced cloudy swelling of the proximal and distal convoluted tubules and congestion 
of the loop of Henle in rats (Boyd and Taylor 1971). However, no renal effects were seen in male rats 
exposed to up to 10 mg/kg/day of toxaphene in feed for 14 days (Trottman and Desaiah 1980). Renal 
injury has also been reported to occur following intermediate exposure to toxaphene. Guinea pigs given 
toxaphene orally at 2 or 5 mg/kg/day for 60 days exhibited histopathologic lesions that included intense 
vacuolation in the kidney's collection cells and glomerulus, cortical tubule cellular degeneration, and 
tubular epithelial cell vacuolation (Chandra and Durairaj 1992). Ultrastructural evaluation revealed an 
increase in the number of mitochondria in the tubular epithelial cells. However, NOAEL and LOAEL 
values for this study were not established because the study report did not include incidence data for the 
kidney lesions. Dose-dependent injuries of the proximal convoluted tubules that were focally severe were 
observed in rats fed 8.6 (males) and 12.6 (females) mg/kg/day toxaphene for 13 weeks (Chu et al. 1986). 
Chu et al. (1988) reported 18% increased kidney weight and renal tubular injury in male rats receiving 
toxaphene from the diet for 26 weeks at 45 mg/kg/day and renal tubular injury in similarly-treated female 
rats. However, Ortega et al. (1957) reported that a dose level of 10 mg/kg/day of toxaphene was not 
nephrotoxic to rats. Marked degenerative fatty changes of the kidney tubular epithelium were observed in 
dogs following intermediate-duration exposure to 4 mg/kg/day toxaphene (Lackey 1949). Eosinophilic
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inclusions that were occasionally accompanied by focal necrosis have also been observed in dogs after 
intermediate exposure to 2 mg/kg/day toxaphene (Chu et al. 1986).
Hematuria was reported in rats receiving toxaphene from the diet for up to 80 weeks at doses in the range 
of 39-83 mg/kg/day (NCI 1979). Bryce et al. (2001) noted no remarkable histopathology following 
examination of tissues (including kidney and urinary bladder) from cynomolgus monkeys administered 
toxaphene by oral capsule at 1 mg/kg/day for 52 weeks.
Endocrine Effects. No information was located regarding endocrine effects in humans following 
oral exposure to toxaphene.
Histopathological evidence of toxaphene-related effects on the thyroid gland (angular collapse of 
follicles, increased epithelial height with multifocal papillary proliferation, and reduced colloid density) 
of male rats was observed following intermediate-duration oral administration at 1.8 mg/kg/day (Chu et 
al. 1986). The morphological changes were dose-dependent, considered mild to moderate in severity, and 
adaptive in nature. The LOAEL for histopathologic thyroid lesions in female rats was 63 mg/kg/day; 
NOAELs were 0.35 mg/kg/day for males and 12.6 mg/kg/day for females. A similarly-designed study by 
Chu et al. (1988) found no evidence of treatment-related histopathological thyroid lesions at 
1.8 mg/kg/day (male rats) and 1.9 mg/kg/day (female rats).
In a 28-day gavage study designed to assess thyroid function in toxaphene-treated male rats, Waritz et al. 
(1996) reported significant (p<0.05) time-related increases in serum TSH and histopathological evidence 
of treatment-related effects that included increased incidences of thyroid follicular cell hypertrophy, 
diffuse intrafollicular hyperplasia, and decreased follicular size (indicative of depletion of colloid stores). 
This study employed a single dose level of 75 mg toxaphene/kg (100 mg/kg/day for the first 3 treatment 
days); the thyroid effects were considered to be associated with increased excretion of T3 and/or T4 
resulting from the induction of hepatic CYPs.
In a study of male rats receiving toxaphene from the diet for 14 days, respective mean relative thymus 
weights at estimated doses of 13.5 and 18 mg/kg/day were 36 and 27% lower than that of controls; these 
effects were not seen at doses of 4.5 or 9 mg/kg/day (Trottman and Desaiah 1980). In another rat study, 
dietary exposure at estimated doses up to and including 8.6 mg/kg/day (males) and 9.8 mg/kg/day 
(females) for 39-42 weeks did not affect spleen or thymus weights (Kennedy et al. 1973).
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Bryce et al. (2001) noted no remarkable histopathology following examination of tissues (including 
thyroid, pituitary, and adrenal glands) from cynomolgus monkeys administered toxaphene by oral capsule 
at 1 mg/kg/day for 52 weeks.
Dermal Effects. No information was located regarding dermal effects in humans following oral 
exposure to toxaphene.
Alopecia and rough hair coats were reported in rats and mice receiving toxaphene from the diet for up to 
80 weeks at estimated TWA doses >39 and >17 mg/kg/day, respectively (NCI 1979).
O cular Effects. No information was located regarding ocular effects in humans following oral 
exposure to toxaphene.
Available information in animals is limited to a report of inflammation and/or enlargement of tarsal 
glands of the eye in three of four cynomolgus monkeys and impacted diverticulae of the eyelid of all four 
monkeys during oral administration of toxaphene at 1 mg/kg/day for 52 weeks (Bryce et al. 2001).
Body W eight Effects. No information was located regarding body weight effects in humans 
following oral exposure to toxaphene.
The influence of oral toxaphene on body weight has been widely studied in laboratory animals. Some rat 
studies employed relatively low single- or multiple-dose levels (< 2 0  mg/kg/day) and found no evidence 
of toxaphene-induced body weight effects following acute- or intermediate-duration oral exposure 
(Crowder et al. 1980; Kennedy et al. 1973; Ortega et al. 1957; Trottman and Desaiah 1980). There was 
no evidence of toxaphene-related body weight effects in intermediate-duration multiple-dose studies of 
rats or mice where the highest toxaphene doses ranged from 26 to 39 mg/kg/day (Allen et al. 1983; Chu et 
al. 1986, 1988; Koller et al. 1983).
NCI (1979) found no evidence of a treatment-related effect on body weight in a range-finding study of 
male and female rats and mice administered toxaphene in the diet for 6 weeks at doses as high as 
242 mg/kg/day (rats) and 250 mg/kg/day (mice). However, in the subsequent chronic study that included 
80 weeks of dietary exposure to toxaphene, groups of male rats receiving toxaphene from the diet at 
131 and 270 mg/kg/day for the first 2 treatment weeks exhibited approximately 14 and 26% lower mean 
body weights, respectively, than their matched controls (NCI 1979). Throughout the remaining 78 weeks
S. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE 52
of treatment, which included two 50% reductions in toxaphene concentrations (after treatment weeks 2 
and 53 due to clinical signs of neurotoxicity), body weights of the toxaphene-treated male rats appeared 
similar to those of matched controls. Estimated TWA doses of approximately 42 and 83 mg/kg/day to the 
low- and high-dose female rats resulted in lower mean body weights throughout most of the study, as 
much as 10 and 16% lower than those of matched controls (NCI 1979). In the mouse portion of the study 
(estimated toxaphene doses of 17 and 34 mg/kg/day for the low- and high-dose groups, respectively), 
mean body weights of the high-dose males were slightly lower than those of matched controls; there 
appeared to be no treatment-related effects on body weight in low-dose males or low- or high-dose 
females.
Lackey (1949) reported weight loss during the initial portion of a study in which four dogs were 
administered toxaphene by oral capsule at 4 mg/kg/day for 44 or 106 days; convulsions were seen on 
occasion. Another dog study found no indication of treatment-related effects on body weight during oral 
dosing of toxaphene at 0.2-5 mg/kg/day for 13 weeks (Chu et al. 1986). There were no signs of 
treatment-related effects on body weight in cynomolgus monkeys administered toxaphene by oral capsule 
for 52-75 weeks, but doses were <1 mg/kg/day (Arnold et al. 2001; Bryce et al. 2001).
Available animal data indicate that pregnant rats may be particularly sensitive to toxaphene-induced 
effects on body weight. Rat dams administered toxaphene by gavage at 32 mg/kg/day (the only dose 
level tested) gained only 50% of the weight gained by control rats (Chernoff et al. 1990). In another 
developmental toxicity study, rat dams administered toxaphene by gavage at 15 mg/kg/day (the lowest 
dose tested) on gestation days 7-16 exhibited 22% decreased body weight gain relative to controls 
(Chernoff and Carver 1976). Crowder et al. (1980) found no evidence of treatment-related effects on 
body weight in pregnant rats administered toxaphene at 6 mg/kg/day (the only dose tested) from gestation 
day 7 to parturition.
3.2.2.3 Im m unological and Lym phoreticu lar Effects
No studies were located regarding immunological effects of toxaphene in humans following oral 
exposure.
Toxaphene has been reported to induce immunosuppressive effects (primarily humoral) in laboratory 
animals. Toxaphene impaired antibody (IgG) production at some, but not all, stages of the IgG response 
in male rats receiving toxaphene from the diet for 9 weeks at an estimated dose of 2.6 mg/kg/day (Koller
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et al. 1983). Similar results were obtained in female mice receiving toxaphene from the diet for 8 weeks 
at an estimated dose of 19.5 mg/kg/day, but not at 2 mg/kg/day (Allen et al. 1983). The study of Allen et 
al. (1983) found no evidence of a delayed hypersensitivity response.
Immunological end points have also been assessed in cynomolgus monkeys administered toxaphene by 
oral capsule for periods up to 75 weeks (Tryphonas et al. 2001). Groups of 10 female cynomolgus 
monkeys were administered toxaphene in capsules at doses of 0 (vehicle controls), 0.1, 0.4, or 
0.8 mg/kg/day for 75 weeks. Groups of male cynomolgus monkeys (5/group) were dosed at 0 (vehicle 
controls) or 0.8 mg/kg/day. Flow cytometry, lymphocyte transformation, natural killer cell activity, and 
serum cortisol levels were evaluated during treatment weeks 33-46. Immunization with SRBC was 
performed on treatment week 44 for a primary response and week 48 for a secondary response 
(observations made through treatment week 52). Immunizations with tetanus toxoid (TT) and 
pneumococcus antigens were performed on treatment week 53 (observations made through treatment 
week 63). Delayed type hypersensitivity testing was initiated on treatment week 66 and completed on 
treatment week 70. No treatment-related effects were observed in the 0.1 mg/kg/day group of treated 
female monkeys. Treatment with toxaphene at 0.4 mg/kg/day resulted in significant (p<0.05) reductions 
in mean primary anti-SRBC IgM responses (indicative of depressed humoral immunity) at post­
immunization weeks 1 and 4 (27 and 35% lower than that of controls) and secondary anti-SRBC IgM 
responses at post-immunization week 5 (10% lower than that of controls). The dose level of 
0.8 mg/kg/day resulted in significantly reduced mean primary anti-SRBC IgM responses at post­
immunization weeks 1-4, significantly reduced mean secondary anti SRBC IgM response at post­
immunization weeks 5 and 8, and significantly reduced primary anti-SRBC IgG responses at post­
immunization weeks 2 and 3 (51 and 43% lower than that of controls). In males, 0.8 mg/kg/day 
toxaphene induced a significant reduction in mean primary anti-SRBC IgM response at post­
immunization weeks 1-3. The mean anti-TT titers were significantly reduced in 0.8 mg/kg/day females 
at post-immunization weeks 2-4. Flow cytometry tests showed that the only effect on leukocyte and 
lymphocyte subsets was a reduction in absolute B lymphocytes (CD20) in 0.8 mg/kg/day females (62% 
lower than controls). There were no detectable treatment-related effects on natural killer cell activity, 
delayed type hypersensitivity, lymphoproliferative response to mitogens, or serum cortisol levels. The 
toxaphene-induced reduction in mean primary anti-SRBC IgM response served as the critical effect for 
deriving an intermediate-duration oral MRL for toxaphene.
All reliable LOAEL values for immunological and lymphoreticular effects in each species and duration 
category are recorded in Table 3-2 and plotted in Figure 3-2.
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Signs of central nervous system stimulation are the hallmark of acute toxaphene intoxication in both 
humans and animals. Case reports of accidental or intentional toxaphene ingestion indicate that 
toxaphene poisoning is usually accompanied by convulsive seizures that can be controlled with 
barbiturates or diazepam (McGee et al. 1952; Wells and Milhorn 1983). The dose necessary to induce 
nonfatal convulsions in humans has been estimated to be approximately 10 mg/kg (CDC 1963). 
Contaminated collard greens coated with toxaphene, eaten on empty stomachs, caused convulsive 
seizures followed by periods of memory loss in three females between the ages of 12 and 2 0 , as well as 
nausea in a 49-year-old woman (McGee et al. 1952).
Convulsions and other clinical signs of toxaphene-induced neurotoxicity have been observed in laboratory 
animals. Chandra and Durairaj (1995) reported clinical signs that included convulsions and sedation in 
guinea pigs receiving a single oral dose of toxaphene at 300 mg/kg. Lackey (1949) administered single 
gavage doses of toxaphene to dogs at doses ranging from 5 to 50 mg/kg and noted convulsions at dose 
levels >10 mg/kg. In the same study report, occasional convulsions were noted in dogs dosed at 
4 mg/kg/day during 44- and 106-day treatment periods. Single oral administration of toxaphene to heifer 
calves at 50-150 mg/kg elicited numerous clinical signs that included hyperexcitability, nystagmus, 
convulsions, and seizures (Steele et al. 1980). In a 13-week oral toxicity dog study, clinical signs of 
neurotoxicity (convulsions, salivation, and vomiting) were elicited during the first 2 days of oral dosing at 
10 mg/kg; these clinical signs were no longer elicited after the dose was reduced to 5 mg/kg/day on 
treatment day 3 (Chu et al. 1986). Tremors and nervousness were reported in rats administered toxaphene 
by gavage for 3 days at doses >25 mg/kg/day; a NOAEL was not identified (Rao et al. 1986). 
Hyperreflexia was observed in rats at an unspecified dose (Boyd and Taylor 1971).
In a chronic toxicity and carcinogenicity study of male and female rats and mice (NCI 1979), hyper­
excitability was reported in high-dose male rats during the first 2 weeks of exposure to toxaphene in the 
diet when the initial concentration (2,560 ppm) delivered an estimated dose of 270 mg/kg/day; this effect 
was not observed in male rats receiving 130 mg/kg/day or in groups of similarly-treated females receiving 
toxaphene at 70 or 147 mg/kg/day during the same 2-week period. Based on the hyperexcitability in the 
high-dose male rats, dietary concentrations were reduced by 50% at treatment week 3 and another 50% at 
treatment week 55 when generalized body tremors were noted in most high-dose male and female rats.
The study authors reported clinical signs that included tremors, leg paralysis, and ataxia from treatment
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weeks 52 through 80, predominantly in toxaphene-treated rats. In the mouse study, hyperexcitability was 
reported during treatment weeks 60-76 in the low-dose male mice (estimated dose of 17 mg/kg/day), but 
not in the high-dose males (34 mg/kg/day); there were no signs of hyperexcitability in either dose group 
(17 and 34 mg/kg/day) of female mice.
There were no clinical signs or histopathological evidence of toxaphene-induced neurological effects in 
male or female cynomolgus monkeys administered toxaphene in a daily capsule for 52 weeks at 
1 mg/kg/day (Bryce et al. 2001).
The electroencephalographic (EEG) pattern of squirrel monkeys was altered by exposure to 1 mg/kg 
toxaphene (Santolucito 1975). In addition to affecting behavior, an oral dose of 120 mg/kg toxaphene 
was reported to alter brain catecholamine metabolism in rats (Kuz'minskaya and Ivanitskiî 1979).
Badaeva (1976) reported brain cell death in pregnant rats gavaged with toxaphene at 12 mg/kg/day during 
gestation. However, the methods used to identify the lesions are not well described in this study and the 
effects were not quantitatively evaluated.
Dietary administration of toxaphene to rats for 14 days at estimated doses as high as 18 mg/kg/day did not 
affect whole brain weight in rats (Trottman and Desaiah 1980), but this is a gross measure and effects on 
specific neuronal populations would not be detected by this measure. Toxaphene-related decreases in 
brain weight were reported in guinea pigs following a single oral dose of 300 mg/kg toxaphene (Chandra 
and Durairaj 1992). The same exposure scenario resulted in a significant decrease of brain phospholipid 
content and a significant increase in brain neutral lipid and cholesterol content (Chandra and Durairaj 
1995). Similar effects were observed in other guinea pigs receiving toxaphene by gavage at 5 mg/kg/day 
for 60 days (Chandra and Durairaj 1995). However, the toxicological significance of these finding is 
uncertain.
The highest NOAEL values and all reliable LOAEL values for neurological effects for each species and 
duration category are reported in Table 3-2 and plotted in Figure 3-2.
Oral toxicity animal studies that assessed neurodevelopmental end points are summarized in Section 3.2.6 
(Developmental Effects).
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3.2.2.5 Reproductive Effects
No studies were located regarding reproductive effects in humans following oral exposure to toxaphene.
Testicular weight was not affected in rats receiving toxaphene from the diet for 14 days at estimated doses 
as high as 18 mg/kg/day (Trottman and Desaiah 1980). Vaginal bleeding was reported in rats receiving 
toxaphene from the diet for 80 weeks at estimated TWA doses of 41.6 and 83.3 mg/kg/day; incidence 
data were not provided in the study report (NCI 1979). There were no effects on litter sizes, pup survival, 
or weanling body weights and no evidence of treatment-related teratogenic effects in a three-generation 
study of male and female rats that received toxaphene from the diet for up to 42 weeks at estimated doses 
as high as 8.6 and 9.8 mg/kg/day, respectively (Kennedy et al. 1973). In another reproductive toxicity 
study (Chu et al. 1988), fertility and offspring growth and viability were not affected by dietary exposure 
of male and female rats to toxaphene at estimated doses as high as 45-46 mg/kg/day; the treatment period 
included 13 weeks prior to mating and continued through the production of F1a and F1b litters. Plasma 
testosterone levels were not affected in male rats administered a single gavage dose of 120 mg toxaphene/ 
kg/day or in other rats dosed at 2.6 mg/kg/day for up to 6 months (Peakall 1976).
Keplinger et al. (1970) performed a multi-generation reproductive toxicity study in which male and 
female Swiss mice received toxaphene from the diet at estimated dose of 4.5 and 4.9 mg/kg/day, 
respectively, through the production of five generations of offspring. There were no indications of 
toxaphene-related adverse effects on lactation, reproduction, average litter size, or offspring growth or on 
viability through five generations.
Bryce et al. (2001) noted no remarkable histopathology following examination of tissues (including 
reproductive tissues) from cynomolgus monkeys administered toxaphene by oral capsule at 1 mg/kg/day 
for 52 weeks. Arnold et al. (2001) found no evidence of toxaphene-related effects on menstrual cycle in 
cynomolgus monkeys administered the chemical in capsules at daily doses ranging from 0.1 to 
0.8 mg/kg/day for up to 75 weeks.
The highest NOAEL values for reproductive effects in each species and duration category are recorded in 
Table 3-2 and plotted in Figure 3-2.
3.2.2.6 Developmental Effects
No studies were located regarding developmental effects in humans following oral exposure to toxaphene.
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Available developmental toxicity studies in animals indicate that toxaphene is not teratogenic. No major 
anatomical defects were seen in rat or mouse fetuses following gestational oral exposure of pregnant 
dams at doses in the range 0.05 to 75 mg/kg/day (Allen et al. 1983; Chemoff and Carver 1976; Chemoff 
and Kavlock 1982; Chemoff et al. 1990; Crowder et al. 1980; Kavlock et al. 1982; Kennedy et al. 1973; 
Olson etal. 1980).
Toxaphene (15, 25, or 35 mg/kg/day) administered to mice by gavage from gestational days 7-16 
produced no adverse effects on fetal growth, viability, or gross morphology even though the toxaphene- 
treated dams displayed dose-dependent reductions in weight gain (Chemoff and Carver 1976). Keplinger 
et al. (1970) found no evidence of treatment-related effects on litter size or offspring growth and viability 
in mice receiving toxaphene from the diet at approximate doses of 4.5-5 mg/kg/day throughout the 
production of five generations of offspring.
Some of the available developmental toxicity animal studies reported treatment-related effects on 
development. Chemoff and Kavlock (1982) noted transient decreases in offspring body weight on 
postnatal day 1 following gavage administration of toxaphene to rat dams at 75 mg/kg/day on gestation 
days 8-12; however, the dose was maternal toxic, as evidenced by 2/25 maternal deaths and >45% 
depressed maternal weight gain. Chemoff et al. (1990) reported significantly increased incidences of 
supernumerary ribs in fetuses from rat dams gavaged at 32 mg/kg/day during gestation days 6-15; 
however, 50% of the treated dams died. Chemoff and Carver (1976) reported significantly decreased 
numbers of sternal ossification centers in 21-day-old fetuses from rat dams administered toxaphene by 
gavage at 15 or 25 mg/kg/day during gestation days 7-16, but not at a dose level of 35 mg/kg/day.
Kavlock et al. (1982) reported significantly decreased renal protein in the kidneys of 21-day-old rat 
fetuses whose mothers had been administered toxaphene by gavage at 12.5 or 25 mg/kg/day during 
gestation days 7-16 and significantly decreased alkaline phosphatase activity in fetal kidneys of the 
25 mg/kg/day dose group.
Allen et al. (1983) assessed immunological end points in 8-week-old offspring of mouse dams that had 
received toxaphene from the diet at estimated doses of 2, 19.5, or 39 mg/kg/day for 3 weeks premating 
and throughout mating, gestation, and lactation. Assessment included a delayed-type hypersensitivity 
assay for cell-mediated immune response, an enzyme-linked immunosorbent assay for humoral immune 
response, and a phagocytosis assay to assess the ability of peritoneal macrophages to engulf SRBCs.
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Toxaphene treatment resulted in significant suppression of macrophage phagocytic function in the 
offspring at all dose levels (32, 79, and 63% suppression in the 2, 19.5, and 39 mg/kg/day dose groups, 
respectively) compared to controls. The humoral antibody response was significantly suppressed at
19.5 mg/kg/day, but was significantly enhanced at 39 mg/kg/day. The cell-mediated immune response 
was suppressed at 19.5 mg/kg/day, but was not significantly different from controls at the low- and high­
dose levels. These results indicate that the perinatal immunological system may be at risk for toxaphene 
toxicity.
Crowder et al. (1980) assessed the effects of toxaphene on results of selected behavioral tests (grasp-hold, 
righting, startle, and placing reflexes; open field and maze performance) in pups from rat dams 
administered toxaphene by gavage at 6 mg/kg/day during mating and throughout gestation (Crowder et al. 
1980). Reflex testing, initiated at 7 days postpartum, revealed no significant treatment-related effects on 
performance; however, the study authors stated that 3 more days were required for 90% of the pups from 
the toxaphene-treated group to correctly respond in the righting reflex test compared to control pups 
(p<0.05). There were no significant differences between toxaphene-treated groups and control in maze 
performance assessed beginning at 55 days postpartum.
Olson et al. (1980) examined the effects of toxaphene on selected behavioral parameters in pups of rat 
dams ingesting the chemical at 0.05 mg/kg/day from gestation day 5 until postpartum day 30. Tests of 
swimming ability and righting reflex were performed daily on postpartum days 7-16. Significantly 
retarded swimming ability was noted on postpartum days 10 (p<0.001), 11 (p<0.0001), and 12 (p<0.05); 
however, the effect was transient and pups exhibited normal swimming ability at testing on postpartum 
day 16. The study authors stated that pups of the toxaphene treatment group also exhibited significantly 
retarded overall righting reflex (p<0.005), but quantitative data were not provided in the study report. 
Maze testing, initiated on postpartum day 70, revealed no apparent treatment-related effect.
The highest NOAEL values and all reliable LOAEL values for developmental effects in each species and 
duration category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.7 Cancer
No studies were located regarding cancer in humans following oral exposure to toxaphene.
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NCI (1979) assessed the toxicity and carcinogenicity of toxaphene in groups of male and female Osborne- 
Mendel rats and male and female B6C3F1 mice exposed to the chemical for 80 weeks via the diet 
followed by 28-30 weeks of recovery prior to terminal sacrifice. Among the mice, respective incidences 
of neoplastic liver nodules or hepatic carcinomas (combined) in concurrent controls, pooled controls, and 
low- and high-dose animals were 2/10, 7/48, 40/49, and 45/46 for males and 0/9, 0/48, 18/49, and 
40/49 for females. Incidences at the low- and high-dose levels (estimated TWA doses of 77.9 and 
83.3 mg/kg/day, respectively) were significantly higher than those of respective concurrent controls. 
Among the rats, incidences of thyroid follicular cell adenomas or carcinomas (combined) in concurrent 
controls, pooled controls, and low- and high-dose animals were 1/7, 2/44, 7/41, and 9/35 for males and 
0/6, 1/46, 1/43, and 7/42 for females. Incidences in high-dose male and female rats (estimated TWA 
doses of 77.9 and 83.3 mg/kg/day, respectively) were significantly higher than those of respective 
controls. Significantly increased incidences of hepatocellular carcinomas were observed in low- and 
high-dose (17 and 34 mg/kg/day, respectively) male mice and high-dose (34 mg/kg/day) female mice. In 
light of more contemporary diagnostic criteria for classification of histopathological liver tumors, an 
expert pathology working group (PWG) was convened to review the original liver slides from the male 
and female mice. A primary report of the PWG findings was not available to ATSDR. However, 
Goodman et al. (2000) provided a summary of the results which indicates that, although many of the 
tumors originally classified as carcinomas were reclassified as adenomas, the incidences of reclassified 
combined adenomas or carcinomas were similar to the incidences of combined neoplastic nodules or 
carcinomas presented in the original study report.
Litton Bionetics, Inc. produced an unpublished report of a cancer bioassay in mice administered 
toxaphene in the diet. The study results were summarized by EPA in an Ambient Water Quality Criteria 
document (EPA 1980a). EPA’s Integrated Risk Information System includes a summary for toxaphene in 
which the results of the unpublished study were used by EPA to derive an oral slope factor (IRIS 2010). 
The following summary of the unpublished study was extracted from EPA (1980a) because the study was 
not available to ATSDR: Groups of male and female B6C3F1 mice (54/sex/group) were administered 
toxaphene in the diet at 0, 7, 20, or 50 ppm for 18 months followed by a 6-month observation period. 
Based on EPA (1988d) chronic reference values for body weight and food consumption in male and 
female B6C3F1 mice, respective estimated doses were 0, 1.2, 3.4, and 8.6 mg/kg/day for the males and 0, 
1.2, 3.5, and 8.6 mg/kg/day for the females. At unscheduled or terminal sacrifice, histopathological 
evaluation of major organs was initiated. A statistically significant (p=0.048) excess of hepatocellular 
tumors (adenomas plus carcinomas) was noted in the high-dose male mice (18/51 versus 10/53 in 
controls). The Cochran Armitage trend test was significant (p=0.020) for dose-related increased
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incidence of hepatocellular tumors in the male mice. There were no significant treatment-related effects 
on the incidence of hepatocellular tumors in any group of treated female mice.
In a study designed to assess the effect of insecticides (including toxaphene) on the induction of lung 
tumors by benzo[a]pyrene, toxaphene was given to female A/J mice (11-12/group) for 12 weeks at 0,
100, or 200 ppm (Triolo et al. 1982). The study assessed a limited number of end points and found no 
evidence for toxaphene-related lung or stomach tumors.
The oral doses associated with individual, lifetime upper-bound cancer risk of 10"4-10"7 are 9x10-5-  
9x10-8 mg/kg/day, assuming that a 70-kg human ingests 2 L water/day. The 10"4-10"7 risk levels are 
indicated in Figure 3-2.
3.2.3 Dermal Exposure
3.2.3.1 Death
No studies were located regarding lethal effects in humans following dermal exposure to toxaphene.
Acute dermal LD50 values obtained in laboratory animals range from 780 to 4,556 mg/kg (Gaines 1969; 
Industrial Biotest 1973; Johnston and Eden 1953; Jones et al. 1968). All of these studies except Gaines 
(1969) reported LD50 values of 1,075 and 780 mg/kg/day for male and female Sherman rats, respectively; 
these values are plotted in Table 3-3. The other studies are limited in design and/or reporting which 
preclude their inclusion in Table 3-3.
3.2.3.2 System ic Effects
No studies were located regarding cardiovascular, musculoskeletal, endocrine, or body weight effects in 
humans or animals following dermal exposure to toxaphene. The highest NOAEL values and all reliable 
LOAEL values for systemic effects in each species and duration category are recorded in Table 3-3.
Respiratory Effects. In humans, fluoroscopic examination of the lungs following acute dermal 
exposure to 500 mg/m3 toxaphene did not reveal abnormalities (Keplinger 1963).
Toxicosis was observed in a herd of pigs that had been treated with a 61% toxaphene solution (equivalent 
to 13.5 g/kg). The symptoms generally subsided when the animals were sprayed with warm water
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Table 3-3 Levels of Significant Exposure to Toxaphene - Dermal
Species
(Strain)
Exposure/
Duration/
Frequency
(Route)
LOAEL
System NOAEL Less Serious Serious
Reference 
Chemical Form Comments
ACUTE EXPOSURE
Death
Rat once
(Sherman) 1G75 M (LD5G) 
mg/kg
Gaines 1969
78G F (LD5G) 
mg/kg
Systemic
Rabbit
(New
Zealand)
4 hr Dermal 130 B (erythema and edema) 
mg/kg
International Research and 
Development Corporation 1973
Pig
(NS)
Resp 13500 (lung congestion and
mg/kg presence of peribronchii
lymphoid follicles)
Dipietro and Haliburton 1979
Renal 13500 (cystic kidney cortex) 
mg/kg
Neurological
Pig
(NS) 13500 (convulsions) 
mg/kg
Dipietro and Haliburton 1979
B = both; hr = hour(s); LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; NS = not specified; Resp : 
respiratory
once
once
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(DiPietro and Haliburton 1979). Various lung lesions were observed in three affected pigs that were not 
treated for toxicosis by spraying with warm water. These lesions differed in the three affected pigs 
examined and included congested cranial lung lobes, numerous peribronchial lymphoid follicles, and 
moderate congestion of the lungs. Hyperemic lungs also were observed in rabbits that died following a 
24-hour dermal application of 3,038 mg/kg toxaphene (Industrial Biotest 1973). It should be noted that 
some studies performed by Industrial Biotest have been found to be less than reliable; thus, the accuracy 
of the above data cannot be assured.
G astro intestinal Effects. No studies were located regarding gastrointestinal effects in humans 
following dermal exposure to toxaphene.
Dilation of veins and intestinal hemorrhage were observed in rabbits dipped in an unspecified dose 
suspension of a wettable powder of toxaphene for 2 minutes (Johnston and Eden 1953).
Hematological Effects. In humans, blood tests conducted after acute dermal exposure to 500 mg/m3 
toxaphene did not reveal any abnormalities (Keplinger 1963).
No studies were located regarding hematological effects in animals following dermal exposure to 
toxaphene.
Hepatic Effects. No studies were located regarding hepatic effects in humans following dermal 
exposure to toxaphene.
Rabbits dipped in an unspecified dose suspension of a wettable powder of toxaphene for 2 minutes had 
pale and mottled livers (Johnston and Eden 1953). Toxaphene applied to intact or burned skin of rabbits 
for 24 hours caused enlarged gall bladders in both the intact and burned groups at doses >3,038 mg/kg 
(Industrial Biotest 1973).
Renal Effects. In humans, urinalysis conducted after acute dermal exposure to 500 mg/m3 toxaphene 
did not reveal any abnormalities (Keplinger 1963).
In pigs, cysts were found in the renal cortex after acute dermal exposure to 13.5 mg/kg/day toxaphene 
(DiPietro and Haliburton 1979).
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Dermal Effects. In humans, acute dermal exposure to 500 mg/m3 toxaphene did not produce dermal 
irritation (Keplinger 1963).
Dermal application of 3,038 mg/kg toxaphene (90% weight to volume [w/v] ratio in xylene) to the skin of 
rabbits caused moderate to severe edema and erythema followed by severe desquamation following a 
24-hour exposure (Industrial Biotest 1973). The skin irritation may have been caused by xylene, which 
has been reported to cause dermal irritation in guinea pigs (Anderson et al. 1986). Exposure to toxaphene 
(500 mg) for 4 hours caused rabbit skin to be only mildly irritated (International Research and 
Development Corporation 1973).
O cular Effects. No studies were located regarding ocular effects in humans following dermal 
exposure to toxaphene.
Mild irritation to the eyelids and loss of eyelid hair were observed after 14 applications of a 20% 
toxaphene solution in kerosene to the eyes of guinea pigs. The eyes were not affected, and the lids 
cleared completely in 10 days (EPA 1985c; summary of an unpublished report for Boots Hercules 
Agrochemicals). The unpublished report was not available to ATSDR.
3.2.3.3 Im m unological and Lym phoreticu lar Effects
No studies were located regarding immunological or lymphoreticular effects in humans or animals 
following dermal exposure to toxaphene.
3.2.3.4 Neurological Effects
No studies were located regarding neurological effects in humans following dermal exposure to 
toxaphene.
Signs of central nervous system toxicity were observed in 40 of 150 pigs 36 hours after being sprayed 
with 300 mL of a 61% toxaphene solution in water (equivalent to 13.5 g/kg). This dose is about 10 times 
the recommended dose for treatment of sarcoptic mange (DiPietro and Haliburton 1979). Inhalation 
and/or oral exposure may have also occurred. Clinical signs included head-pressing, ataxia, depression, 
lethargy, diarrhea, and convulsive seizures. Within a day after spraying with warm water, the animals 
were much improved, and complete recovery was seen within 5 days. Muscular weakness was reported 
in rabbits exposed by 24-hour dermal application of a 90% w/v solution of toxaphene in xylene at doses
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>6,834 mg/kg, but not at doses <4,556 mg/kg (Industrial Biotest 1973); however, this study was limited in 
that the solvent, xylene, was not tested alone. Similar dermal application to burned skin resulted in 
muscular weakness at doses >3,038 mg/kg; there was no indication of muscular weakness at a dose of 
2,025 mg/kg.
No studies were located regarding the following effects in humans or animals following dermal exposure 
to toxaphene:
3.2.3.5 Reproductive Effects
3.2.3.6 Developmental Effects
3.2.3.7 Cancer
3.3 GENOTOXICITY
Table 3-4 summarizes available in vivo genotoxicity information for toxaphene.
A higher incidence of chromosomal aberrations was observed in cultured lymphocytes taken from the 
blood of eight women exposed to toxaphene than in lymphocytes taken from unexposed women (Samosh
1974). The exposed women had entered a field that had recently been sprayed with an analog of 
toxaphene and were described as presenting "mild to moderate" clinical symptoms. The nature of the 
symptoms was not reported. The women were likely to have been exposed by both inhalation and dermal 
routes.
In a dominant lethality test, toxaphene did not cause increased fetal death or decreased numbers of 
implants in mouse dams mated to males that had been administered toxaphene orally at doses of 40 or 
80 mg/kg/day for 5 days or by single intraperitoneal injection at 36 or 180 mg/kg (Epstein et al. 1972). 
Mortality was noted in 9/12 and 2/9 of the high-dose orally- and intraperitoneally-exposed males, 
respectively, indicating that sufficiently high doses were tested.
Toxaphene did not cause liver deoxyribonucleic acid (DNA) damage in 90-day-old female 
Sprague-Dawley rats administered the chemical twice (21 and 4 hours prior to sacrifice) by gavage at up 
to 36 mg/kg/dose (Kitchin and Brown 1994). Hedli et al. (1998) found no evidence of DNA adduct 
formation in livers of male CD-1 mice administered toxaphene by gavage for 7 days at doses up to and 
including 100 mg/kg/day.
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Table 3-4. Genotoxicity of Toxaphene In Vivo
Species (test system) End point Results Reference
Mammalian systems
Human lymphocytes/occupational Chromosomal aberrations - Samosh 1974
exposure
Mouse dominant lethal test Gene mutation - Epstein et al. 1972
Mouse liver cells DNA adducts - Hedli et al. 1998
-  = negative
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Toxaphene was mutagenic in reverse mutation assays using Salmonella typhimurium strains TA98 and 
TA100 (containing the pKm101 plasmid) in the absence of metabolic activation systems (Hooper et al. 
1979; Mortelmans et al. 1986; Schrader et al. 1998; Steinberg et al. 1998). However, mutagenic 
responses were diminished or abolished with the addition of metabolic activation systems (Hooper et al. 
1979; Schrader et al. 1998). Negative or only weakly positive results were obtained in reverse mutation 
assays using S. typhimurium strains TA 1535 and TA1537 (non-plasmid containing strains). Young et al. 
(2009) reported weakly mutagenic responses in S. typhimurium strain TA100 in the presence and absence 
of exogenous metabolic activation.
Hooper et al. (1979) determined that certain components of the mixture of chemicals making up technical 
toxaphene were much less mutagenic than the mixture as a whole. Specifically, the components that were 
considered to possess the highest insecticidal or acute mammalian toxicity activity (e.g., 
heptachlorobornane, gem-dichloro components, and nonpolar fractions) were less mutagenic to S. 
typhimurium strain TA100 than was the complete toxaphene mixture (or the polar fraction). These 
findings may have relevance to public health in that the components of complex mixtures such as 
toxaphene may distribute unevenly in the environment (see Chapter 6).
Mortelmans et al. (1986) reported positive results for gene mutation in N. crassa in the absence of 
metabolic activation. Positive results were obtained in an assay for the induction of X prophage in 
Escherichia coli (Houk and DeMartini 1987). Significantly increased frequency of sister chromatid 
exchanges in the presence and absence of metabolic activation (S9) were reported in a cultured cell line 
derived from human lymphoid cells; however, the increases were <2 -fold greater than solvent controls 
(Sobti et al. 1983). Significantly increased frequency of sister chromatid exchanges were observed in 
toxaphene-treated Chinese hamster lung cells; the increase was slightly <2-fold higher than that of 
controls (Steinel et al. 1990). Toxaphene did not significantly increase the frequency of sister chromatid 
exchanges in Chinese hamster V79 cells with or without metabolic activation and did not significantly 
alter the frequency of HGPRT mutations at concentrations up to and including those resulting in 
cytotoxicity (Schrader et al. 1998). Bartos et al. (2005) reported positive results for toxaphene-induced 
DNA damage in an SOS Chromotest using E. coli PQ37 in the absence of metabolic activation, but 
reported negative results in a umuC test for DNA damage in S. typhimurium strain TA1535/pSK1002 in 
the absence of metabolic activation. Both assays test induction of the SOS repair system. Toxaphene did
3. HEALTH EFFECTS
Table 3-5 summarizes available in vitro genotoxicity information for toxaphene.
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE 67
3. HEALTH EFFECTS
Table 3-5. Genotoxicity of Toxaphene In Vitro
Results
Species (test system) End point
With Without 
activation activation Reference
Prokaryotic organisms
Salmonella typhimurium strain 
TA100
Gene mutation - + Hooper et al. 1979
S. typhimurium strain TA98 Gene mutation ND + Hooper et al. 1979
S. typhimurium strain TA98 Gene mutation - + Mortelmans et al. 1986
S. typhimurium strain TA100 Gene mutation + + Mortelmans et al. 1986
S. typhimurium strain TA1535 Gene mutation - - Mortelmans et al. 1986
S. typhimurium strain TA1537 Gene mutation - (+) Mortelmans et al. 1986
S. typhimurium strain TA98 Gene mutation ND + Steinberg et al. 1998
S. typhimurium strain TA100 Gene mutation ND + Steinberg et al. 1998
S. typhimurium strain TA100 Gene mutation + + Young et al. 2009
S. typhimurium strain TA97 Gene mutation (+) + Schrader et al. 1998
S. typhimurium strain TA98 Gene mutation (+) + Schrader et al. 1998
S. typhimurium strain TA100 Gene mutation + + Schrader et al. 1998
S. typhimurium strain TA102 Gene mutation - - Schrader et al. 1998
S. typhimurium strain TA104 Gene mutation (+) (+) Schrader et al. 1998
S. typhimurium strain TA1535 DNA damage 
(umuC test)
NT - Bartos et al. 2005
Escherichia coli K-12 A prophage 
induction
+ + Houk and DeMarini 
1987
E. coli PQ37 DNA damage 
(SOS chromotest)
NT + Bartos et al. 2005
Plasmid DNA isolated from E. 
coli
DNA damage ND - Griffin and Hill 1978
Fungi and plant systems Gene mutation
Neurospora crassa Gene mutation ND + Mortelmans et al. 1986
Mammalian cells
Human lymphoid cells LAZ-007 Sister chromatid 
exchange
- - Sobti et al. 1983
Chinese hamster V79 fibroblasts Gene mutation - - Schrader et al. 1998
Chinese hamster V79 fibroblasts Sister chromatid 
exchange
- NT Schrader et al. 1998
Chinese hamster lung (Don) 
cells
Sister chromatid 
exchange
NT ± Steinel et al. 1990
ND = no data; NT = not tested; -  = negative; + = positive; (+) = weakly positive; (±) = equivocal
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not induce DNA damage in plasmid DNA isolated from E. coli in the absence of metabolic activation 
(Griffin and Hill 1978).
In summary, the weight of evidence from available in vitro assays indicates that toxaphene is genotoxic. 
Only limited information was located regarding the potential genotoxicity of toxaphene in vivo.
3.4 TOXICOKINETICS
Studies in laboratory animals indicate that toxaphene is well absorbed by the intestinal tract and probably 
well absorbed by the lungs. Dermal absorption has also been demonstrated. Once absorbed, toxaphene 
distributes throughout the body. Studies using radiolabeled toxaphene indicate that distribution to fat 
predominates over distribution to other organs, and levels are detectable in fat tissue for several months 
following exposure. Toxaphene is rapidly and extensively degraded in mammals following oral 
administration. In vivo and in vitro studies indicate that the principal metabolic pathways involve 
dechlorination, dehydrodechlorination, and oxidation. Conjugation is also likely, but it is not a major 
route of metabolism. The primary route of excretion is via the feces (70% of an administered dose), but 
toxaphene is also excreted in the urine.
3.4.1 Absorp tion
3.4.1.1 Inhalation Exposure
Limited human data indicate that inhaled toxaphene is absorbed (Keplinger 1963; Warraki 1963); 
however, no quantitative data are available. Limited unpublished animal data also indicate that inhaled 
toxaphene is absorbed; hepatic effects were reported in rats that survived inhalation exposure to 
toxaphene dust (4 or 12 mg/m3) for 3 months (cited in EPA 1985c as an unpublished report for Hercules 
Incorporated; the primary report was not available to ATSDR).
3.4.1.2 Oral Exposure
No data were located regarding the extent of oral absorption of toxaphene in humans. However, accounts 
of death and systemic effects from accidental ingestion of toxaphene-contaminated food provide evidence 
that gastrointestinal absorption occurs (McGee et al. 1952).
The presence of toxaphene residues in the fat of rats (Mohammed et al. 1985; Pollock and Kilgore 1980b; 
Saleh and Casida 1978; Saleh et al. 1979), mice (Crowder and Whitson 1980; Saleh et al. 1979), guinea
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pigs, hamsters, rabbits, monkeys, and chickens (Saleh et al. 1979) following ingestion demonstrates that 
ingested toxaphene is absorbed. The identification of toxaphene in the milk of cows following ingestion 
is also evidence of its absorption (Claborn et al. 1963; Zweig et al. 1963).
Although there are no direct studies regarding the extent of toxaphene absorption, 56.5% of an orally 
administered dose was present in the feces and 9% of the dose was present in the urine of rats, mostly as 
metabolites. Very little was present as the parent compound, indicating that considerable metabolism had 
occurred (Chadurkar and Matsumura 1979). Less than 10% of the administered dose was detected in 
tissues 1 day after oral administration of radiolabeled toxaphene to rats, suggesting that absorption and 
redistribution may have occurred over the 24 hours following administration (Crowder and Dindal 1974). 
The proportion of the administered dose that was not redistributed may have been metabolized and 
eliminated.
The data presented above suggest that toxaphene would be absorbed by humans following the 
consumption of drinking water or food contaminated with the chemical. Its absorption appears to be 
extensive and is enhanced when it is dissolved in a vehicle that is readily absorbed. The bioavailability of 
toxaphene is increased when it is administered in or with vegetable oils like corn oil or peanut oil, and the 
toxicity of toxaphene is potentiated (EPA 1980a). Thus, toxaphene may be more toxic when ingested in 
oily foods than when ingested in contaminated water.
3.4.1.3 Dermal Exposure
No studies were located in humans regarding the dermal absorption of toxaphene.
The detection of high toxaphene levels in cow's milk (21-45 ppm) after dipping the cattle in a toxaphene 
solution (0.25% w/w toxaphene plus 0.03% w/v dioxathion) indicates that toxaphene is absorbed 
following dermal exposure (Keating 1979). Toxaphene toxicosis was reported in swine 36 hours after the 
dermal application of toxaphene in a 61% solution (equivalent to 13.5 g/kg) (DiPietro and Haliburton
1979).
Under conditions of high dosage, dermal absorption of toxaphene may be efficient enough to cause 
toxicosis or to produce detectable residues in cow’s milk. Toxaphene appears to be well absorbed 
following dermal exposure in animals, but the extent of absorption has not been quantified. Other
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evidence suggests that absorption in humans may also be substantial following dermal exposure 
(Keplinger 1963).
3.4.2 D istribution
3.4.2.1 Inhalation Exposure
No studies were available in humans or animals regarding the distribution of toxaphene following 
inhalation exposure. Although cases of inhalation exposure have been reported, there were no data that 
detailed distribution of toxaphene residues in various tissues.
3.4.2.2 Oral Exposure
Limited information is available regarding distribution in humans following oral exposure to toxaphene. 
Toxaphene residues have been detected in samples of adipose tissue taken from children (Witt and 
Niessen 2000) and in maternal and cord blood (Butler Walker et al. 2003). Ingestion of contaminated 
food, particularly fish and marine mammals, was the assumed exposure route.
Results of tissue analysis following the oral administration of radiolabeled toxaphene to rats indicate that 
fat is the principal storage tissue (Ohsawa et al. 1975; Pollock and Kilgore 1980b). Other evidence in 
animals indicates that muscle may also be a storage site for toxaphene as suggested by the observation of 
a high distribution of toxaphene in muscle following an oral dose in rats, and by evidence that toxaphene 
residues persist in muscle for up to 20 days post-administration (Crowder and Dindal 1974). The oral 
administration of 14C-toxaphene in olive oil to rats at a dose of 10 mg/kg resulted in toxaphene residue 
levels of 6.4 mg/kg in fat 7 days following administration. Residue levels in all other tissues were 
<0.2 mg/kg (Pollock and Kilgore 1980b). The oral administration of 14C-toxaphene in corn oil to rats at 
doses of 19 and 8.5 mg/kg resulted in residue levels of 0.78 and 0.52 mg/kg, respectively, in fat 7 days 
after administration. Residue levels in all other tissues were <0.3 mg/kg (Ohsawa et al. 1975). Although 
the levels detected in fat by Pollock and Kilgore (1980b) are higher than those detected by Ohsawa et al. 
(1975), a direct comparison cannot be made because the two studies used different sized rats, analyzed 
their tissues at different times after administration, and used different vehicles.
The highest level of activity, except for the gastrointestinal tract, was in the brown fat following 
administration of 16 mg/kg 14C-toxaphene in peanut oil to rats (Mohammed et al. 1985). High 
concentrations of toxaphene residues were also detected in the adrenal cortex, bone marrow, liver, and
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kidney. Levels of radioactive residues peaked at 3 hours. At 24 hours after administration, most 
radioactivity was found in the white fat. Lesser amounts of the radiolabel were detected in liver and 
kidney.
Mice that received an oral dose of 25 mg/kg 36Cl-toxaphene in corn oil retained 36Cl activity in fat, brain, 
kidney, liver, muscle, and testes. Levels were highest in fat (10.6 ppm) when tissues were analyzed 
8 days after administration (Crowder and Whitson 1980).
Toxaphene and its metabolites were detected in the liver, kidney, bone, brain, heart, lung, muscle, spleen, 
and testes of rats 7 days after the oral administration of 8.5 and 19 mg/kg 14C-toxaphene (Ohsawa et al.
1975). After the oral administration of a single dose of 20 mg/kg 36Cl-toxaphene to rats, the greatest 
levels of radioactivity were seen at 12 hours in almost all tissues. Levels in blood cells peaked after 
3 days. The total fat content after 12 hours was only 0.86% of the total dose, but this exceeded the 
fraction of the dose found in the kidney (0.43%), testes (0.28%), and brain (0.23%) (Crowder and Dindal 
1974). Approximately 77% of the dose was detected in the stomach at 12 hours, and <10% of the dose 
remained in the body after 1 day. At 12 hours after administration, 5.3% of the dose was present in the 
muscle. Although this was significantly more than the amount seen in fat and other tissues, the 
concentration of activity in muscle is low due to the large amount of muscle in the body. Crowder and 
Dindal (1974) only determined the fraction of the dose based on proportions of radioactivity found in 
each tissue that may have been derived from a component of the original mixture or a metabolite.
Cynomolgus monkeys were administered toxaphene in glycerol/corn oil via gelatin capsule at 
1 mg/kg/day for 1 year (Andrews et al. 1996). At 10 weeks, the blood levels appeared to peak out at 
approximately 40 ppb; levels in adipose tissue leveled out at 4,000 ppb between weeks 15 and 20.
Heifer calves receiving toxaphene at oral bolus doses of 50, 100, or 150 mg/kg 14C-toxaphene had 
measurable toxaphene residues in the liver, kidney, and brain 7 days after administration. These tissues 
were the only ones sampled, so it is not possible to assess the amount of toxaphene that distributed to fat 
(Steele et al. 1980). This study found that liver residues varied exponentially with dosage, as shown in 
Table 3-6.
Furthermore, liver residue levels correlated with predicted fatality with an accuracy of about 80%. Based 
upon these tissue distribution results, the authors concluded that liver residue values could serve as a 
biomarker of toxaphene poisoning. Kidney and brain levels of toxaphene could not be used as
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Table 3-6. Mean Toxaphene Residues in Cows Following Oral Exposure to
Toxaphene
Dose (mg/kg)
Toxaphene residue
Liver
(ppm)
Kidney
(ppm)
Brain
(ppm)
50a 2.88 3.45 2.67
100b 7.66 2.75 4.02
150a 22.26 5.50 3.88
aValues represent mean of six animals. 
bValues represent mean of seven animals.
Source: S teele et al. 1980
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biomarkers, because residue levels of the pesticide in these organs did not correlate with observed 
mortality. Additionally, brain levels are not as consistent as liver values. Oral administration of 
16 mg/kg 14C-toxaphene to rats resulted in distribution of radioactivity to the adrenal cortex, primarily 
localized in the zona fasciculata. Only low levels of radioactivity were detected in the zona glomerulosa 
and the zona reticularis, and no radioactivity was found in the medulla (Mohammed et al. 1985). The 
zona fasciculata is responsible for glucocorticoid synthesis. A toxaphene-induced 50% inhibition of 
ACTH-stimulated adrenal corticosterone synthesis in vitro is supported by this pattern of toxaphene 
distribution in vivo. Pretreatment of rats with toxaphene in their diet for 5 weeks also resulted in a 
significant inhibition of corticosteroid synthesis when compared to controls. Hence, the distribution of 
toxaphene to the zona fasciculata was correlated with an adverse physiological effect.
Administration of 14C-toxaphene in olive oil at a dose of 2.6 mg/kg to pregnant rats resulted in its 
distribution to the fat. Fetuses contained the lowest levels of radioactivity relative to other tissues 
analyzed (Pollock and Hillstrand 1982). After 1 day, the residue level in the fetus was 84 ppb; the residue 
level after 3 days averaged 28 ppb. Residue levels in the fat of the mothers exceeded 7,000 ppb. The 
authors reported that the overall amount of placental transfer was similar to that of polychlorinated 
biphenyls (PCBs), of which <1% of the dose was transferred.
All studies reviewed consistently demonstrate that toxaphene is distributed throughout the body and 
preferentially stored in fat. Although toxaphene was identified in the fat up to 30 days after 
administration, the overall tissue activity level was very low. Apparently, toxaphene is rapidly 
metabolized, and its metabolites and components are not persistent. However, it is not known whether 
the toxaphene metabolites or the original components that persist in fat are toxic. Therefore, these 
persistent residues could theoretically reenter the circulation from the fat stores and cause additional 
delayed toxicity. Toxaphene has been shown to cross the placenta and become localized in the fetal 
adrenal. Based on the findings in all animals (Saleh et al. 1979), it would seem likely that fat would also 
be a principal storage site for toxaphene in humans following its ingestion. Toxaphene localizes in the 
liver after initial exposure but then redistributes to fat over a longer period of time. Tissue samples 
obtained from a chronic dog study demonstrated that after 2 years exposure, toxaphene (as estimated from 
tissue chlorine levels) was measurable only in fat (Hercules Research Center 1966). The levels in liver, 
kidney, and brain were negligible. Fat samples obtained at the interim periods of 6 and 12 months had 
toxaphene levels comparable to those seen at 24 months, indicating that accumulation of toxaphene in 
adipose tissue may reach a saturation point, resulting in steady-state levels, with uptake being equal to 
excretion.
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3.4.2.3 Dermal Exposure
No human or animal data were located regarding distribution of toxaphene following dermal exposure.
3.4.2.4 O ther Routes o f Exposure
Intravenous administration of 14C-toxaphene to mice at a dose of 16 mg/kg resulted in the appearance of 
radioactivity in the liver, fat, bile, adrenal glands, kidneys, and ovaries within 20 minutes of 
administration. The distribution significantly changed after 4 hours, with an increase in radioactivity in 
the abdominal fat and the intestinal contents. There were decreases in other tissues after 4 hours. Highest 
levels of radioactivity were still localized in the fat 16 days after administration (Mohammed et al. 1983). 
In autoradiographic studies of pregnant albino mice intravenously injected with 14C-toxaphene 
(16 mg/kg), Mohammed et al. (1983) found low levels of activity in fetal tissues. This activity was highly 
concentrated in the fetal liver and adrenal gland. These results, as after oral administration, suggest that 
the transplacental transfer of toxaphene after intravenous administration is relatively low. The tissue 
accumulation of intravenously administered 14C-toxaphene was also examined in normolipidemic and 
hypolipidemic female NMRI mice (Mohammed et al. 1990b). In normolipidemic mice, the radiolabel 
first distributed to the liver and adrenal glands 20 minutes after administration of the labeled toxaphene. 
After 4 hours, the label was primarily found in the abdominal fat. The distribution of the radiolabel in the 
hypolipidemic mice was different from the controls. After 20 minutes, the labeled toxaphene was found 
in the liver, adrenal gland, heart, and kidneys. After 4 hours, nearly all of the label was found in the liver. 
The results of the study indicate that lipid metabolism may play an important role in the tissue distribution 
of toxaphene and thus its toxicity.
3.4.3 Metabolism
Toxaphene is rapidly and extensively degraded in mammals following oral administration (Figure 3-3).
In vivo and in vitro studies indicate that the principal metabolic pathways involve dechlorination, 
dehydrodechlorination, and oxidation. Conjugation is also likely, but it is not a major route of 
metabolism. Administration of 36Cl-toxaphene to rats at a dose of 13 mg/kg resulted in the excretion of 
36Cl-chloride ion in the urine. This was the only metabolite identified in the urine by Ohsawa et al.
(1975), and it accounted for 50% of the administered radioactivity. Results obtained with 36Cl- and 
14C-toxaphene differed. With either label, the hexane extracts of urine and feces contained some
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE 75
3. HEALTH EFFECTS
Figure 3-3. Proposed Metabolic Scheme for a Toxicant Isolated from Toxaphene
Toxicant B 
V
Note: Toxicant B = 2,2,5-endo-6-exo-8,9,10-heptachlorobornane 
Metabolite II = 2,5-endo-6-exo-8,9,10-hexachlorobornane 
Metabolite III = 2,-exo-5-endo-6-exo-8,9,10-hexachlorogornane 
Metabolite IV = 2,5-endo-6-exo-8,9,10-heptachlorogornene 
Metabolite V = 2,5-endo-8,9,10-pentachlorotricyclene
Source: Saleh and Casida 1978
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unmetabolized material. The percentage of administered activity was negligible in urine and 
approximately 8-12% in feces. Hence, most excreted material consisted of metabolites from toxaphene 
components. The combined chloroform extracts of urine and feces contained a much higher proportion of 
the administered 14C-activity (27%) than of the 36Cl-activity (11.2%). These results indicate that the 
chloroform fraction consists of partially dechlorinated metabolites, and a predominance of these products 
were found in the urine. The aqueous fraction contained 11.4% of the 14C-dose and 0.5% of the 36Cl dose. 
The low amount of 36Cl activity in the aqueous extracts indicated that this fraction contained metabolites 
(5-10%) that had been completely dechlorinated (Ohsawa et al. 1975). About 2% of the 14C-activity 
appeared as expired products, probably 14C-carbon dioxide. Thus, these results indicate that toxaphene is 
metabolized mostly to partially dechlorinated products, with a small proportion being completely 
dechlorinated and a small proportion unmetabolized.
Pollock and Kilgore (1980b) confirmed the observations of Ohsawa et al. (1975). Less than 5% of the 
total activity from an orally-administered dose of 10 mg/kg 14C-toxaphene was extractable from urine into 
hexane. Thin-layer chromatography (TLC) of the urine extract indicated that the components in the urine 
were more polar than toxaphene. No parent compound was found in the urine. These results provide 
additional evidence that most of the toxaphene absorbed is metabolized.
The complexity of toxaphene makes it difficult to understand its metabolism fully. It appears that all of 
its components undergo rapid metabolism, yet each component has its own rate of biotransformation. A 
small fraction of fecal radioactivity that was extractable into hexane indicated that some toxaphene 
components could be excreted unchanged. However, it is possible that some metabolite residues may 
share chromatographic properties similar to the original component of toxaphene.
Pollock and Kilgore (1980b) also extracted the lipid tissue of rats treated with either 14C-labeled 
toxaphene, Fraction 2, or Fraction 7. Fractions 2 and 7 are nonpolar and polar components, respectively, 
of toxaphene obtained from chromatographic separation of the toxaphene mixture. When compared to 
the chromatograms of extracts from fat fortified with 14C-toxaphene, the fat of treated rats had 12% more 
activity in its polar region. Chromatograms of fat extracts from rats treated with each fraction indicated 
that two additional compounds were generated that accounted for 11% of the administered activity. With 
Fraction 2, the additional compounds were of greater polarity. In contrast, the additional compounds 
generated from Fraction 7 were less polar. The decreased polarity of these metabolites may result in their 
persistence in the fat and decrease the excretion of Fraction 7. The study does not indicate whether these 
new compounds were identical.
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Metabolism of toxicant B (2,2,5-endo-6-exo-8,9,10-heptachlorobomane), a toxic component of 
toxaphene, yielded several fecal metabolites when administered orally to mice, rats, hamsters, guinea 
pigs, rabbits, monkeys, and chickens (Saleh et al. 1979). The greatest amount of fecal metabolites was 
seen in monkeys and rabbits (20%), with 3-9% in other species, indicating that species differ with respect 
to metabolic rate and/or pathway (Saleh et al. 1979). The extensive metabolism seen in monkeys suggests 
that similar findings may result in humans; however, urinary metabolites were not monitored.
The chromatographic pattern of these fecal metabolites was characterized by short retention times, which 
suggested that dechlorination occurred (Ohsawa et al. 1975; Saleh and Casida 1978; Saleh et al. 1979). In 
several in vitro systems, especially in rat microsomes under anaerobic conditions with NADPH, and in 
rats under in vivo conditions, toxicant B is dechlorinated at the germinal dichloro group to yield 3,5-endo- 
6-exo-8,9,10-hexachlorobornane (II) and 2-exo-5-endo-6-exo-8,9,10-hexachlorobornane (III)
(Figure 3-3). Toxicant B is also dehydrodechlorinated to 2,5-endo-6-exo-8,9,10-hexachloroborn-2,3-ene 
(IV) and 2,5-endo-8,9,10-pentachlorotricyclene (V) in rats in vivo and in other in vitro systems (Saleh and 
Casida 1978). There is no evidence that humans either do or do not metabolize toxaphene via this 
pathway.
Rat liver microsomes did not transform metabolite I unless they were fortified with NADPH, indicating 
that cytochrome P-450 was required. Furthermore, the direction of metabolism was dependent upon the 
oxidative conditions. Only under anaerobic conditions did dechlorination of toxicant B occur, yielding 
metabolites II and III. Since most gastrointestinal reactions are anaerobic, it follows that metabolites II 
and III would also be present in the feces (Saleh and Casida 1978). The hexachlorobornane ratio (III/II) 
was relatively equivalent in the feces, fat, and liver of rats treated with toxicant B, in addition to the 
microsomal system. The consistency of this ratio suggested that the mechanism involved in this reaction 
was similar among tissues (Saleh and Casida 1978). An alternative (and perhaps more likely) explanation 
is that most of the metabolism occurs in the anaerobic conditions of the intestine. Then compounds II and 
III are absorbed and distributed to the various tissues, thus keeping the original ratio found in the 
intestines.
Dechlorination of toxicant B resulted under aerobic conditions in the generation of five nonhydroxyl 
compounds in rat microsomes fortified with NADPH (Chadurkar and Matsumura 1979). As reported by 
Saleh and Casida (1978), toxicant B was metabolized to a greater extent under anaerobic conditions than
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under aerobic conditions. It is possible that this dechlorination reaction was representative of reductive 
reactions that would be more favorably executed under anaerobic conditions.
Metabolites II and III were not produced under aerobic conditions. However, other unidentified products 
were generated. The requirement of NADPH and anaerobic conditions for production of metabolites II 
and III suggests the involvement of the mixed function oxidase systems (Chadurkar and Matsumura 1979; 
Saleh and Casida 1978).
Acetonitrile extracts of feces and urine from rats receiving a single oral dose of 14C-toxaphene at 
15 mg/kg confirmed previously discussed findings that most of the toxaphene was metabolized. Gas­
liquid chromatography/electron capture (GLC/EC) analysis of TLC fractions from urine and feces 
revealed the presence of methylation products. This showed that fecal and urinary metabolites included 
acidic and other hydroxyl compounds (Chadurkar and Matsumura 1979). Further analysis indicated that 
approximately 9 and 1% of the urinary and fecal metabolites, respectively, were sulfate conjugates. 
Glucuronide conjugates comprised 9.5 and 7.5% of the urinary and fecal metabolites, respectively. The 
presence of sulfate and glucuronide conjugates supported the conclusion that oxidative metabolism 
occurred.
Drenth et al. (1998) noted that toxaphene induced hepatic CYP450 activity in the rat at a single oral dose 
level of 40 mg/kg, but not at lower dose levels.
Toxaphene has been shown to induce selected CYP450 isozymes both in vitro and in vivo. Hedli et al. 
(1998) reported dose-related increased levels of total CYP450 and cytochrome b5 in hepatic microsomal 
fractions from male CD-1 mice administered toxaphene by daily gavage for 7 days at doses of 0, 10, 25, 
50, or 100 mg/kg/day. Significant, toxaphene-induced increases in immunodetectable levels of CYP2B, 
but not CYP4A1, were detected. Dehn et al. (2005) observed significantly increased CYP1A and CYP2B 
activities in human HepG2 cells exposed to toxaphene for 24 hours at high concentrations (1, 5, or 
10 mM) or 48 hours at lower concentrations (0.01-1 mM). The increases in CYP2B were of greater 
magnitude than those of CYP1A. Dehn et al. (2005) noted that glutathione levels declined when CYP2B 
activity was significantly elevated, but increased significantly in the absence of significant CYP450 
activation, suggesting that activities of glutathione and CYP450 isozymes may influence one another.
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3.4.4.1 Inhalation Exposure
No human or animal data were located regarding excretion following known inhalation exposure to 
toxaphene.
3.4.4.2 Oral Exposure
It is evident from distribution studies that toxaphene and its metabolites are not persistent in tissues; 
36Cl-labeled metabolites remained for 9 days and 14C-labeled metabolites remained for 16 days in the fat 
of animals. Metabolism studies indicate that toxaphene is rapidly and extensively biodegraded. 
Consequently, the rate of toxaphene elimination is very high. Table 3-7 summarizes excretion results 
from studies in which rats were orally administered radiolabeled toxaphene and its components.
An average of 52.6% of an orally administered 20 mg/kg 36Cl-toxaphene dose was excreted over 9 days 
(approximate half-life of excretion). Approximately 30% of this amount was excreted in the urine and 
70% was excreted in the feces. Fecal excretion reached a plateau 2-3 days after administration. The 
cumulative urinary excretion steadily increased over the 9 days. Much of the activity in the urine and 
feces was attributable to the 36Cl-chloride ion. Therefore, dechlorination is a principal metabolic route of 
toxaphene that facilitates its elimination (Crowder and Dindal 1974). In an excretion study conducted by 
Ohsawa et al. (1975) in rats with 36Cl-toxaphene, a 13 mg/kg dose resulted in the excretion of 76% of the 
radioactivity after 14 days. Approximately 50% of the activity was detected in the urine. The amount of 
activity excreted in the urine apparently followed the pattern established by Crowder and Dindal (1974) 
where the cumulative urinary excretion of the dose steadily increased and eventually equaled the fecal 
elimination. Ohsawa et al. (1975) also found that the 36Cl-chloride ion appeared almost entirely in the 
urine. The half-time for the elimination of 36Cl was 2-3 days, a rate equivalent to the excretion of 
36Cl-sodium chloride.
Rats treated orally with 8.5 and 19 mg/kg of 14C-toxaphene showed no dose-related differences with 
respect to the excretion of radioactivity (Ohsawa et al. 1975). After 14 days, >50% of the total activity 
was excreted in urine. Only 8-12% of the dose detected in the feces was suspected of being parent 
compound. The remainder of the activity in the urine and the feces was thought to be partially or 
completely dechlorinated products.
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Table 3-7. Summary of Excretion Data: Percentage of Dose Excreted in 
Urine and Feces Following Oral Administration to Rats of 
Radiolabeled Toxaphene and its Components
Chemical
Dose
(mg/kg) Vehicle
Days after Percent dose 
administration Urine Feces Reference
36Cl-Toxaphene 2G Peanut oil/gum acacia 1 1.5 23.4 Crowder and Dindal 
19l4
36Cl-Toxaphene 2G Peanut oil/gum acacia 9 15.3 3l.3 Crowder and Dindal 
19l4
36Cl-Toxaphene 14 Corn oil 14 49.1 26.9 Ohsawa et al. 19l5
14C-Toxaphene S.5 Corn oil 14 21.3 34.l Ohsawa et al. 19l5
14C-Toxaphene 19 Corn oil 14 31.S 2l.S Ohsawa et al. 19l5
14C-Toxaphene 2.6 Olive oil 5 22.G 2S.3 Pollock and 
Hillstrand 19S2
14C-Toxaphene 1G Olive oil l 22.5 35.l Pollock and Kilgore 
19SGb
14C-Fraction 2 1 Olive oil l 3G.S 3S.6 Pollock and Kilgore 
19SGb
14C-Fraction l G.6 Olive oil l 23.5 32.6 Pollock and Kilgore 
19SGb
14C-Toxicant A G.S4 Corn oil 14 2S.3 3S.4 Oshawa et al. 19l5
14C-Toxicant B 2.6 Corn oil 9 26.l 4l.S Ohsawa et al. 19l5
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Radiolabeled toxicants A and B, obtained by chromatographic separation of 14C-toxaphene, were orally 
administered to rats at doses of 0.84 and 2.6 mg/kg, respectively. Radioactivity from the 14C-radiolabeled 
toxicants was excreted rapidly and to a slightly greater extent than toxaphene (Ohsawa et al. 1975).
Parent compounds constituted only 8.6 and 2.6% of the fecal residues of toxicants A and B, respectively. 
However, the dosages used were lower than for toxaphene, and only one animal was tested. Rats orally 
administered 10 mg/kg 14C-toxaphene in olive oil excreted 58% of the total activity in urine and feces 
within 7 days after administration (Pollock and Kilgore 1980b). This agreed closely with the excretion 
pattern reported by Ohsawa et al. (1975). Rats were also orally administered the 14C-labeled isolated 
fractions of toxaphene, Fraction 2 and Fraction 7, which are nonpolar and polar, respectively. Of these 
three compound mixtures, the greatest percentage of excreted dose was seen with Fraction 2; the least was 
seen with Fraction 7. The metabolites derived from polar Fraction 7 were less polar, which resulted in 
greater persistence in fat and a reduced rate of excretion. In contrast, the nonpolar Fraction 2-derived 
polar metabolites were more rapidly excreted. Radioactivity measured in the urine of rats receiving 
Fraction 2 was significantly higher than from those administered Fraction 7 or toxaphene.
Another possible explanation for the unexpected order of excretion is the unexplained contribution of 
methanol-insoluble activity in the feces. Only the methanol-extractable activity was reported. Ohsawa et 
al. (1975) reported that some fecal radioactivity was methanol-insoluble and was not detected. 
Consequently, this may have significantly altered the measurements of total excreted activity. Less polar 
metabolites from Fraction 7 may be present in the methanol-insoluble extract from feces.
Excretion of radioactivity derived from 14C-toxaphene in pregnant rats was found to be similar to that of 
virgin female rats (Pollock and Hillstrand 1982). Although there was a weight difference between the 
pregnant and nonpregnant rats, approximately 50% of the total activity was excreted in the urine and 
feces over 5 days after the oral administration of 2.6 mg/kg in olive oil. The increased amount of fatty 
tissue had no effect on the excretion of 14C-toxaphene.
Toxaphene fed to cows in their feed at levels of 20, 60, 100, and 140 ppm for 8 weeks was excreted at all 
dosage levels. Residues in milk increased rapidly and reached a maximum within 4 weeks after feeding 
commenced. The levels of toxaphene found in milk were dose-dependent. Upon the cessation of 
toxaphene administration, there was a rapid decrease in toxaphene residues in the milk. The rate of 
decrease was the same at all dosage levels during the 1st week. Decreases in milk levels after the first 
week were slower for animals fed toxaphene at levels >20 ppm (Claborn et al. 1963), as shown in 
Table 3-8. Detectable amounts of toxaphene were found in the milk of cows 7-9 days after feeding of
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Table 3-8. Toxaphene Levels in Milk from Cows Fed Toxaphene in Their Diet
Diet concentration 
(ppm)
Concentration of milk (ppm)a
Weeks of feeding
Weeks after cessation of 
toxaphene feeding
1 4 S 1 3
2G G.2G G.36 G.23 G.Gl -
6G G.56 G.6S G.4S G.13 G.Gl
1GG G.Sl 1.15 G.91 G.15 G.12
14G 1.44 1.89 1.S2 G.32 G.2G
aValues represent m eans of three samples. 
Source: Claborn et al. 1963
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE S3
toxaphene at levels of 2.5-20 ppm commenced (Zweig et al. 1963). As with the higher feeding levels 
discussed above (Claborn et al. 1963), plateaus were achieved after the fourth week, except at the lowest 
dose of 2.5 ppm, where a maximum was achieved at 9 days. The animals were fed toxaphene for 1­
2.5 months. Toxaphene was no longer detected in the milk within 14 days after cessation of toxaphene 
administration (Zweig et al. 1963).
The high concentration of radioactivity in the gall bladder from 14C-toxaphene orally administered to 
quail confirmed the likelihood that the biliary pathway plays an important role in toxaphene excretion 
(Biessmann et al. 1983).
The detection of toxaphene residue in human breast milk samples is testament to its pharmacokinetics in 
humans. Ingestion of contaminated food and/or water is the most likely primary source of exposure. 
Toxaphene residues were detected at a mean concentration of 67.7 ng/g fat in human milk samples 
collected between July 1996 and April 1997 from 12 residents of Kewatin, an arctic region of northern 
Canada (Newsome and Ryan 1999). Mean toxaphene residue concentrations ranging from 6.03 to 
12.1 ng/g fat were determined from human milk samples that had been collected from other regions of 
Canada at earlier times (Newsome and Ryan 1999). Toxaphene residues detected in breast milk samples 
from women living in different parts of Finland were estimated to be 10 ng/g fat (Mussalo-Rauhamaa et 
al. 1988). Toxaphene-like chlorinated bornanes have been measured in breast milk samples from women 
in areas of Russia (Polder et al. 1998, 2003), Germany (Skopp et al. 2002b), and Hong Kong and south 
China (Hedley et al. 2010).
3.4.4.3 Dermal Exposure
No human data were located regarding excretion following dermal exposure to toxaphene.
Information regarding the excretion of toxaphene in animals following dermal absorption is limited. 
Evidence for the excretion of toxaphene in milk is found in a study conducted with cows that were 
sprayed twice daily with 1 ounce of 2.0% toxaphene oil solution or sprayed twice at 3-week intervals with 
0.5% sprays of toxaphene. Residues of toxaphene in milk resulting from daily oil sprays reached a 
maximum after the third day of spraying. When cows were sprayed twice at 3-week intervals, maximum 
residues in milk were detected 1 or 2 days after spraying (Claborn et al. 1963). Cows that were dipped in 
a solution containing 0.25% toxaphene also excreted toxaphene in the milk at levels of 21-45 ppm 1 day 
after dipping. Toxaphene levels fell to 5 ppm 19 days after exposure ceased (Keating 1979). The
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absorption, distribution, and excretion of toxaphene were evident from these studies, but insufficient 
information regarding the dose of toxaphene precludes any estimation of the extent and rate of excretion.
3.4.4.4 O ther Routes o f Exposure
Mohammed et al. (1983) reported that 14C-toxaphene was rapidly distributed to most tissues and organs 
following intravenous administration in mice. Between 20 minutes and 4 hours after injection, there was 
a significant increase in the radioactivity observed in the intestinal contents. The presence of radioactivity 
in the intestine probably represented the biliary excretion of 14C-toxaphene and its metabolites. Sixteen 
days after administration, the tissue showing the highest concentration of 14C toxaphene was abdominal 
fat, which had concentrations about 10% of those found 4 hours after administration.
Based on the rapid and extensive metabolism seen in all animals, the fate of toxaphene in humans is 
probably similar. The negligible quantities of parent compound in the excreta and the lack of persistence 
of metabolites in the tissues indicate that toxaphene and its components are readily removed from the 
body. Low-level exposure is not expected to cause significant harm to humans. Theoretically, however, 
acute high-level exposure may saturate metabolic pathways and consequently allow toxaphene to 
accumulate in the tissues for a longer period of time (>16 days).
3.4.5 Physio log ica lly  Based Pharm acokinetic (PBPK)/Pharmacodynamic (PD) Models
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
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route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance- 
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates o f these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions.
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species. 
Figure 3-4 shows a conceptualized representation of a PBPK model.
If PBPK models for toxaphene exist, the overall results and individual models are discussed in this 
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations.
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Figure 3-4. Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance
Inhaled c h e m ic a l------1 |------► Exhaled chem ical
C hem ica ls  
contacting skin
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source: adapted from Krishnan and Andersen 1994
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Wen and Chan (2000) developed a two-compartment pharmacokinetic model to predict absorption, 
elimination, and tissue burden of toxaphene in rats; it does not incorporate data regarding 
biotransformation or clearance of toxaphene metabolites. The model includes six tissue compartments 
(blood, brain, liver, muscle, fat, and carcass) and incorporates dose-dependent flux rates and first-order 
absorption and elimination kinetics. Time-course tissue distribution data from male albino rats 
administered 36Cl-toxaphene served as basis for model development. The model was partially validated 
using time-course tissue distribution and depuration data from pregnant Sprague-Dawley rats 
administered 14C-toxaphene orally. Pharmacokinetically based dosimetry indicated that absorption of 
toxaphene was fast in fat, whole body, carcass, and blood; relatively slow in liver and muscle; and slow in 
brain. Elimination was rapid in whole body, muscle, and blood; moderate in carcass and brain; and slow 
in liver and fat. Tissue burden was highest in fat, whole body, and blood; intermediate in liver; and 
lowest in brain. In male rats, fecal and urinary excretion represented the major and minor elimination 
routes, respectively. Fecal and urinary excretion were of approximately equal magnitude in pregnant 
female rats.
3.5 MECHANISMS OF ACTION
3.5.1 Pharm acokinetic Mechanisms
Pharmacokinetic mechanisms of action for toxaphene have not been well studied. Toxaphene is rapidly 
absorbed by the gastrointestinal tract and lungs. Absorption through the skin can also occur, but appears 
to be less efficient because dermal doses that cause overt toxicity in laboratory animals are an order of 
magnitude higher than those causing similar toxicity following oral exposure. Toxaphene is more rapidly 
absorbed if  it is mixed in oily (lipophilic) solvents, probably because interactions with polar areas on the 
cell membrane are reduced. Once absorbed, toxaphene rapidly distributes to all organs of the body; 
however, the pesticide tends to concentrate in fatty tissues and muscle from which it is slowly released 
over a period of weeks. Circulating toxaphene is primarily metabolized by hepatic mixed-function 
oxidases. Toxaphene and its metabolites are excreted in the feces and urine, and most of it is eliminated 
from the body within a few days.
3.5.2 Mechanisms o f Toxic ity
Toxaphene-induced neurological effects may result from a general disruption of nervous system function. 
Toxaphene has been shown to inhibit brain ATPases (Fattah and Crowder 1980; Moorthy et al. 1987; 
Morrow et al. 1986; Rao et al. 1986; Trottman and Desaiah 1979; Trottman et al. 1985). Results of in
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vitro assays performed by Morrow et al. (1986) indicated that polar toxaphene fractions were more potent 
inhibitors of rat brain ATPase than other nonpolar or intermediate polar fractions or even toxaphene itself. 
Pollock and Kilgore (1980a) reported that nonpolar fractions of toxaphene were more toxic to houseflies 
and mice (in vivo) than polar fractions. Morrow et al. (1986) proposed that this discrepancy may be 
explained by the fact that in vivo, the ATPases are membrane-bound in a hydrophobic environment, 
whereas preparation of cell membranes in the in vitro assays could cause disruption within the 
hydrophobic environment and result in the exposure of polar groups. In any event, diminished ATPase 
activity in nervous tissue could have a profound effect on neural transmission because of the tissue's high 
metabolic rate.
Several investigators have demonstrated that toxaphene inhibits ATPases in the liver and kidney as well 
(e.g., Fattah and Crowder 1980; Mourelle et al. 1985; Trottman and Desaiah 1979; Trottman et al. 1985). 
These enzymes are involved in all aspects of cellular activity, and their inhibition can ultimately result in 
disturbances in hepatic and renal function, which could trigger injury responses.
Toxaphene has the potential to alter central nervous system neurotransmitter activity. Toxaphene acted as 
a noncompetitive y-aminobutyric acid (GABA-A) antagonist at the chloride channel (also known as the 
picrotoxin binding site) in brain synaptosomes (Lawrence and Casida 1984; Matsumura and Tanaka 
1984). GABA is an inhibitory neurotransmitter; antagonism of GABAergic neurons within the central 
nervous system leads to generalized central nervous system stimulation by inhibiting chloride influx, 
leading to hyperpolarization and increased neuronal activity. Moreover, the ability of toxaphene to 
induce convulsions is closely related to its affinity for the picrotoxin binding site. Toxaphene has also 
been shown to alter catecholamine metabolism in the brain (Kuz'minskaya and Ivanitskii 1979).
Kuz'minskaya and Alekhina (1976) and Gertig and Nowaczyk (1975) reported that both short- and long­
term oral administration o f toxaphene to rats caused disturbances in energy metabolism as evidenced by 
changes in hepatic lactate dehydrogenase activity. However, results of Peakall (1979) indicated that these 
changes are not severe enough to have definite physiological consequences (measured as serum lactate 
and pyruvate levels) under nonstress conditions. The results of Kuz'minskaya and Alekhina (1976) and 
Gertig and Nowaczyk (1975) suggest that toxaphene exposure, coupled with stress, could result in 
detrimental effects on hepatic energy utilization and, ultimately, in hepatic injury.
Mechanisms responsible for toxaphene-induced immunosuppressive effects in laboratory animals are not 
presently known. Gauthier and coworkers demonstrated that toxaphene induces phagocytosis, production
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of reactive oxygen species (ROS), and apoptosis in human neutrophils in vitro (Gauthier et al. 2001), and 
that caspases and ROS are likely involved in the degradation of cytoskeletal proteins (Lavastre et al. 
2 00 2).
Possible modes of action for toxaphene carcinogenicity have been assessed to some extent; available 
information is summarized in reports of de Geus et al. (1999), Goodman et al. (2000), and Lamb et al. 
(2008). Results of available in vivo genotoxicity assays have not demonstrated a genotoxic response. 
Although toxaphene was mutagenic in bacterial systems in the absence of metabolic activation, the 
mutagenic effect was reduced or abolished in the presence of metabolic activation; this finding suggests 
that toxaphene may be inactivated in vivo. There was no evidence of toxaphene-induced DNA adduct 
formation or peroxisomal proliferation in hepatic DNA or microsomes from mice administered toxaphene 
at oral doses as high as 100 mg/kg; however, these mice exhibited significant increases in 
immunodetectable levels of hepatic CYP 2B (Hedli et al. 1998). Toxaphene-induced increases in hepatic 
CYP 2B levels and liver enlargement are consistent with the action of phenobarbital, a nongenotoxic 
rodent liver tumor promoter. Toxaphene and phenobarbital have each been shown to inhibit intercellular 
communication, a possible mode of nongenotoxic carcinogenicity. The weight of evidence presently 
suggests a nongenotoxic mode of action for toxaphene tumorigenicity.
3.5.3 Anim al-to-Hum an Extrapolations
Due to a lack of information regarding potential interspecies differences in the toxicokinetics of 
toxaphene, it is assumed that humans and animals share similar metabolic pathways. Comparative 
information regarding the toxic effects of toxaphene is limited to findings of similar neurological effects 
in humans and laboratory animals following exposure to high levels of toxaphene. In the absence of 
information regarding other systemic effects of toxaphene toxicity in humans, it is assumed that the 
systemic effects observed in laboratory animals are of human relevance as well.
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial. The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE 90
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment. Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen. Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992).
Results of some assays suggest that toxaphene may be weakly estrogenic. Toxaphene was reported to 
induce weak estrogenic effects in most assays of human breast estrogen-sensitive MCF7 cells (J0rgensen 
et al. 1997; Soto et al. 1994, 1995; Stelzer and Chan 1999) and one assay of rat uterine leiomyoma- 
derived cells (Hodges et al. 2000). In an assay that employed human hepatoma cells transfected with 
estrogen receptor and luciferase reporter gene, Kim et al (2004) reported that toxaphene exerted an 
agonistic effect on estrogen receptor a and an antagonistic effect on estrogen receptor p. Results of 
Graham et al. (2003) indicate that toxaphene may exhibit estrogen-like activity by modulating prolactin 
mRNA levels in GH3 pituitary-derived cells. Toxaphene did not induce an estrogenic response in other 
assays using mouse uterus cells and MCF7 cells (Arcaro et al. 2000; Ramamoorthy et al. 1997) or yeast- 
based estrogen reporter genes (Ramamoorthy et al. 1997; Rehmann et al. 1999). Yang and Chen (1999) 
reported that toxaphene acted as an antagonist of estrogen-related receptor a-1. Drenth et al. (2000) 
reported that technical toxaphene exerted an antiestrogenic effect in stably transfected human T47D.Luc 
breast cancer cells.
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3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.
Relevant animal and in vitro models are also discussed.
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the 
extent of their exposure. Exposures of children are discussed in Section 6 .6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s). Damage 
may not be evident until a later stage of development. There are often differences in pharmacokinetics 
and metabolism between children and adults. For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth 
and development, levels o f particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification. There may also be differences in excretion,
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE 92
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults. Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical. For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993).
It is not known whether children are more susceptible than adults to toxaphene toxicity. No human data 
are available regarding age-related susceptibility to toxaphene. Results of one animal study (Olsen et al.
1980) indicate that critical stages of neurological development may be periods of increased vulnerability. 
Olson et al. (1980) reported significantly retarded swimming ability and righting reflex in 10-12-day-old 
pups of rat dams that ingested toxaphene throughout gestation and lactation; however, the effect was 
transient and pups exhibited normal swimming ability at testing on postpartum day 16. 
Immunosuppression has been demonstrated in some animals exposed to toxaphene (Allen et al. 1983; 
Koller et al. 1983; Tryphonas et al. 2001). Infants and children are especially susceptible to 
immunosuppression because their immune systems do not reach maturity until 1 0 -1 2  years of age 
(Calabrese 1978).
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. However, several 
factors can confound the use and interpretation of biomarkers of exposure. The body burden of a
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substance may be the result of exposures from more than one source. The substance being measured may 
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from 
exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken. It may be difficult to 
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids 
(e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to 
toxaphene are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity. Note that these markers are not often substance specific. They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused 
by toxaphene are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 B iom arkers Used to  Identify o r Q uantify Exposure to  Toxaphene
Following acute exposure to high doses, toxaphene can be readily detected in human blood (Griffith and 
Blanke 1974; Taylor et al. 1979; Tewari and Sharma 1977). If exposure is via inhalation, however, 
absorption is probably not sufficient to yield quantifiable levels in the blood (EPA 1980a). Toxaphene 
and/or toxaphene residues have been detected in breast milk, urine, stomach washings, umbilical cord 
blood, and adipose tissue samples from children (Munn et al. 1985; Tewari and Sharma 1977; Vaz and 
Blomkvist 1985; Butler Walker et al. 2003; Witt and Niessen 2000). Tissue samples taken from dogs 
sacrificed at intervals in a 2 -year study demonstrated that levels of toxaphene in fat were proportional to 
the levels in the feed, and that tissue levels were essentially stable over the period of 2 years (Hercules
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Research Center 1966). Levels detected in tissues generally reflect only very recent exposures (<1 week) 
because toxaphene is rapidly cleared from the body. Metabolites of toxaphene are excreted 
predominantly in the urine and feces; however, analytic procedures for detecting toxaphene metabolites 
are not sensitive or reliable enough to allow for screening for metabolites in the blood or excreta.
3.8.2 B iom arkers Used to  Characterize Effects Caused by Toxaphene
Toxaphene causes a number of physiological effects including central nervous system excitation, liver 
enzyme induction, renal tubular degeneration, and immune suppression. However, none of these effects 
is specific to toxaphene exposure.
For more information on biomarkers for renal and hepatic effects of chemicals see Agency for Toxic 
Substances and Disease Registry/CDC (1990) and for information on biomarkers for neurological effects, 
see OTA (1990).
3.9 INTERACTIONS WITH OTHER SUBSTANCES
Toxaphene is likely to interact with other chemicals, such as other pesticides, that also induce hepatic 
microsomal mixed-function oxidase systems. For example, Deichmann and Keplinger (1970) observed 
that the toxaphene 96-hour LD50 values were increased by about 2 times in rats pretreated with aldrin and 
dieldrin, and these values were increased by about 3 times in rats pretreated with DDT. Aldrin, dieldrin, 
and DDT are all known to induce microsomal enzymes. Equitoxic concentrations of toxaphene plus 
parathion, diazinon, or trithion yielded LD50 values that were higher than expected based on an 
assumption of additivity, indicating that toxaphene antagonized the lethal effects of these three pesticides 
(Keplinger and Deichmann 1967).
Another example of microsomal enzyme induction by toxaphene resulting in altered activity of other 
chemicals was reported by Jeffery et al. (1976). They described the case of a farmer who was being 
treated with warfarin for thrombophlebitis and was observed to have a loss of warfarin effect that 
coincided with exposures to a toxaphene-lindane insecticide. The authors concluded that the toxaphene 
mixture induced the hepatic microsomal enzymes (for up to 3 months), thereby increasing the metabolism 
of warfarin.
Triolo et al. (1982) investigated the effects of toxaphene administered in the diet on benzo(a)pyrene 
(BP)-induced lung tumors in mice (BP was administered by oral intubation). There was no increase in the
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incidence of these tumors when toxaphene was administered alone, but toxaphene significantly reduced 
the incidence of BP-induced lung tumors when given in combination. This reduction correlated with a 
toxaphene-induced reduction in BP hydroxylase activity in the lung. The results of this study suggest that 
toxaphene antagonizes the tumorigenic effect of BP, possibly by inhibiting the biotransformation of BP to 
a reactive metabolite or by promoting degradative metabolism of BP to nonactive forms in the target 
tissue.
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to toxaphene than will most 
persons exposed to the same level of toxaphene in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). 
These parameters result in reduced detoxification or excretion of toxaphene, or compromised function of 
organs affected by toxaphene. Populations who are at greater risk due to their unusually high exposure to 
toxaphene are discussed in Section 6.7, Populations with Potentially High Exposures.
Subsets of the human population that may be unusually susceptible to the toxic effects of toxaphene 
include pregnant women, their fetuses, nursing babies, young children, people with neurologic diseases 
(particularly convulsive disorders), and individuals with protein-deficient diets. Others at increased risk 
include people with hepatic, renal, or respiratory diseases, those with immune system suppression, and 
those ingesting alcohol or consuming therapeutic or illicit drugs.
Pregnant women, fetuses, nursing infants, and very young children may be at greater risk of adverse 
health effects from pesticide exposure than the general population (Calabrese 1978). Exposure to 
organochlorine insecticides, such as toxaphene, may adversely affect reproductive physiology (i.e., 
hormonal balance) in certain women (Calabrese 1978). Embryos, fetuses, and neonates up to age 2­
3 months may be at increased risk of adverse effects following pesticide exposure because their enzyme 
detoxification systems are immature (Calabrese 1978). Animal studies suggest that detoxification of the 
toxaphene mixture may be less efficient in the immature human than the metabolism and detoxification of 
the single components such as toxicant A or B (Olson et al. 1980). Infants and children are especially 
susceptible to immunosuppression because their immune systems do not reach maturity until 1 0 -1 2  years 
of age (Calabrese 1978).
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Placental transfer of toxaphene has been documented in animals (Pollock and Hillstrand 1982).
Toxaphene residues have also been detected in the milk of exposed cows (Claborn et al. 1963; Zweig et 
al. 1963). Adverse effects have been observed in the offspring of experimental animals exposed to 
toxaphene during gestation and nursing at doses that typically elicited maternal toxicity. Results of 
experimental studies indicate that maternal toxaphene exposure may induce behavioral effects in neonates 
and in nursing babies (Crowder et al. 1980; Olson et al. 1980). Toxaphene exposure during gestation and 
nursing has been suggested to be associated with immunosuppression in offspring (Allen et al. 1983). 
Other effects of maternal toxaphene exposure observed in the offspring were histologic changes in fetal 
liver, thyroid, and kidney tissues (Chu et al. 1988).
Toxaphene exposure by inhalation, ingestion, or dermal application has induced neurotoxic effects 
manifested in part by seizures and other functional, biochemical, and morphological alterations (Badaeva 
1976; Dille and Smith 1964; DiPietro and Haliburton 1979; Kuz'minskaya and Ivanitskii 1979; Lawrence 
and Casida 1984; McGee et al. 1952; Wells and Milhorn 1983). Persons with latent or clinical neurologic 
diseases may be at an increased risk of adverse effects following toxaphene exposure.
Persons consuming diets deficient in protein may also be at increased risk of adverse effects from 
exposure to toxaphene. It has been estimated that 30% of women and 10% of men aged 30-60 ingest less 
than two-thirds of the required daily allowance (RDA) for protein (Calabrese 1978). An experimental 
study showed that central nervous system effects occurred sooner and at lower doses in rats ingesting 
toxaphene and diets deficient in protein (Boyd and Taylor 1971).
People with liver disease of a genetic origin (i.e., Gilbert's syndrome) and viral infections are at increased 
risk of developing toxic effects due to insecticide exposure (Calabrese 1978). Liver effects have been 
observed in both humans and animals following acute exposure to toxaphene. Liver enzymes were 
transiently elevated in a young man who attempted suicide by ingesting toxaphene (Wells and Milhorn 
1983). Liver effects were observed in experimental studies with animals following acute, intermediate, or 
chronic exposure to toxaphene (Allen et al. 1983; Boyd and Taylor 1971; Chandra and Durairaj 1992, 
1995; Chu et al. 1986, 1988; Garcia and Mourelle 1984; Gertig and Nowaczyk 1975; Hedli et al. 1998; 
Kennedy et al. 1973; Koller et al. 1983; Kuz'minskaya and Alekhina 1976; Lackey 1949; Mehendale 
1978; Peakall 1976; Trottman and Desaiah 1980).
Persons with diseases that affect renal, adrenal gland, or respiratory function may be at increased risk of 
adverse effects due to toxaphene exposure. Renal function was temporarily affected in a young man who
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attempted suicide by ingesting toxaphene (Wells and Milhom 1983). Respiratory function was adversely 
affected in two men occupationally exposed to toxaphene (Warraki 1963). The kidney (Boyd and Taylor 
1971; Chu et al. 1986; Fattah and Crowder 1980; Trottman and Desaiah 1979; Trottman et al. 1985) and 
adrenal gland (Kuz'minskaya and Ivanitskii 1979; Mohammed et al. 1985) are recognized as target organs 
of toxaphene toxicity in experimental animals.
People susceptible to the toxic effects of toxaphene may develop compromised immune function. People 
with suppressed immune systems may also be at increased risk of developing more severe effects from 
toxaphene exposure. Toxaphene has produced primarily humoral immunosuppressive effects in 
experimental animals (Allen et al. 1983; Koller et al. 1983; Tryphonas et al. 2001).
The induction of hepatic microsomal enzymes, such as mixed function oxidases, by pesticides such as 
toxaphene may also affect the metabolism of some drugs and alcohol (Calabrese 1978). The efficacy of 
prescription drugs may be reduced because of the increased rate of metabolism. For example, Jeffery et 
al. (1976) observed a decrease in the effectiveness of warfarin in a farmer who had been exposed to a 
toxaphene-lindane insecticide. Furthermore, because toxaphene is a neurotoxic agent, neurological 
effects associated with other agents or drugs may be exacerbated in persons exposed concomitantly to 
toxaphene.
3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to toxaphene. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to toxaphene. When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice. The following texts provide specific information about treatment following exposures 
to toxaphene:
Dart RC, ed. 2004. Pesticides. In: Medical toxicology. 3rd ed. Philadelphia, PA: Lippincott Williams
& Wilkins, 1489-1496.
Holland MG. 2002. Insecticides: Organochlorines, pyrethrins, and DEET. In: Goldfrank LR, 
Flomenbaum NE, Lewin NA, et al., eds. Goldfrank’s toxicologic emergencies. 7th ed. New York, NY: 
Mc-Graw-Hill Medical Publishing Division, 1366-1378.
Leikin JB, Paloucek FP, eds. 2002. Leikin and Paloucek's poisoning and toxicology handbook. 3rd ed. 
Hudson, OH: Lexi-Comp, Inc., 1199.
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Rhee JW, Aks SE. 2007. Organochlorine insecticides. In: Shannon MW, Borron SW, Burns MJ, eds. 
Haddad and Winchester’s clinical management of poisoning and drug overdose. 4th ed. Philadelphia, 
PA: Saunders Elsevier, 1231-1236.
3.11.1 Reducing Peak Absorp tion  Follow ing Exposure
Human exposure to toxaphene may occur by inhalation, ingestion, or by dermal contact. Toxaphene and 
other chlorinated hydrocarbons are efficiently absorbed from the gastrointestinal tract, particularly in the 
presence of dietary lipids. Although relatively nonvolatile, absorption following inhalation exposure to 
dusts and sprays probably occurs through mucociliary trapping and transport followed by gastrointestinal 
absorption. Toxaphene caused toxicosis following dermal application of the pesticide to farm animals; 
therefore, absorption across the skin is a health concern as well.
For oral exposure, do not induce emesis. Gastric lavage may be considered if the patient presents in a 
timely manner. Precaution should be taken to avoid aspiration, however. Activated charcoal may be 
administered to potentially decrease absorption following ingestion, although the efficacy of this 
treatment is uncertain.
For inhalation exposure, treatment commonly includes moving the exposed individual to fresh air, then 
monitoring for respiratory distress. Injuries to the airways and lungs are likely to be manifested as severe 
respiratory irritation and persistent cough. Provide emergency airway support and 100% humidified 
supplemental oxygen with assisted ventilation if needed.
Decontamination is the first step in reducing absorption following dermal exposure. Contaminated 
clothing should be removed. Skin should be washed with soap and water. Decontamination includes 
irrigation of the eyes with copious amounts of water or saline (if available).
3.11.2 Reducing Body Burden
Once absorbed, toxaphene bioaccumulates in adipose tissue and is metabolized and excreted over several 
days to a few weeks following exposure. For organochlorines that undergo enterohepatic and 
enteroenteric recirculation, cholestyramine has been administered to potentially increase fecal 
elimination, although the efficacy of this treatment for toxaphene poisoning is uncertain. Exchange 
transfusion, peritoneal dialysis, hemodialysis, and hemoperfusion are not likely to be beneficial because 
of the large volume of distribution of toxaphene, resulting in a small proportion of removable toxin.
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3.11.3 Interfering w ith  the Mechanism o f A ction  fo r  Toxic Effects
The most serious toxicological effects of exposure to chlorinated hydrocarbon pesticides are central 
nervous system excitability. Organochlorine compounds are thought to interfere with the normal flux of 
sodium and potassium ions across the axon membrane, disrupting central nervous system activity and 
resulting in generalized central nervous system excitation, which may lead to convulsions and seizures in 
severe cases. Toxaphene-induced central nervous system stimulation is believed to result from the 
noncompetitive inhibition of y-aminobutyric acid-dependent chloride ion channels that are found on the 
neuron. The putative role of y-aminobutyric acid in the central nervous system is to suppress neuronal 
activity. Thus, if its actions are blocked, neuronal activity increases. Unchecked neuronal excitation can 
lead to tremors, convulsions, seizures, and death.
Although mechanisms of neurotoxicity vary among individual chlorinated hydrocarbon pesticides, 
toxaphene, DDT, chlordane, lindane, heptachlor, kepone, and mirex are each considered moderately toxic 
following acute oral administration (animal LD50 >50 mg/kg). Several cases of toxaphene-induced 
seizures in humans have been reported (McGee et al. 1952; Wells and Milhorn 1983). The acute 
management of seizures with anticonvulsants such as diazepam (a y-aminobutyric acid agonist), 
phenobarbital, and phenytoin has been recommended (Schenker et al. 1992). These drugs tend to 
suppress neuronal activity, thus counteracting the stimulatory effects of toxaphene. High exposures to 
organochlorines can lead to stimulation of the peripheral nervous system. Seizure control can be achieved 
by administration of GABA agonists such as benzodiazepines; phenobarbital or propofol may be 
considered if benzodiazepines are ineffective.
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of toxaphene is available. Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of toxaphene.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would
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reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Inform ation on Health Effects o f Toxaphene
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
toxaphene are summarized in Figure 3-5. The purpose of this figure is to illustrate the existing 
information concerning the health effects of toxaphene. Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect. The dot does not necessarily imply 
anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”. A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
The data describing the toxic effects of toxaphene in humans are generally limited to a small number of 
case reports of toxicity following ingestion, inhalation, or dermal contact. Some controlled studies in 
humans exist, but the data are incomplete or unreliable. Thus, although human toxicity information 
exists, animal data must be considered in order to adequately assess the risk of toxaphene exposure. The 
database for the health effects of toxaphene following ingestion in experimental animals is substantial. 
However, as can be seen in Figure 3-5, very little information is available on the effects of inhalation and 
dermal exposure to toxaphene in animals. Furthermore, the health effects associated with acute-duration 
exposure are more fully characterized than those associated with intermediate or chronic-duration 
exposure.
3.12.2 Identification o f Data Needs
Acute-Duration Exposure. Limited human and animal data are available regarding effects of acute-
duration inhalation exposure to toxaphene. One controlled human study reported a NOAEL of
500 mg/m3 for repeated 30-minute exposures to toxaphene aerosols (Keplinger 1963). Animal data are
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restricted to secondary source accounts of death and hepatocellular necrosis in laboratory animals 
exposed to toxaphene by inhalation; the primary sources for this information were unpublished reports 
that were not available to ATSDR. Data on the acute effects of inhaled toxaphene do not appear 
necessary because all uses for toxaphene have been banned in the United States and its territories (EPA 
1990b).
No adequate human data are available regarding the effects of acute-duration oral exposure to toxaphene. 
Available animal data include acute lethality studies in multiple laboratory species (Boyd and Taylor 
1971; Chandra and Durairaj 1995; Chernoff and Carver 1976; Chernoff et al. 1990; Epstein et al. 1972; 
Gaines 1969; Jones et al. 1968; Lackey 1949). Acute-duration oral exposure to toxaphene has resulted in 
adverse effects on the nervous system, immunological system, body weight, and liver (Chandra and 
Durairaj 1995; Chernoff and Carver 1976; Chernoff et al. 1990; Chu et al. 1986; Hedli et al. 1998; Lackey 
1949; Rao et al. 1986; Steele et al. 1980; Trottman and Desaiah 1980; Waritz et al. 1996). The study of 
Chu et al. (1986) identified the highest NOAEL (5 mg/kg/day) associated with the lowest LOAEL 
(1 0  mg/kg/day for clinical signs of neurotoxicity in dogs) and serves as the point of departure for deriving 
an acute-duration oral MRL for toxaphene. Additional animal studies of acute-duration oral exposure to 
toxaphene are not necessary.
Data from animal studies indicate that dermal exposure to toxaphene can be lethal, but at doses that are an 
order of magnitude higher than those for oral administration of the pesticide (Gaines 1969; Johnston and 
Eden 1953; Jones et al. 1968). Additional acute-duration dermal studies do not appear necessary because 
all uses for toxaphene have been banned in the United States and its territories (EPA 1990b).
Interm ediate-Duration Exposure. Available information regarding intermediate-duration exposure 
to toxaphene is limited to animal studies that employed the oral exposure route and identified 
neurological, hepatic, renal, developmental, and immunological end points (Allen et al. 1983; Chu et al. 
1986, 1988; Kennedy et al. 1973; Koller et al. 1983; Lackey 1949; NCI 1979; Olsen et al. 1980; 
Tryphonas et al. 2001; Waritz et al. 1996). The study of Tryphonas et al. (2001) identified the highest 
NOAEL (0.1 mg/kg/day) associated with the lowest reliable LOAEL (0.4 mg/kg/day for depressed 
humoral immunity in cynomolgus monkeys) and served as the basis for deriving the MRL. Additional 
animal studies do not appear necessary. All uses for toxaphene have been banned in the United States 
and its territories (EPA 1990b). Monitoring of workers at waste sites where toxaphene is found and 
people living in close proximity to such sites might provide useful information. Additional information
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regarding the potential for health effects in human populations consuming food sources such as fish with 
documented levels of toxaphene residues would be useful.
Chronic-Duration Exposure and Cancer. Available information regarding noncancer and cancer 
effects is limited to chronic-duration oral studies in animals. Neurological, immunological, and body 
weight effects were reported in rats and mice (NCI 1979) and cynomolgus monkeys (Arnold et al. 2001; 
Bryce et al. 2001; Tryphonas et al. 2001) administered toxaphene orally for chronic durations. A chronic- 
duration oral MRL was not derived for toxaphene because the study that identified the highest NOAEL 
(0.4 mg/kg/day) associated with the lowest LOAEL (0.8 mg/kg/day for significantly depressed humoral 
immune response) after 52 weeks of toxaphene treatment identified a LOAEL of 0.4 mg/kg/day for 
another measure of humoral immune response after <52 weeks of toxaphene treatment (Tryphonas et al. 
2001). Therefore, the intermediate-duration oral MRL should be protective of immunological effects 
following chronic-duration oral exposure to toxaphene. Lifetime oral studies found increased incidences 
of thyroid tumors in rats and hepatic tumors in mice exposed to high oral doses of toxaphene (NCI 1979). 
Additional chronic-duration toxicity and carcinogenicity studies in animals do not appear necessary. All 
uses for toxaphene have been banned in the United States and its territories (EPA 1990b). Monitoring of 
workers at waste sites where toxaphene is found and people living in close proximity to such sites might 
provide useful information. Additional information regarding potential for health effects in human 
populations consuming food sources such as fish with documented levels of toxaphene residues would be 
useful.
G enotoxicity. Limited information is available regarding the genotoxicity of toxaphene in humans. A 
higher incidence of chromosomal aberrations was observed in cultured lymphocytes taken from the blood 
of eight women exposed to toxaphene compared to lymphocytes taken from unexposed women (Samosh
1974). Additional assessment of the genotoxic potential of toxaphene would be helpful in the unlikely 
event that populations with significant exposure to toxaphene can be identified.
Available in vivo genotoxicity data from animals are limited to a dominant lethality test in which 
toxaphene did not cause increased fetal death or decreased numbers of implants in mouse dams mated to 
males that had been administered toxaphene orally (Epstein et al. 1972); a study that reported the lack of 
DNA damage in rats administered toxaphene once by gavage at up to 36 mg/kg/day (Kitchin and Brown 
1994); and a study that found no evidence of DNA adduct formation in livers of mice administered 
toxaphene by gavage for 7 days at doses up to and including 100 mg/kg/day (Hedli et al. 1998).
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Available in vitro assays provide positive and negative results. Bacterial reverse mutation assays provide 
evidence of a mutagenic effect in the absence of metabolic activation systems (Hooper et al. 1979; 
Mortelmans et al. 1986; Schrader et al. 1998; Steinberg et al. 1998) and diminished or abolished 
mutagenic responses with the addition of metabolic activation systems (Hooper et al. 1979; Schrader et al. 
1998). Other in vitro genotoxicity assays provide equivocal results (Bartos et al. 2005; Griffin and Hill 
1978; Houk and DeMartini 1987; Mortelmans et al. 1986; Schrader et al. 1998; Sobti et al. 1983; Steinel 
et al. 1990). Additional in vivo data would be useful to more rigorously assess the potential genotoxicity 
of toxaphene.
Reproductive Toxicity. No information was located regarding toxaphene-induced reproductive 
effects in humans. The available information from multigeneration studies in rats indicates that 
toxaphene does not adversely affect reproductive end points (Kennedy et al. 1973; Keplinger et al. 1970). 
Additional studies do not appear necessary.
Developmental Toxicity. No information was located regarding toxaphene-induced developmental 
effects in humans. Toxaphene was reported to cause inferior swimming and righting ability in young 
mouse pups (9-12 days postpartum, but not at 16 days postpartum) of dams administered toxaphene by 
gavage at 0.05 mg/kg/day (the only dose tested) throughout gestation and lactation (Olson et al. 1980). 
Allen et al. (1983) reported suppression of phagocytic function in peritoneal macrophages from offspring 
of rat dams receiving toxaphene in the diet at 19.5 mg/kg/day prior to mating and during gestation and 
lactation; however, phagocytic function was enhanced at a higher dose level (39 mg/kg/day). Crowder et 
al. (1980) found no evidence of developmental toxicity following oral exposure of rat dams to toxaphene 
at 6 mg/kg/day (the only dose tested) during gestation. A comprehensive developmental toxicity study 
could be designed to provide supporting or refuting evidence to the findings of Olson et al. (1980).
Im m unotoxicity. No information was located regarding immunologic effects of toxaphene in 
humans. Toxaphene-related depressed IgG production was reported in adult rats (Koller et al. 1983). 
Depressed humoral responses were noted in rat neonates exposed via their mothers (Allen et al. 1983) and 
in cynomolgus monkeys administered toxaphene orally for up to 75 weeks (Tryphonas et al. 2001). 
Additional studies of toxaphene-induced immunotoxicity in laboratory animals do not appear necessary at 
this time.
Neurotoxicity. Neurological effects have been reported in several cases of inadvertent or intentional 
ingestion of unknown “large amounts” of toxaphene (McGee et al. 1952; Wells and Milhorn 1983).
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Convulsions were induced in dogs (Chu et al. 1986; Lackey 1949) and heifers (Steele et al. 1980) 
following acute oral exposure to toxaphene. NCI (1979) reported clinical signs of neurotoxicity in rats 
and mice administered toxaphene orally for chronic durations. The animal data indicate that dogs are 
particularly sensitive to toxaphene neurotoxicity. Additional studies of the neurological effects in 
toxaphene-exposed animals do not appear necessary. All uses for toxaphene have been banned in the 
United States and its territories (EPA 1990b). Monitoring of workers at waste sites where toxaphene is 
found and people living in close proximity to such sites might provide useful information. Additional 
information regarding the potential for health effects in human populations consuming food sources such 
as fish with documented levels of toxaphene residues would be useful.
Epidem iological and Human Dosim etry Studies. Most of the available information on the 
effects of toxaphene in humans comes from cases of acute poisoning following accidental or intentional 
ingestion of toxaphene and from occupational exposures in agricultural industries. Limitations inherent in 
these studies include unquantified exposure concentrations and durations, and concomitant exposure to 
other pesticides. Despite their inadequacies, those studies suggest that toxaphene can adversely affect the 
liver, kidneys, lungs, and central nervous system (McGee et al. 1952; Warraki 1963; Wells and Milhorn 
1983). All uses for toxaphene have been banned in the United States and its territories (EPA 1990b). 
Monitoring of workers at waste sites where toxaphene is found and people living in close proximity to 
such sites might provide useful information. Additional information regarding the potential for health 
effects in human populations consuming food sources such as fish with documented levels of toxaphene 
residues would be useful.
Biom arkers o f Exposure and Effect.
Exposure. Toxaphene levels have been measured in blood, fat, urine, and feces (Ohsawa et al. 1975; 
Pollock and Kilgore 1980b). No studies demonstrate a reliable correlation between blood levels and 
levels of exposure. Fat samples contain toxaphene levels proportional to treatment levels (Pollock and 
Kilgore 1980b), but fat samples are difficult to obtain from humans. Levels of toxaphene in milk fat may 
provide a more accurate estimate of exposure than body fat or blood (Keating 1979), but these samples 
can only be obtained from a small portion of the population. Because toxaphene is rapidly eliminated 
from the body, tissue levels are a useful measure only shortly following exposure to toxaphene.
Persistent toxaphene congeners in fat might serve as useful biomarkers of exposure and would be most 
likely associated with exposure to weathered toxaphene.
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Effect. No specific biomarkers of effects have been identified for toxaphene. Toxaphene has been 
demonstrated to cause a number of adverse health effects including central nervous system excitation, 
liver and kidney damage, and developmental and immunosuppressive effects. These effects are not 
specific for toxaphene and no studies exist that demonstrate good correlation of toxaphene levels with 
human health effects. Neurological tests such as electroencephalographic monitoring can record levels of 
central nervous system activity. Liver and kidney function tests exist that detect hepatic and renal 
impairment. Microsomal enzyme activity may indicate early effects in the liver. Effects on the immune 
system can be measured by measuring immunoglobulin levels. Although each of these tests can indicate 
the presence of disease in the systems affected by toxaphene, the effects can be caused by a number of 
other disease states.
Absorp tion, D istribution, Metabolism, and Excretion. Quantitative evidence on the absorption 
of toxaphene in humans and animals following all routes of exposure is very limited. Female animals 
dipped in toxaphene excrete the substance in milk and also sometimes experience toxicosis (Claborn et al. 
1963). Humans and animals have become seriously ill following accidental or intentional ingestion of 
toxaphene. The evidence clearly indicates that toxaphene is absorbed. Reports that specifically evaluate 
its rate or extent of absorption as a result of inhalation, oral, and dermal exposure would be useful.
No studies were located regarding the distribution of toxaphene in humans or animals following 
inhalation or dermal exposures. No evidence is available regarding the distribution of toxaphene in 
humans following ingestion. However, animal studies conducted in several species indicate that 
distribution following oral absorption is similar across species (Mohammed et al. 1983; Ohsawa et al. 
1975; Pollock and Kilgore 1980b), and it is assumed that distribution of the pesticide in humans would be 
similar. Once absorbed, toxaphene and its components are distributed initially throughout the blood 
compartment and then to fat. Studies that investigate the distribution of toxaphene following inhalation 
or dermal exposure would be helpful in order to evaluate whether toxaphene behaves similarly across all 
routes of exposure.
Information was not available regarding the metabolism of toxaphene following dermal or inhalation 
exposure in animals or humans. This information would be useful for estimating health effects by these 
routes. Moreover, no information was available regarding the metabolites formed by humans following 
ingestion. Evidence from animals receiving toxaphene orally indicates that dechlorination, 
dehydrodechlorination, and oxidation are principal metabolic pathways (Crowder and Dindal 1974; 
Ohsawa et al. 1975). Although several metabolites have been isolated and identified (Ohsawa et al.
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1975), several others remain unknown. Their identification will help elucidate the toxaphene metabolic 
pathway(s).
Quantitative information regarding the metabolites produced would suggest which biodegradation 
pathways are favored and provide insight into the enzyme kinetics. Information regarding the overall rate 
of metabolism and the rates of specific reactions would be useful. In addition, such studies might also 
provide information to help facilitate the metabolism of the toxaphene mixture in accidentally exposed 
humans.
No studies in humans were found regarding the excretion of toxaphene. Excretion data from animal 
studies are available for oral and dermal exposure routes. Mice that received toxaphene intravenously 
were found to have toxaphene present in the intestinal content, suggesting biliary excretion (Mohammed 
et al. 1983). The presence of several metabolites in the urine and feces suggests that toxaphene 
degradation is extensive and complex (Ohsawa et al. 1975; Pollock and Kilgore 1980b). Though 
metabolism of toxaphene facilitates its excretion, and the kinetics of toxaphene metabolism are related to 
the kinetics of excretion, they are not the same. Since metabolites may also contribute to the toxic effects 
attributed to toxaphene, it would be beneficial to conduct studies that would establish elimination rates for 
each toxaphene metabolite or for similar metabolic products. Such studies may also provide information 
to facilitate the rapid removal of toxaphene and its metabolites in exposed people.
Virtually all toxicokinetic properties reported in this profile were based on results from acute-duration 
exposure studies. Very limited information was available regarding intermediate- or chronic-duration 
exposure to toxaphene. Since toxaphene is known to induce hepatic enzymes, the kinetics of metabolism 
during chronic exposure probably differ from those seen during acute exposure. Thus, additional studies 
on the metabolism of toxaphene during intermediate- or chronic-duration exposure would be useful.
Comparative Toxicokinetics. The absorption, distribution, metabolism, and excretion of toxaphene 
have been studied in animals, but only information on absorption is available in humans. In several 
mammalian species, it is evident that toxaphene is absorbed, metabolized in the liver (with some 
elimination probably occurring via the hepatobiliary system), and then possibly some parent compound 
and metabolites are distributed to fat (Ohsawa et al. 1975; Pollock and Kilgore 1980b). Very little is 
excreted unchanged. In studies of mammals, the extent of metabolism increased with the physiological 
complexity of the species. Based on this trend, humans would be expected to metabolize toxaphene 
extensively in a manner qualitatively similar to animals.
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3. HEALTH EFFECTS
Methods fo r Reducing Toxic Effects. The medical procedures used to reduce the toxic effects of 
toxaphene are well established and are those used to treat organochlorine poisoning or poisoning due to 
other chemicals with central nervous system stimulatory properties. However, data on how to best reduce 
body burden and also on how to prevent the inhibition of y-aminobutyric acid-dependent chloride ion 
channels would be useful.
Children’s Susceptib ility . Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above.
No human data are available regarding age-related susceptibility to toxaphene. Results of one animal 
study (Olsen et al. 1980) indicate that critical stages of neurological development may be periods of 
increased vulnerability. Immunosuppression has been demonstrated in some animals exposed to 
toxaphene (Allen et al. 1983; Koller et al. 1983; Tryphonas et al. 2001), and it is known that infants and 
children are especially susceptible to immunosuppression because their immune systems do not reach 
maturity until 10-12 years of age (Calabrese 1978). As identified in the Developmental Toxicity 
subsection, a well-designed, developmental toxicity animal study could provide additional insight into 
age-related susceptibility to toxaphene.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: 
Exposures of Children.
3.12.3 Ongoing Studies
Search of the Federal Research in Progress database (FEDRIP 2010) revealed no ongoing studies of 
toxaphene-related health effects.
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1 CHEMICAL IDENTITY
Information regarding the chemical identity of toxaphene is located in Table 4-1.
4.2 PHYSICAL AND CHEMICAL PROPERTIES
Information regarding the physical and chemical properties of toxaphene is located in Table 4-2. 
Toxaphene is not a single molecular substance; rather, it is a complex mixture of congeners including 
chlorinated bornanes, bornenes, bornadienes, camphenes, and dihydrocamphenes (de Geus et al. 1999). 
The congeners typically contain 6-10 chlorine atoms each (de Geus et al. 1999; Lau et al. 1996). 
Representative structures for the different types of toxaphene congeners are shown in Figure 4-1. 
Although thousands of toxaphene congeners are theoretically possible based on these structures, only a 
few hundred are expected to be present at significant concentrations in technical toxaphene (de Geus et al. 
1999; Lamb et al. 2008; Simon and Manning 2006).
The chemical structure of specific toxaphene congeners has been described using a variety of 
nomenclature systems, some of which are summarized in de Geus et al. (1999). This Toxicological 
Profile for Toxaphene employs the nomenclature system developed by Dr. Harun Parlar to refer to 
specific congeners (Coelhan and Parlar 1996).
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4. CHEMICAL AND PHYSICAL INFORMATION
Table 4-1. Chemical Identity of Toxaphene
Characteristic Information Reference
Chemical name Toxaphene ChemIDplus Advanced 
2010
Synonym(s) Campheclor; chlorinated camphene; 
polychlorocamphene; chlorocamphene; 
octachlorocamphene; technical toxaphene
ChemIDplus Advanced 
2010
Registered trade name(s) Agricide Maggot Killer; Alltox; Camphofene 
Huilex; Geniphene; Hercules 3956; 
Hercules Toxaphene; Motox; Penphene; 
Phenicide; Phenatox; Strobane-T; 
Synthetic 3956; Toxakil
IARC 1979
Chemical formula C10H10Cl8 (approximately) O'Neil et al. 2006
Chemical structurea (H3 C)2
| HCH ] —  Cl8 
CH^ ^
Paris and Lewis 1973
Identification numbers: 
CAS Registry 
NIOSH RTECS 
EPA Hazardous Waste 
DOT/UN/NA/IMCO 
HSDB
8001-35-2
XW5250000
P123
NA 2761/toxaphene 
1616
ChemIDplus Advanced 
2010; NIOSH 2005 
HSDB 2010 
NIOSH 2005 
HSDB 2010
aStructure representative of the predominant chlorinated camphene compounds present in technical toxaphene.
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; IARC = International Agency for Research on Cancer; NIOSH = 
National Institute for Occupational Safety and Health; RTECS = Registry of Toxic Effects of Chemical Substances
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4. CHEMICAL AND PHYSICAL INFORMATION
Table 4-2. Physical and Chemical Properties of Toxaphene3
Property Inform ation R eference
Molecular weight 431.8 (approximately) BCPC 2003
Color/form Yellow, waxy, amber NIOSH 2005; O'Neil et al. 2006
Physical state Solid O'Neil et al. 2006
Melting point 65-90 °C O'Neil et al. 2006
Boiling point Not applicable 
(dechlorinates at 155 °C)
O'Neil et al. 2006
Density at 25 °C 1.65 g/cm3 BCPC 2003
Odor
Odor threshold:
Mild, piney, chlorine- and camphor­
like odor
NIOSH 2005
Air 0.14 ppm (detection) Sigworth 1965; Ruth 1986
Water 2.4 mg/m3
0.14 ppm (detection)
HSDB2010
Solubility: Murphy et al. 1987
Water 0.55 mg/L
Organic solvent(s) 
Partition coefficients:
Freely soluble in aromatic 
hydrocarbons
Readily soluble in organic solvents, 
including petroleum oils
BCPC 2003; O'Neil et al. 2006
Log K0w 3.3-6.64 EPA 1981a; F iske ta l. 1999
Log KoC 3-5 EPA 1981a; Soubaneh et al. 
2008; Wauchope et al. 1992
Vapor pressure 6.69x1 O'6 mm Hg at 20 °C Murphy et al. 1987
Henry's law constant 6x10"6 atm-m3/mol at 20 °C Murphy et al. 1987
Autoignition temperature No data
Flashpoint 135 °C (closed cup, 60% solution) 
115 °C (tag closed cup, 90% 
solution)
HSDB2010
Flammability limits in air Solid is not flammable, but is 
usually dissolved in combustible 
liquid
HSDB2010
Conversion factors (25 °C) 1 ppm x  17.95(average)=1 mg/m3; 
1 mg/m3 x  0.056 (average)=1 ppm
Calculated
Explosive limits No data
t e c h n ic a l  toxaphene is a complex mixture of hundreds of polychlorinated bicyclic terpenes consisting predominantly 
of chlorinated cam phenes (Jansson and Wideqvist 1983; Paris and Lewis 1973). Toxaphene contains 67-69%  
chlorine by weight (de Geus et al. 1983).
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Figure 4-1. Representative Carbon Skeleton Structures of the Toxaphene 
Congeners with Numbered Carbon Atomsa
4. CHEMICAL AND PHYSICAL INFORMATION
Bornane Bornene Bornadiene
Camphene Dihydrocamphene
aCongeners typically contain 6 -10  chlorine atoms. 
Source: de Geus et al. 1999
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
Toxaphene does not occur naturally (Canada Department of National Health and Welfare 1978; EPA 
1976a; IARC 1979). It is a complex mixture of at least 670 chlorinated terpenes (Jansson and Wideqvist 
1983). Technical toxaphene can be produced commercially by reacting chlorine gas with technical 
camphene in the presence of ultraviolet radiation and catalysts, yielding chlorinated camphene containing 
67-69% chlorine by weight (EPA 1976a; Korte et al. 1979; Vetter and Scherer 1998). It has been 
available in various forms: a solid containing 100% technical toxaphene; a 90% solution in xylene or oil; 
a 40% wettable powder; 5-20 and 40% dusts; 10 and 20% granules; 4, 6, and 9% emulsifiable 
concentrates; 1% baits; a 2:1 toxaphene; DDT emulsion; and a 14% dust containing 7% DDT (IARC 
1979; IUPAC 1979; Penumarthy et al. 1976).
In 1982, EPA canceled the registrations of toxaphene for most uses as a pesticide or pesticide ingredient, 
except for certain uses under specific terms and conditions (EPA 1982a, 1993a; USDA 1995). All 
registered uses were banned in 1990 (EPA 1990b), and existing stocks of the pesticide were not allowed 
to be sold or used in the United States after March 1, 1990 (USDA 1995). In 1976, toxaphene was 
produced primarily by Hercules Incorporated, Wilmington, Delaware (Penumarthy et al. 1976). 
Production by a total of three U.S. companies (Hercules Incorporated, Tenneco, and Vicksburg Chemical 
Co., a division of Vertac) during 1976 totaled 19 million kg, which was a 29% decline from the 
production level of 27 million kg in 1975 (IARC 1979). Montgomery and Welkom (1990) listed 
Hercules Incorporated, Brunswick, Georgia, and Sonford Chemical Company, Port Neches, Texas, as 
selected manufacturers of toxaphene; however, no production estimates were provided. Total U.S. 
production in 1977 was estimated to be 18.1 million kg (HSDB 2010). In 1982, it was estimated that 
3.7 million pounds (<2 million kg) were produced in the United States (EPA 1987a). This represents a 
decline of more than 90% from 1972, when toxaphene was the most heavily manufactured insecticide in 
the United States, with a production volume of 23,000 tons (21 million kg) (Grayson 1981). The Toxics 
Release Inventory (TRI) lists one facility in Idaho and one facility in Texas that were involved in 
toxaphene production during 2008 (TRI08 2010). No other information regarding recent production of 
toxaphene in the United States was found.
Especially in the United States, the definition of "technical toxaphene" was patterned after the Hercules 
Incorporated product (Hercules Code Number 3956) marketed under the trademark name of 
"Toxaphene." Hercules Incorporated has essentially let the name of toxaphene lapse into the public
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domain so that many products with similar properties are referred to as toxaphene (Worthing and Walker 
1987). Other companies used slightly different manufacturing processes, leading to a chlorinated 
camphene mixture with degrees of total chlorination and a distribution of specific congeners that are not 
the same as the Hercules Incorporated product. For instance, the toxaphene-like product commonly 
marketed under names like "Stroban(e)" had a slightly lowered degree of chlorination and used slightly 
different camphene or pinene feedstocks (Walter and Ballschmiter 1991).
Since the early 2000s, efforts have been underway to eliminate the production and use of toxaphene 
worldwide. The Stockholm Convention, an international treaty designed to restrict the production and use 
of various chemical substances among its member nations, includes toxaphene on a list of persistent 
organic pollutants or POPs (Stockholm Convention 2008). Under the rules of the convention, production 
or use of toxaphene is completely banned and exemptions are not available. The convention, which 
initially went into effect in 2005, listed over 150 participating nations as of June, 2010.
While most attention has been focused on the intentional production of polychlorinated camphenes 
(PCCs) as pesticide agents, there is evidence that PCC congeners may be an unintentional byproduct of 
manufacturing processes that use chlorination, such as those for paper and pulp (Rantio et al. 1993).
Because toxaphene is a Priority Pollutant under the Clean Water Act, it is required to be included in the 
TRI (EPA 2005). All registered uses of toxaphene on food commodities were canceled by 1990 (EPA 
1982a, 1990b), and the sale and use of existing stocks of the pesticide in the United States were prohibited 
after March 1, 1990 (USDA 1995). Therefore, current information included in the TRI regarding the 
processing or use of toxaphene at industrial facilities is expected to be related to the storage and disposal 
of toxaphene supplies or the use of this substance in onsite processing and as a manufacturing aid. These 
facilities are not expected to be involved in production or import of toxaphene for pesticidal use in the 
United States. Table 5-1 summarizes the number of facilities in each state that processed or used 
toxaphene in 2008, the ranges of maximum amounts on site, if reported, and the activities and uses as 
reported in the TRI (TRI08 2010). The data listed in this table should be used with caution since only 
certain types of facilities are required to report. This is not an exhaustive list.
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Table 5-1. Facilities that Produce, Process, or Use Toxaphene
State3
Number of 
facilities
Minimum 
amount on site 
in poundsb
Maximum 
amount on site 
in poundsb Activities and usesc
AL 1 0 99 12
AR 5 0 99,999 2, 5, 7, 9, 12
CA 3 0 9,999 12
ID 1 0 99 1,3, 12
IL 2 0 999 12
IN 3 0 9,999 2, 3, 12, 13, 14
KY 1 1,000 9,999 12
LA 3 0 9,999 12
MI 3 0 999 12, 14
MS 1 1,000 9,999 2, 3, 8
NE 3 100 999,999 12
NJ 1 100 999 12
NV 2 1,000 99,999 2, 3, 12
OH 4 0 99,999 12
OK 2 0 99,999 12
OR 2 100 9,999 12
PA 1 0 99 12
SC 1 10,000 99,999 12
TX 6 0 9,999,999 1d, 3, 12
UT 2 0 9,999 12
WI 1 0 99 8
aPost office state abbreviations used.
bAmounts on site reported by facilities in each state.
cActivities/Uses:
1. Produce 6. Impurity
2. Import 7. Reactant
3. Onsite use/processing 8. Formulation Component
4. Sale/Distribution 9. Article Component
5. Byproduct 10. Repackaging
dProduction is reported for only one facility in Texas.
Source: TRI08 2010 (Data are from 2008)
11. Chemical Processing Aid
12. Manufacturing Aid
13. Ancillary/Other Uses
14. Process Impurity
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5.2 IMPORT/EXPORT
In 1972, a total of 8,000 metric tons (7.25 million kg) of toxaphene, or 35% of the annual production, was 
exported (EPA 1974b; SRI 1993; USITC 1991). The TRI lists four states containing facilities that were 
involved with the import of toxaphene into the United States during 2008 (TRI08 2010). No other 
information was found regarding the import of toxaphene into or the export of toxaphene from the United 
States.
5.3 USE
Toxaphene was formerly used as a nonsystemic stomach and contact insecticide with some acaricidal 
activity. Being nonphytotoxic (except to cucurbitus), it was used to control many insects thriving on 
cotton, corn, fruit, vegetables, and small grains and to control the Cassia obtusifola soybean pest. 
Toxaphene was also used to control livestock ectoparasites such as lice, flies, ticks, mange, and scab 
mites (Knipling and Westlake 1966; Meister 1988; Worthing 1979). Toxaphene’s relatively low toxicity 
to bees and its long persisting insecticidal effect made it particularly useful in the treatment of flowering 
plants. Toxaphene was not used to control cockroaches because its action on them is weaker than 
chlordane (IARC 1979). Toxaphene was used at one time in the United States to eradicate fish (Muirhead 
Thomson 1971). The principal use was for pest control on cotton crops (IUPAC 1979; Verschueren 
1983). In 1974, an estimated 20 million kg used in the United States was distributed as follows: 85% on 
cotton; 7% on livestock and poultry; 5% on other field crops; 3% on soybeans; and <1% on sorghum 
(IARC 1979). Based on estimates of EPA (1974b) for 1972, 75% of the toxaphene production for that 
year was for agricultural use; 24% was exported; and 1% was used for industrial and commercial 
applications.
Toxaphene solutions were often mixed with other pesticides partly because toxaphene solutions appear to 
help solubilize other insecticides with low water solubility. Toxaphene was frequently applied with 
methyl or ethyl parathion, DDT, and lindane (IARC 1979; WHO 1974).
Through the early 1970s, toxaphene or mixtures of toxaphene with rotenone were used widely in lakes 
and streams by fish and game agencies to eliminate biologic communities that were considered 
undesirable for sport fishing (Lockhart et al. 1992; Stern et al. 1993). This practice was especially 
prominent in parts of Canada and the northern United States for fish restocking experiments on smaller 
glacial lakes. Because the toxic effects of toxaphene may persist for many years in an aquatic system,
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difficulties in establishing the desired sports fisheries were among the first strong indications that 
toxaphene was a persistent and bioaccumulative material. Such uses of toxaphene by fish and game 
agencies have apparently been discontinued in the United States and Canada.
Toxaphene use in this country has declined drastically since 1975, when it was reported to be the most 
heavily used pesticide (Sanders 1975). The total used was estimated at only 9,360 tons (8.5 million kg) in 
1980 and 5,400 tons (4.9 million kg) in 1982 (WHO 1984). In November 1982, EPA canceled the 
registrations of toxaphene for most uses as a pesticide or pesticide ingredient (EPA 1982a). In the period 
following November 1982, its use was restricted to controlling scabies on sheep and cattle; grasshopper 
and army worm infestations on cotton, corn, and small grains; and specific insects on banana and 
pineapple crops in Puerto Rico and the U.S. Virgin Islands; and for emergency use only (to be determined 
on a case-by-case basis by EPA) (EPA 1982a; WHO 1984). Formulations suitable for other purposes 
could be sold or distributed until December 31, 1983, for use only on registered sites (EPA 1982a). The 
distribution or sale of remaining stocks of toxaphene formulations were permitted until December 31, 
1986, for use on no-till corn, soybeans, and peanuts (to control sicklepod), and dry and southern peas, and 
to control emergency infestations. All registered uses of toxaphene mixtures in the United States and any 
of its territories were canceled in 1990 (EPA 1990b).
5.4 DISPOSAL
Toxaphene may not be disposed of by water or ocean dumping or by burning in the open air. The 
recommended disposal method is incineration in a pesticide incinerator at a temperature and residence 
time combination that will result in complete destruction of the chemical (EPA 1989a). Any emissions 
generated by incineration must meet the requirements of the Clean Air Act Amendments, Title III, and 
any liquids, sludges, or solid residues produced should be disposed of in accordance with federal, state, 
and local pollution control requirements. Municipal solid waste incinerators may be used, providing that 
they meet the criterion of a new pesticide incinerator and are operated under supervision (EPA 1989a). 
Landfill has also been identified as a recommendable method of disposal of toxaphene (IRPTC 1985). 
Thermal desorption is reported to be an effective technology for treating soils contaminated with 
toxaphene (Troxler et al. 1993). Federal, state, and local regulations governing the treatment and disposal 
of wastes containing toxaphene are presented in Chapter 8.
No information was found in the available literature on the amounts of toxaphene disposed of in the 
United States by any disposal method.
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1 OVERVIEW
Toxaphene has been identified in at least 68 of the 1,699 hazardous waste sites that have been proposed 
for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). However, the number of sites 
evaluated for toxaphene is not known. The frequency of these sites can be seen in Figure 6-1.
Toxaphene is a complex mixture of several hundred polychlorinated bicyclic terpene congeners (de Geus 
et al. 1999; Jansson and Wideqvist 1983; Lamb et al. 2008; Lau et al. 1996; Paris and Lewis 1973; Simon 
and Manning 2006). The transport and transformation of each of these components is influenced by its 
individual physical/chemical properties, in addition to those of the mixture as a whole. Although some 
data in the available literature indicate selective volatilization and metabolism of individual fractions of 
the mixture, the environmental fate of the mixture rather than of individual components has been studied 
by most investigators.
Toxaphene has been widely dispersed to the environment mainly as a result of its past use as an 
insecticide. The mixture partitions to the atmosphere, surface water and groundwater, soil and sediment 
particulates, and adipose tissue. As a result of its volatility and environmental persistence, toxaphene 
continues to be transported over long distances in the atmosphere (Andersson et al. 1988; Bidleman and 
Olney 1975; MacLeod et al. 2002; Paasivirta et al. 2009; Swackhamer and Hites 1988; Zell and 
Ballschmiter 1980). The half-life (first-order kinetics) for reaction of atmospheric toxaphene with 
photochemically produced hydroxyl radicals has been estimated to be at least 4-5 days for vapor-phase 
components of toxaphene (Howard 1991; Kelly et al. 1994); however, many congeners exist 
predominantly in the particulate phase and subsequently have longer atmospheric residence times and 
greater potential for long-range transport. Toxaphene strongly adsorbs to particles and is relatively 
immobile in soils (EPA 1981a; Soubaneh et al. 2008; Swann et al. 1983; Wauchope et al. 1992). In 
water, toxaphene is strongly adsorbed to suspended particulates and sediments and is bioconcentrated by 
aquatic organisms to fairly high levels, with bioconcentration factors (BCFs) on the order of 4,200­
60,000 (Sanborn et al. 1976; Schimmel et al. 1977). Toxaphene also appears to be biomagnified in 
aquatic food chains. Toxaphene is biotransformed relatively rapidly in soils and sediments under 
anaerobic conditions, with a half-life or half-disappearance time in the range of weeks to months (EPA 
1979a). However, the mixture appears to be relatively resistant to biotransformation in these media under 
aerobic conditions (half-life = years) (EPA 1979a; de Geus et al. 1999; Nash and Woolson 1967; Parr and 
Smith 1976; Smith and Willis 1978).
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Recently, efforts have been made to differentiate between the form of toxaphene as it was formerly used 
as a pesticide, known as technical toxaphene, and the "weathered" form of this substance after years of 
environmental transport and degradation processes have had their effect (EPA 2010e). Weathered 
toxaphene is considered to be the most relevant form when assessing the current potential for human 
exposure to toxaphene. In order to achieve the best understanding of what individuals may be exposed to 
in the environment, recent studies have measured the levels of individual toxaphene congeners present in 
environmental samples. Congeners p-26, p-50, and p-62 are reported to be persistent in fish, marine 
mammals, human serum, and breast milk (Simon and Manning 2006). The toxicological implications of 
environmentally-persistent congeners of weathered toxaphene have not been adequately assessed.
Human exposure to toxaphene currently appears to be limited to ingestion of low concentrations of the 
mixture in food, particularly fish, and possibly to inhalation of ambient air. The most probable 
populations potentially exposed to relatively high concentrations of the mixture are individuals residing in 
the vicinity of hazardous waste disposal sites contaminated with toxaphene. Other subpopulations with 
potentially higher exposure rates may be northern Native American groups that eat aquatic mammals, 
which may contain residues of toxaphene (Muir et al. 1992), recreational or subsistence hunters in the 
southern United States that consume significant amounts of game animals (especially species like 
raccoons) (Ford and Hill 1990), and people who consume certain types of sportfish caught in the Great 
Lakes (ATSDR 2009).
6.2 RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report releases into the environment (EPA 2005). This is not an exhaustive list. 
Manufacturing and processing facilities are required to report information to the TRI only if they employ 
10 or more full-time employees; if their facility is included in Standard Industrial Classification (SIC) 
Codes 10 (except 1011, 1081, and 1094), 12 (except 1241), 20-39, 4911 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4931 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4939 (limited to facilities that combust coal and/or oil for the purpose of generating 
electricity for distribution in commerce), 4953 (limited to facilities regulated under RCRA Subtitle C,
42 U.S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 
7389 (limited to facilities primarily engaged in solvents recovery services on a contract or fee basis); and
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if their facility produces, imports, or processes >25,000 pounds of any TRI chemical or otherwise uses 
>10,000 pounds of a TRI chemical in a calendar year (EPA 2005).
Toxaphene has been detected in the atmosphere, soils, surface waters and sediments, rainwater, aquatic 
organisms, and foodstuffs. Historically, toxaphene has been released to the environment mainly as a 
result of its past use as an agricultural insecticide (EPA 1979f). Toxaphene-like mixtures of PCC 
congeners may also be released to the environment as unintentional byproducts from manufacturing 
processes involving chlorination, such as those used for paper and pulp (Rantio et al. 1993). There are no 
known natural sources of the mixture.
Because toxaphene is a Priority Pollutant under the Clean Water Act, it is required to be included in the 
TRI (EPA 2005). However, since most registered uses of toxaphene as a pesticide were canceled in 1982 
(EPA 1982a) and all registered uses were canceled in the United States and its territories after 1990 (EPA 
1990b), production of toxaphene for domestic use in the United States has ceased. Consequently, most 
releases of toxaphene reported to TRI for 2008 were disposals to landfills (TRI08 2010).
Current sources of toxaphene in the environment that may result in exposure for the U.S. population is 
long-range atmospheric transport from countries currently producing or using toxaphene (e.g., Mexico 
and countries in Central America, eastern Europe, the former Soviet Union, and parts of Asia) 
(Swackhamer et al. 1993; Voldner and Li 1993) and continued releases from previously contaminated 
U.S. soils and waters.
6.2.1 A ir
Estimated releases of 64 pounds (0.029 metric tons) of toxaphene to the atmosphere from 14 domestic 
manufacturing and processing facilities in 2008, accounted for <0.1% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI08 2010). These releases are 
summarized in Table 6-1.
As a result of its past use as an insecticide on crops in the southern United States, toxaphene was 
dispersed directly to the atmosphere by aerial and ground application (EPA 1979f). Volatilization of the 
mixture from treated crop and soil surfaces following application also introduced substantial amounts of 
toxaphene to the atmosphere. For example, Willis et al. (1980, 1983) reported volatilization losses from 
treated cotton canopies of up to 80% of applied toxaphene within 11 days after treatment. Seiber et al.
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or
Use Toxaphenea
Statec RFd
Reported amounts released in pounds per yearb
Aire Waterf UIg Landh Otheri On-site*
Total release
Off-sitek On- and off-site
AR 2 10 0 0 0 833 10 833 843
IL 1 0 0 0 0 1 0 1 1
LA 1 3 0 0 9 0 12 0 12
NV 1 0 0 0 28 0 28 0 28
OH 0 0 0 79 75 0 154 155
OK 1 40 0 0 415,473 0 415,513 0 415,513
OR 1 1 0 0 1,961 0 1,962 0 1,962
TX 6 0 0 0 0 6 0 6
UT 1 3 0 0 0 0 3 0 3
WI 1 0 0 0 0 0 0 0 0
Total 14 64 0 0 417,550 908 417,535 988 418,523
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an
exhaustive list. Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
S torage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection
Source: TRI08 2010 (Data are from 2008)
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(1979) also reported that volatilization from leaf and soil surfaces was the major removal mechanism for 
toxaphene applied to cotton crops under field conditions. These investigators reported differential 
vaporization of the mixture (i.e., selectively greater loss of the more volatile components from soil and 
leaf surfaces), which was matched by a corresponding enrichment of these components in ambient air 
samples.
Toxaphene shows a strong tendency to sorb to particulates, and there has been a tendency to believe that 
toxaphene residuals in older hazardous waste sites would be relatively inert. Studies based primarily on 
theoretical considerations and computer screening models suggest that the PCCs could volatilize to the 
atmosphere unless a waste site has a clay cap thicker than approximately 0.3 m. The potential for 
volatilization increases if the soil matrix in which the toxaphene is buried has a significant sand fraction 
(Jury et al. 1990). These theoretical findings seem compatible with field measurements on several 
pesticides that showed the volatilization rates for toxaphene applied to soils were significantly higher than 
rates for triazine herbicides or alachlor (Glotfelty et al. 1989a). Toxaphene has been identified in air 
samples collected at 3 of the 68 NPL hazardous waste sites where it was detected in some environmental 
media (HazDat 2007).
6.2.2 W ater
No releases of toxaphene to surface water from domestic manufacturing and processing facilities required 
to report to the TRI were reported for 2008 (TRI08 2010). Estimated releases of 988 million pounds 
(0.448 metric tons) of toxaphene off-site, which include transfers to publicly owned treatment works 
(POTWs), accounted for 0.23% of the estimated total environmental releases from facilities required to 
report to the TRI. The 2008 TRI release information is summarized in Table 6-1.
Toxaphene has been released to surface waters as a result of its direct application to lakes as a piscicide 
(EPA 1979f), in waste water releases from manufacturing and formulation plants (Durant and Reimold 
1972), and in activities associated with the disposition of residual pesticides. For example, Mirsatari et al. 
(1987) described the release of aircraft rinse water to drainage ditches following aerial application of 
toxaphene, and the compound has been detected in surface water samples taken from disposal ponds at a 
Superfund site (EPA 1986a). NOAA (1974) reported that toxaphene concentrations in the effluent of a 
manufacturing plant decreased over a 4-year period from an average maximum monthly concentration of 
2,332 ppb in August 1970 to 6 ppb in July 1974.
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Because neat technical toxaphene sorbs to particulates and is markedly hydrophobic, it has been argued 
that toxaphene would not be able to migrate more than about 10 cm down a soil profile and, therefore, 
would not be of concern as a groundwater contaminant. Such arguments tend to overlook the fact that 
technical toxaphene used as a pesticide was usually mixed with a hydrocarbon solvent (e.g., xylene) as a 
carrier, which increased the mobility of toxaphene in soils. Data compiled by the EPA on pesticides in 
groundwater indicates that toxaphene was found in groundwater in one state as a result of normal 
agricultural use (Ritter 1990). Also, when such pesticide preparations have been introduced at old waste 
disposal sites, the toxaphene may be able to move into groundwater with the carrier-solvent. This 
scenario has been documented at a waste disposal site in California (Jaquess et al. 1989). The authors see 
this as a possibility at many waste disposal sites containing solvent materials, with toxaphene detections 
in groundwater at NPL sites, in the Mississippi Delta, and near Houston, Texas, supporting similar 
pollution pathways. Toxaphene has been identified in surface water and groundwater samples collected 
at 14 and 27 of the 68 NPL hazardous waste sites, respectively, where it was detected in some 
environmental media (HazDat 2007). For most groundwater supplies, however, any significant residence 
time in poorly oxygenated or anaerobic subsoil vadose zones would be expected to allow for anaerobic 
biochemical degradation of toxaphene.
6.2.3 Soil
Estimated releases of 0.418 million pounds (189 metric tons) of toxaphene to soils from 17 domestic 
manufacturing and processing facilities in 2008, accounted for about 99.8% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI08 2010). No underground 
injection releases were reported (TRI08 2010). The TRI release data are summarized in Table 6-1.
Toxaphene has been released directly to soils primarily as a result of its past use as an insecticide on 
agricultural crops (EPA 1979f). Disposal of spent livestock-dipping solutions (McLean et al. 1988) and 
wastes from manufacturing and formulation processes (EPA 1979f) were other significant sources of soil 
contamination. Mirsatari et al. (1987) reported that toxaphene has been found as a contaminant at 
pesticide disposal sites at concentrations in soils or sediment approaching or exceeding 100 ppm. 
Toxaphene was listed as a chemical of concern at the Crystal City Airport Superfund site in Crystal City, 
Texas. The mixture was detected in surface soil samples taken at the airport following abandonment of 
agricultural chemicals at the site by defunct aerial application operators (EPA 1987b). Toxaphene was 
also found in pesticide contaminated soils at four other Superfund sites in Litchfield, Arizona; Albany, 
Georgia; Marrianna, Florida; and Malone, Florida; concentrations in these soils ranged from 18 to
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1,505 mg/kg (ppm) (Troxler et al. 1993). Toxaphene has been identified in soil and sediment samples 
collected at 40 and 22 of the 68 NPL hazardous waste sites, respectively, where it was detected in some 
environmental media (HazDat 2007).
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partition ing
A combination of monitoring and modeling efforts during the 1980s has firmly established the 
importance of atmospheric pathways as a major source of PCC inputs to regions in the upper latitudes far 
removed from regions where it was heavily used as an agricultural pesticide. Adaptations to regional 
transport models initially developed to study acid rain phenomena showed the physical possibility for 
atmospheric transport of toxaphene from locations in the southern United States to the Great Lakes 
Region of the northern United States and Canada (Hoh and Hites 2004; James and Hites 2002; MacLeod 
et al. 2002; Voldner and Schroeder 1989, 1990).
A series of studies by Canadian researchers has gathered detailed information on levels of toxaphene in 
various environmental compartments in regions ranging from Lake Baikal in Russia, to the Sargasso Sea, 
to the southeastern United States, to various areas in Canada and the Canadian Arctic (Barrie et al. 1993; 
Bidleman et al. 1989, 1992, 1993, 1995; Cotham and Bidleman 1991; Lockhart et al. 1992; McConnell et 
al. 1993; Muir et al. 1990, 1992). These studies help provide at least partial validation for the predictions 
from regional transport models and document the continued supply of PCC materials to areas in the 
northern hemisphere far removed from areas of former significant toxaphene use.
Researchers working with the atmospheric transport of toxaphene have assembled useful time series 
observations for sites along the southern Atlantic coast in the United States, in the Canadian Maritime 
provinces, and at stations in the Canadian Arctic (Bidleman et al. 1989, 1992, 1995). Comparisons of 
levels in environmental media during the 1990s with baseline concentrations in the 1970s and early 1980s 
did not suggest declines in toxaphene contaminants, with ambient air concentrations in particular 
remaining about the same or even increasing. Especially in high latitude areas, impacts from toxaphene 
were still a matter of concern nearly a decade after the United States began phasing out the use of 
toxaphene as a pesticide agent.
Toxaphene is a mixture of many congeners, each of which has its own unique Henry's law constant. A 
Henry's law constant of 6x10-6 atm-m3/mol at 20 °C was measured for the mixture, which suggests that
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many components of toxaphene will volatilize to the atmosphere from water and soil surfaces. A half-life 
(first-order kinetics) of 6 hours to 12 days has been estimated for the volatilization of toxaphene from a 
model river, one meter deep, with a flow rate of 1 m/second and a wind velocity of 3 m/second (Howard 
1991). The results of numerous field dissipation and atmospheric monitoring studies indicate that the 
atmosphere is indeed the most important environmental medium for transport of the mixture. In addition 
to the field dissipation studies cited in Section 6.2.1 (Seiber et al. 1979; Willis et al. 1980, 1983), 
significant partitioning of toxaphene to the atmosphere has been reported in a model agroecosystem study 
(Nash et al. 1977) and from fallow field soils (Glotfelty et al. 1989a).
The persistence of toxaphene in the atmosphere allows the mixture to be transported long distances from 
the application sites. The presence of toxaphene in surface waters of the Great Lakes originated from the 
aerial transport and deposition of the mixture from application sites in the southern United States (EPA 
1984b; Hoh and Hites 2004; James and Hites 2002; Ma et al. 2005a, 2005b; MacLeod et al. 2002). 
Detection of toxaphene in the tissues of fish taken from a remote lake on Isle Royale in Lake Superior 
was also cited as evidence of long-range atmospheric transport (Swackhamer and Hites 1988).
Numerous other investigations have reported long-range atmospheric transport of toxaphene to remote 
locations. Toxaphene was detected in ambient air samples taken over the western North Atlantic Ocean 
and Bermuda. The source of the contamination was attributed to cotton-growing areas in the southern 
United States 1,200 km away (Bidleman and Olney 1975). The presence of toxaphene in biota of the 
Barents Sea in Northern Europe has been attributed to transport via air currents from areas of historical 
use in southeastern Europe and around the rivers that flow into the Aral Sea (Paasivirta et al. 2009). 
Maximum concentrations of toxaphene found in North American peat bogs corresponded to the period of 
maximum production and use of the compound in the United States in the mid-1970s (Rapaport and 
Eisenreich 1986). The composition of the toxaphene residues in the peat cores indicated that they were 
delivered to the peat surface by atmospheric transport and deposition with the dominant wind circulation 
patterns from primary source regions in the southern and southeastern United States. The presence of 
toxaphene in the following sources has also been attributed to its long-range atmospheric transport: fish 
taken from remote lakes in northern Canada (Muir et al. 1990); fish from pristine areas in the North 
Atlantic Ocean, North Pacific Ocean, and Antarctic Ocean (Zell and Ballschmiter 1980); and fish, birds, 
and seals from the western North Atlantic Ocean, Arctic Ocean, Greenland, Canada, and Sweden 
(Andersson et al. 1988). Evidence of regional-scale transport of the mixture in the drainage basin of the 
Chesapeake Bay has also been reported (Glotfelty et al. 1989b).
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Atmospheric toxaphene is transported back to soil and water surfaces by wet and dry deposition processes 
(Glotfelty et al. 1989b; Hoff et al. 1993a; Villeneuve and Cattini 1986). Several investigators have 
reported that washout in rain appears to be more important than the dry deposition of toxaphene 
(Bidleman et al. 1981; EPA 1984b). Hoff et al. (1993a) cited an unpublished 1992 report from the Great 
Lakes Protection Fund/Environment Canada in which the wet and dry deposition fluxes of PCCs to the 
Great Lakes were estimated to be 3.5-12.5 and 1.5-6.3 kg/year, respectively. Dry deposition accounted 
for only 15% of the input of atmospheric toxaphene into a rural estuary in South Carolina (Harder et al. 
1980). Based on a range of assumptions about the concentration of PCCs in the Great Lakes, Hoff et al. 
(1993a) estimated that the annual loading of toxaphene by gas exchange may be more than an order of 
magnitude higher than the input by wet or dry deposition. The authors noted that even though potential 
errors in the assumptions for the gas transfer of PCCs were very large, they were not large enough to 
make wet and dry deposition fluxes comparable to the estimates of the gas phase mass transfer of 
toxaphene across the air/water interface. Burniston et al. (2005) measured toxaphene concentrations in 
precipitation into Lake Ontario from 1994 to 1998. These authors reported that estimates of wet 
deposition flux were 50% of the estimated gas deposition flux based on loadings of toxaphene for Lake 
Ontario via precipitation during 1998.
For higher latitude regions, there is more uncertainty about the importance of specific deposition 
mechanisms. Especially in Arctic areas, model estimates and available monitoring data suggest that dry 
particle deposition may be more important than scavenging through snowfall (Cotham and Bidleman
1991). The mechanisms for toxaphene show many similarities with fate and transport processes for 
hexachlorobenzene (HCB) and perhaps several other organochlorine toxicants. The hydrophobic 
properties of these organochlorines encourage partitioning in either a volatile or semi-volatile phase or in 
forms sorbed to particulates. These properties then facilitate the incorporation of the contaminants into 
food chains starting with algae, zooplankton, and macroinvertebrates. This in turn encourages 
biomagnification at higher trophic levels (Cotham and Bidleman 1991; Hargrave et al. 1992).
Toxaphene released to soils will persist for long periods of time. The high Koc (soil organic carbon 
partition coefficient) values for toxaphene (log Koc=3-5) (EPA 1981a; Soubaneh et al. 2008; Wauchope et 
al. 1992) suggest that the mixture should be strongly sorbed to soil particulates and, therefore, should be 
relatively immobile to leaching and inhibited from volatilizing from subsurface soils (Swann et al. 1983). 
Field studies have verified this behavior. Half-lives (first-order kinetics) ranging from approximately 
1 year (Adams 1967) to 14 years (Nash and Woolson 1967) have been reported for toxaphene in soils. In 
surface soils, where volatilization will be a significant transport process, half-lives of 2 and 4 months have
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been reported for samples taken at the top 2.5 and 7.5 cm, respectively (Seiber et al. 1979). Between 
85 and 90% of the total toxaphene residues were found in the upper 23 cm (cultivated layer) of a sandy 
loam test soil 13 years after the last foliar application of the mixture (Nash and Woolson 1968). Following 
multiple annual applications of toxaphene to cotton crops grown in a clay soil, Swoboda et al. (1971) 
detected 90-95% of toxaphene residues in the top foot of the 5-foot profile sampled; toxaphene was not 
detected in any of the drainage water samples taken from the site. About 93% of the toxaphene found in 
runoff from a treated cotton field on a silty clay soil was bound to the sediment fraction; only 7% was 
found in the aqueous fraction of the runoff (McDowell et al. 1981). Toxaphene concentrations in runoff 
varied seasonally, and losses in two of the years studied totaled only 0.5-1% of the amount applied. 
Runoff losses from a cotton crop grown in the Mississippi Delta were found to be 0.4% of applied 
toxaphene (Lorber and Mulkey 1982). Raff and Hites (2004) measured toxaphene levels in suspended 
sediment samples along the Mississippi River. Based on these data and water discharge rates, the authors 
estimated a release of 200-1,000 kg of toxaphene into the Gulf of Mexico from the main stem of the river 
during 2002. The source of toxaphene was attributed to nonpoint source runoff from agricultural lands.
According to the simulation models Foliar Washoff of Pesticides (FWOP), Chemical Runoff and Erosion 
from Agricultural Management Systems (CREAMS), and Pesticide Runoff Simulator (PRS), up to 3% of 
applied toxaphene may be lost in runoff and erosion from treated agricultural fields; all of the toxaphene 
would be associated with the sediment fractions (Smith and Carsel 1984). To evaluate the effects of 
toxaphene on groundwater and surface water quality under different land management practices,
Donigian and Carsel (1987) used three models: the Pesticide Root Zone Model (PRZM); the Analytical 
Transient One-, Two-, and Three-Dimensional Simulation of Waste Transport in the Aquifer System 
(AT123D); and the Stream Transport and Agricultural Runoff of Pesticides for Exposure Assessment 
(STREAM). The dissolved mean toxaphene concentration in surface water predicted by the STREAM 
model for a 1.0 kg/ha application rate was 11.6 ppb for conventional-till, 4.9 ppb for reduced-till, and
3.4 ppb for no-till practices. Surface water runoff loadings and concentrations of toxaphene and several 
other pesticides typically decreased under the conservation tillage scenarios, but groundwater loadings 
and concentrations generally increased as a result of decreased runoff and increased groundwater 
recharge. The authors did not provide estimates of groundwater concentrations for toxaphene because 
this pesticide did not demonstrate mean annual loadings high enough to require estimation of groundwater 
concentrations.
The mobility of toxaphene in soils also is influenced by soil moisture status and the presence of other 
organic solvating materials (Jaquess et al. 1989). Toxaphene did leach from laboratory columns of sand
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and sandy loam soils treated with organic solvents and emulsifiers when the columns were allowed to dry 
completely between wetting cycles. The mixture did not leach from the amended columns when a similar 
amount of water was applied on a continuous basis. Drying of the soil allowed crevices to form in the 
columns which expedited movement of the mixture. Toxaphene dissolved in the organic solvent or 
contained in the emulsifier amendment could leach through the macropores.
There is also evidence that voltatilization is the primary route of loss from toxaphene-treated foliage. In a 
study by Seiber et al. (1979), residues of toxaphene were analyzed in cotton leaves and associated air 
samples up to 58 days after a 9 kg/ha application of toxaphene to a cotton field in the San Joaquin Valley, 
California. Analyses of the cotton leaf samples indicated a 59% loss of toxaphene at 28 days post­
application. Leaf residues declined from 661 ppm on the day of application to 135 ppm on day 50 post­
application, with an observed trend toward greater loss of the more highly volatile components. A 
corresponding enrichment of volatile toxaphene components was observed in air samples. There was no 
indication of chemical degradation in these samples in spite of the presence of abundant sunlight, oxygen, 
and atmospheric oxidant throughout the study.
Toxaphene is highly insoluble in water (0.55 mg/L) (Murphy et al. 1987). Toxaphene in surface waters 
that is not volatilized to the atmosphere is sorbed to sediments or suspended particulates, which are 
ultimately deposited in sediments (EPA 1979a). The lower-solubility, more-chlorinated components of 
the mixture are preferentially sorbed to particulates and sediments. Paris et al. (1977) reported that the 
less soluble, more highly chlorinated fractions of toxaphene also appear to be selectively sorbed to aquatic 
microorganisms that are consumed by other organisms and, consequently, would be expected to 
bioaccumulate up the food chain.
Uptake factors (mg toxaphene sorbed per microorganism/concentration of toxaphene in the medium) 
ranged from 3.4x103 to 1.7x104 for a variety of bacteria, fungi, and algae (Bacillus subtilis, 
Flavobacterium harrisonii, Aspergillus sp., Chlorellapyrenoidosa) (Paris et al. 1977). Direct sorption of 
toxaphene onto sediment, plankton, and other suspended solids deposited in the sediment has also been 
reported in three lakes in Wisconsin where the mixture was applied for the control of nongame fish. 
Toxaphene sorbed to sediments was not found to be readily desorbed (Veith and Lee 1971).
Toxaphene is bioconcentrated in the tissues of aquatic organisms. The major toxaphene congeners found 
in fish from pristine environments in the Canadian Rocky Mountains have been found to be the 
Cl7-Cl9 camphenes (i.e., hepta-, octa-, and nonachlorobornenes) (Bruns and Birkholz 1993).
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Experimentally determined bioconcentration factors (BCFs) for several aquatic organisms have been 
found to range from 4,200 to 60,000. In a flow-through bioassay conducted with the longnose killfish 
(F. similis), BCFs of up to 33,300 in fry and 60,000 in juvenile fish after 28 days of exposure were 
reported; BCFs in adults ranged from 4,200 to 6,800 after 14 days of exposure (Schimmel et al. 1977). 
Oysters (C. virginica) exposed to 1 ppb toxaphene have been found to accumulate up to 23 ppm in tissue 
after 24 weeks exposure; tissue concentrations decreased to nondetectable levels at the end of a 12-week 
depuration period (Lowe et al. 1971). In a model ecosystem study using radiolabeled toxaphene, BCFs of 
6,902 for algae, 9,600 for snails, 890 for mosquitoes, and 4,247 for fish (Gambusia affinis) were reported 
(Sanborn et al. 1976).
Toxaphene has also been detected in the tissues of aquatic organisms in numerous field studies (see 
Section 6.4.4). For example, mean toxaphene concentrations of 11 ppm in lipid tissue for lake trout 
(Salvelinus namaycush) and 7 ppm in lipid tissue for whitefish (Coregonus clupeaformis) taken from a 
remote lake on Isle Royale in Lake Superior have been reported (Swackhamer and Hites 1988). Studies 
conducted in a natural ecosystem in northwestern Ontario on the fate of toxaphene in lake trout 
(S. namaycush) and white suckers (Catastomus commersoni) indicated depuration half-lives for total 
toxaphene ranging from 232 days (lake trout, initial intraperitoneal dose 7.0 ^g/g) to 524 days (white 
suckers, initial intraperitoneal dose 3.5 ^g/g), with first-order kinetics assumed (Delorme et al. 1993). 
Depuration half-lives for two of the more persistent toxaphene congeners, octachlorobornane T2 and 
nonachlorobornane T12, ranged from 294 days (lake trout; T2, initial intraperitoneal dose 7.0 ^g/g) to 
716 days (white suckers; T2, initial intraperitoneal dose 3.5 ^g/g) with first-order kinetics assumed. The 
overall results of this study indicated significant interspecies differences in the ability to eliminate 
toxaphene, as well as possible intraspecies differences in the ability to eliminate different toxaphene 
congeners.
Toxaphene also appears to be biomagnified in aquatic food chains, although not to the extent of PCBs or 
other chlorinated insecticides, such as DDT. Stapleton et al. (2001) found that PCB burdens were greater 
than toxaphene burdens for each Great Lakes fish species collected during 1997-1998 with the exception 
of deepwater sculpin. Evans et al. (1991) reported trophic biomagnification of toxaphene, with toxaphene 
concentration increasing by an average factor of 4.7 from plankton (mean concentration, 0.55 ppm) to fish 
(deepwater sculpin: mean concentration, 2.57 ppm). DDE and PCBs were found to be more strongly 
biomagnified, increasing 28.7 and 12.9 times, respectively, in average concentration from plankton to 
sculpin. Whittle et al (2000) measured food web toxaphene concentrations in four of the Great Lakes 
(Table 6-2). Based on these data, toxaphene biomagnification factors were determined to be 32.03 in
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Table 6-2. Food Web Total Toxaphene Concentrations (ng/g Wet Weight) 
Measured in Lake Superior, Lake Huron, Lake Erie, and Lake Ontario
Species Lake Superior Lake Huron Lake Erie Lake Ontario
Lake trout 1.926 0.365 0.081 0.639
Herring 1.024 a - -
Sculpin 0.546 0.312 - 0.245
Smelt 0.291 0.119 0.016 0.066
Alewife - 0.139 - 0.049
Diporeia 0.197 0.131 0.029 0.090
Mysis 0.091 0.020 - 0.034
Plankton 0.062 0.015 <0.015 0.021
aNot analyzed.
Source: Whittle et al. 2000
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Lake Superior, 24.33 in Lake Huron, 10.08 in Lake Erie, and 30.43 in Lake Ontario. In a study that 
included analyses of tissue residue levels in 16 species of fish, birds, amphibians, and reptiles, 
biomagnification of toxaphene was reported in three oxbow lakes in northeastern Louisiana (Niethammer 
et al. 1984). Tissue residue concentrations were highest in tertiary consumers (carnivores) and lowest in 
primary consumers (herbivores); toxaphene was not detected in the limited number of surface water or 
sediment samples taken from the lakes. The source of the toxaphene was apparently the surrounding 
cotton and soybean cropland, which had historically received heavy pesticide applications. 
Biomagnification was also reported in a study that included analyses of tissue residue levels in eight 
species of fish and water snakes in the area of the Yazoo National Wildlife Refuge, Mississippi (Ford and 
Hill 1991). Biomagnification of several organochlorine pesticides, including toxaphene, was apparent 
from soil sediments (geometric mean concentration, approximately 0.1 ppm) to mosquito fish, a larger 
secondary consumer and forage fish (geometric mean concentration, 0.25 ppm), to the spotted gar, a 
tertiary consumer (geometric mean concentration, 2.71 ppm). There was, however, no clear pattern of 
biomagnification in larger secondary consumers such as smallmouth buffalo and carp, or in tertiary 
consumers such as water snakes.
Biomagnification of toxaphene in marine ecosystems appears to be species dependent (de Boer and 
Wester 1993). The two main toxaphene congeners found in marine mammals such as seals and beluga 
whales are an octa- and a nonachlorobornane, which are present only as minor constituents in technical 
toxaphene (Vetter et al. 1993, 1994). No biomagnification of toxaphene in a Canadian arctic marine food 
chain was reported in a study conducted by Muir et al. (1988a). Toxaphene was detected in the muscle 
tissue of the arctic cod (Boreogadus saida) at a mean concentration of 0.018 ppm, but not in the blubber 
and liver of the ringed seal (Phoca hispida), which preys on the cod, or the fat of the polar bear (Ursus 
maritimus), which preys on the seal. Similar results were found by Andersson et al. (1988), who 
performed limited sampling of biota from various trophic levels in marine food chains in the western 
North Atlantic Ocean, Greenland, Sweden, and Canada. They reported that toxaphene concentrations in 
fish, bird, and seal tissues ranged from 0.33 to 17 ppm in fat tissue for all trophic levels versus 0.14­
990 ppm for DDT and PCB residues. These results were interpreted as being indicative of less 
biomagnification and/or more effective metabolism of toxaphene at higher trophic levels, as compared 
with DDT and PCB.
In another study, however, toxaphene was found in the tissues of white-beaked dolphins (Lagenorhynchus 
albirostris) and pilot whales (Globicephala melaena) taken off the coast of Newfoundland in 1980 and 
1982 (Muir et al. 1988b). The toxaphene peaks from the gas liquid chromatography (GLC) analyses of
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the dolphin blubber indicated considerable metabolism of the mixture, as compared with toxaphene 
residues detected in the local fish populations preyed upon by the dolphins. Other studies in the area of 
Baffin Bay, Canada, have found cetacean blubber with an average toxaphene congener concentration of
9.2 ppm for male narwhals. Tissue concentrations in individual males ranged up to 13.2 ppm (Muir et al.
1992). De Boer and Wester (1993) also found evidence of biomagnification of toxaphene in the marine 
food chain from fish to fish predators, and reported biomagnification factors (BMFs) of approximately 
40 for harbor porpoise/fish and 100 for whitebeaked dolphin/fish. Comparison of the chromatograms 
from whitebeaked dolphin (blubber) and fish (hake liver) indicated similar metabolism of toxaphene for 
both species.
Tissue residue data from marine ecosystems have been used by Hargrave et al. (1993) to calculate the 
following ranges of BMFs (ng PCC/g lipid predator per ng PCC/g lipid prey) for various predator-prey 
links among arctic marine organisms. In a hypothetical food web, the following ranges in BMF values 
were reported: arctic cod and char/zooplankton (19.7-36.7); ringed seal/arctic cod and char (0.1-0.2); 
beluga/arctic cod and char (2.0-2.3); narwhal/arctic cod and char (3.3-3.4); small lysianassid amphipods/ 
arctic cod and char (0.7-2.7); small lysianassid amphipods/ringed seal (4.7-15.5); small lysianassid 
amphipods/beluga (0.4-1.1); Eurythenes gyrillus/arctic cod and char (9.1-11.1); E. gyrillus/narwhal (2.8­
3.2); E. gyrillus /beluga (4.6-4.8); E. gyrillus/ringed seal (55.3-65.3); E. gyrillus/eelpout (4.4-19.2); and 
eelpout/small lysianassid amphipods (0.2-2.7).
6.3.2 Transform ation and Degradation
Toxaphene is not a single molecular substance, but rather a mixture of hundreds of congeners including 
chlorinated bornanes, bornenes, bornadienes, camphenes, and dihydrocamphenes (see Section 4.2). The 
form of toxaphene as it was originally applied in the past as a pesticide is referred to as technical 
toxaphene. The composition of technical toxaphene released to the environment changes over time as the 
congeners degrade at different rates. Degradation proceeds mainly through dechlorination and 
dehydrochlorination, resulting in a shift in composition toward lower chlorinated homologs (Buser et al. 
2000; Lamb et al. 2008). The changed form of toxaphene is commonly referred to as weathered 
toxaphene (Lamb et al. 2008; Simon and Manning 2006). In order to achieve the best understanding of 
what individuals may be exposed to in the environment, recent studies have measured the levels of 
individual toxaphene congeners present in environmental samples. Some of the toxaphene congeners that 
have been reported in the literature are listed in Table 6-3. Congeners p-26, p-50, and p-62 are reported to 
be persistent in fish, marine mammals, human serum, and breast milk (Simon and Manning 2006). The
6. POTENTIAL FOR HUMAN EXPOSURE
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE 135
6. POTENTIAL FOR HUMAN EXPOSURE
Table 6-3. Names and Parlar Identification Numbers of Some Toxaphene 
Congeners Reported in the Literature
Name CAS number Parlar number
2,2,3-exo,8,9,10(E)-Hexachlorocamphene - p-11
2-exo,3-endo,8,8,9,10(E)-Hexachlorocamphene - p-12
2,2,5,5,9,10,10-Heptachlorobornane - p-21
2-endo,3-exo,5-endo,6-exo,8,8,10,10-0ctachlorobornane 142534-71-2 p-26
2,2,5-endo,6-exo,8,9,10-Heptachlorobornane (Toxicant B) - p-32
2,2,5,5,9,9,10,10-0ctachlorobornane - p-38
2,2,3-exo,5-endo,6-exo,8,9,10-0ctachlorobornane - p-39
2-endo,3-exo,5-endo,6-exo,8,9,10,10-0ctachlorobornane 166021-27-8 p-40
2-exo,3-endo,5-exo,8,9,9,10,10-0ctachlorobornane 165820-16-6 p-41
2,2,5-endo,6-exo,8,8,9,10-0ctachlorobornane (Toxicant A1) - p-42a
2,2,5-endo,6-exo,8,9,9,10-0ctachlorobornane (Toxicant A2) - p-42b
2-exo,5,5,8,9,9,10,10-0ctachlorobornane 165820-17-7 p-44
2-endo,3-exo,5-endo,6-exo,8,8,9,10,10-Nonachlorobornane 6680-80-8 p-50
2,2,5,5,8,9,10,10-0ctachlorobornane - p-51
2,2,5-endo,6-exo,8,8,9,10,10-Nonachlorohornane - p-56
2,2,5-endo,6-exo,8,9,9,10,10-Nonachlorobornane - p-59
2,2,5,5,8,9,9,10,10-Nonachlorobornane 154159-06-5 p-62
2-exo,3-endo,5-exo,6-exo,8,8,9,10,10-Nonachlorobornane - p-63
2,2,5,5,6-exo,8,9,9,10,10-Decachlorobornane - p-69
2-exo,3-endo,6-exo,8,9,10-Hexachlorobornane (Hx-Sed) - -
2-endo,3-exo,5-endo,6-exo,8,9,10-Heptachlorobornane (Hp-Sed) - -
2-exo,3-endo,5-exo,8,9,10,10-Heptachlorobornane (TMX-1) - -
2-exo,3-endo,-5-exo,9,9,10,10-0ctachlorobornane (B7-1453) - -
2-endo,3-exo,5-endo,6-exo,8,8,9,10-0ctachlorobornane (B8-1412) - -
Sources: de Geus et al. 1999; EPA 2010e; Gooch and Matsumura 1985; Lau et al. 1996; Vetter et al. 2001; Xia et 
al. 2009
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congeners Hx-Sed and Hp-Sed are known degradation products of toxaphene (Buser et al. 2000; EPA 
2010e).
6.3.2.1 A ir
The worldwide, long-range atmospheric transport of the mixture suggests that toxaphene is relatively 
resistant to transformation in the atmosphere. Since the production of toxaphene involves exposing 
chlorinated camphenes to ultraviolet radiation, the congeners in the final mixture are resistant to 
degradation from direct photolysis (EPA 1976a; Korte et al. 1979). Consequently, toxaphene in the 
atmosphere is not expected to degrade readily by direct photolysis when attached to particulates.
However, a half-life of approximately 4-5 days (first-order kinetics) has been estimated for the reaction 
of vapor-phase toxaphene with photochemically produced hydroxyl radicals (Howard 1991; Kelly et al.
1994). The higher chlorinated congeners have longer half-lives since they tend to exist in the particulate 
phase rather than the vapor phase. Rapaport and Eisenreich (1986) cited an atmospheric residence time of 
46-70 days for the mixture. They noted that the toxaphene found in peat cores taken from remote regions 
in the northern United States and Canada was deposited from the atmosphere in a relatively 
untransformed state.
6.3.2.2 W ater
Little information was found in the available literature on the biodegradation of toxaphene in aquatic 
systems. Toxaphene is resistant to chemical and biological transformation in aerobic surface waters (de 
Geus et al. 1999). It is not expected to undergo direct photolysis or photooxidation (EPA 1979a). 
Hydrolysis is also not an important fate process; a hydrolytic half-life (first-order kinetics) of >10 years 
for pH 5-8 at 25 °C has been estimated (EPA 1976d, 1979a). Detoxification of toxaphene in eight 
Wisconsin lakes was reported to be due to adsorption rather than biodegradation (EPA 1977).
Buser et al. (2000) measured half-lives ranging from <1 day to several days for technical toxaphene 
congeners in anaerobic sewage sludge from a municipal waste water treatment plant. The non-gem- 
chloro-substituted congeners P26 and P50 degraded less rapidly than the gem-chloro-substituted 
congeners, which is consistent with the relatively high percentage of the P26 and P50 congeners detected 
in environmental samples (Buser et al. 2000; Lamb et al. 2008). Degradation was said to proceed through 
reductive dechlorination resulting formation of Hp-Sed and Hx-Sed and other metabolites. Lacayo et al.
(2004) studied the degradation of toxaphene in water in aerobic and anaerobic bioreactors operating in 
sequence using a mixed culture inoculum. Reported degradation was 87% after 6 weeks and 98% after
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39 weeks, with the majority of the degradation occurring under anaerobic conditions. Levels of 
toxaphene congeners with greater chlorine substitution decreased more rapidly than those with lesser 
chlorine substitution.
6.3.2.3 Sediment and Soil
Toxaphene has been reported to be quite persistent in aerobic surface soils. Nash and Woolson (1967) 
reported a half-life of 11 years (first-order kinetics) in an aerobic sand loam soil that had received high 
application rates (112 and 224 kg/ha, corresponding to approximately 50 and 100 ppm) of toxaphene. 
Seiber et al. (1979) reported half-lives of approximately 2 months (top 2.5 cm) and 4 months (top 7.5 cm) 
in aerated topsoil that had been treated with toxaphene at an application rate of 9 kg/ha. While the 
observed declines in toxaphene concentrations were primarily due to vaporization, at least one toxaphene 
component was reported to be significantly degraded. The mechanism of degradation was postulated to 
be dehydrochlorination or reductive chlorination, but this was not investigated further. Studies by Parr 
and Smith (1976) and Smith and Willis (1978) in a silty loam soil indicated no transformation of 
toxaphene in moist amended (i.e., alfalfa meal added) or unamended samples incubated under aerobic 
conditions, but rapid transformation (65-96% over 4 weeks) in amended and unamended samples 
incubated under anaerobic conditions. The transformation was reported to be a dechlorination reaction. 
No transformation was observed in autoclaved samples. A 50% loss of toxaphene in 6 weeks due to 
biodegradation in anaerobic, flooded soils was reported; however, no biodegradation was found in aerobic 
sediments (EPA 1979a).
There is conflicting information in the literature regarding the transformation of toxaphene in sediments. 
Seiber et al. (1979) found that in sediment samples taken from the bottom of a drainage ditch a year or 
more after application of toxaphene to an adjacent field (13.5 kg/ha), several major components of 
toxaphene, including toxicant B (congener p-32), were significantly degraded. Reductive dechlorination 
appeared to be a major mechanism of degradation. This mechanism results in lower weight products than 
occur in technical toxaphene, at least some of which are relatively stable in the environment. As a 
consequence, the authors emphasized that the environmental and toxicological significance of these 
products needs to be determined. Using a microcosm system, Williams and Bidleman (1978) reported 
that toxaphene transformation in an anaerobic salt marsh sediment was mediated chemically, rather than 
biologically. The transformation, believed to be a reductive dechlorination, was rapid, occurring within 
2-6 days even in sterilized samples. In contrast, Mirsatari et al. (1987) found no transformation of 
toxaphene in autoclaved (i.e., sterile) sediment and soil samples over a 60-day test period. In addition, no
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transformation was observed in unsterile sediment samples incubated under aerobic conditions for 
6 weeks. Rapid transformation (half-life 1 week) was observed only in unsterile sediment samples 
amended with organic matter and incubated under anaerobic conditions. The microbially mediated 
transformation was apparently a reductive dechlorination. Clark and Matsumura (1979) added 
radiolabeled toxaphene to sediments and incubated them for 30 days under aerobic and anaerobic 
conditions. As in the Mirsatari et al. (1987) study, no transformation was observed in autoclaved 
samples. However, toxaphene was transformed in the aerobically incubated samples by the bacterium, 
Pseudomonas putida. Clark and Matsumura (1979) stated that toxaphene biotransformation is likely to 
proceed initially as a dechlorination reaction under anaerobic conditions followed by oxidative 
transformation of the less chlorinated products under aerobic conditions. Thus, toxaphene apparently 
undergoes some biotransformation in the sediment layers of rivers and lakes under both anaerobic and 
aerobic conditions.
Lacayo-Romero et al. (2006) studied the degradation of toxaphene congeners in contaminated soils using 
anaerobic bioreactors. These authors reported that the congeners p-11 and p-12 were degraded while the 
concentration of p-15 increased, suggesting that the less chlorine substituent toxaphene congeners are 
formed during the degradation of the greater chlorine substituted congeners. Ruppe et al. (2004) 
identified 20 metabolites resulting from anerobic bacterial transformation of technical toxaphene in 
sediments and soils. The most recalcitrant of the toxaphene metabolites were 2-exo,3-endo, 
6-exo,8,9,10-hexachlorobornane (B6-923) and 2-endo,3-exo,5-endo,6-exo,8,9,10-heptachlorobornane 
(B7-1001).
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to toxaphene depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens. Concentrations of 
toxaphene in unpolluted atmospheres and in pristine surface waters are often so low as to be near the 
limits of current analytical methods. In reviewing data on toxaphene levels monitored or estimated in the 
environment, it should also be noted that the amount of chemical identified analytically is not necessarily 
equivalent to the amount that is bioavailable. The analytical methods available for monitoring toxaphene 
in a variety of environmental media are detailed in Chapter 7.
As a result of its past widespread use as an insecticide and its persistence, toxaphene has been detected in 
ambient air, surface water and groundwater, soils and sediments, rainwater, and food. Data reported in
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this section have been obtained largely from national surveys in an attempt to present a representative 
national perspective of toxaphene contamination of various environmental media. However, toxaphene 
contamination of certain media may be a more serious problem on a regional basis than indicated by these 
national averages. For example, higher soil concentration levels can be expected in cotton growing areas 
of the South, and higher tissue residue levels have been found in fish taken from the Great Lakes.
A factor complicating the analysis of toxaphene in various environmental media is the difficulty in 
making trend comparisons for monitoring information collected before the early 1980s. Reliable 
detection of low levels of PCCs became possible only with the adoption of capillary column GC 
technology in the early 1980s. The prevailing earlier packed-column methods were usually unable to 
provide reliable total toxaphene readings for the large numbers of congeners (each present in minute 
amounts) encountered in most samples (Schmitt et al. 1990). For instance, U.S. Fish and Wildlife Service 
programs like the National Pesticide Monitoring Program (now the National Contaminant Biomonitoring 
Program or NCBP) started in the 1970s; however, due to problems in quantification with the older 
analytical technologies, results of these programs cannot be compared with toxaphene sampling results 
obtained since 1990 (Schmitt et al. 1990). These problems seriously interfere with drawing conclusions 
for such media as sediments or tissue samples, and make it almost impossible to make trend 
determinations for ambient water.
Another complicating factor is the mounting evidence that wastes from paper and pulp operations may be 
a source of toxaphene-like materials. Much of this research comes from countries where toxaphene was 
never used as a pesticide agent, but where anomalous findings of PCC materials were encountered. There 
is a tendency in such cases to conclude that all of the PCC congeners are the result of hemispheric or 
global atmospheric transport pathways, but in some cases, PCC from paper and pulp wastes may help 
explain localized hotspots (Jarnuzi et al. 1992a, 1992b; Paasivirta and Rantio 1991; Rantio et al. 1993). 
Shanks et al. (1999) concluded that pulp and paper mills were not sources of toxaphene to Lake Superior 
or northern Lake Michigan at the time of the study based on similar concentrations measured in samples 
upstream from the mills compared with those measured in downstream samples.
Reliable evaluation of the potential for human exposure to toxaphene depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens. In reviewing data on 
toxaphene levels monitored in the environment, it should also be noted that the amount of chemical 
identified analytically is not necessarily equivalent to the amount that is bioavailable. Also, analytical
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methods used in the past have been based on analysis of technical toxaphene and may not have detected 
some congeners that are expected to be present in the weathered form of toxaphene (EPA 2010e).
6.4.1 A ir
Toxaphene has been detected in ambient air and rainwater samples collected at a number of sites in the 
United States; however, the available data are not current. No information was found in the available 
literature regarding ambient indoor exposure levels of toxaphene.
Toxaphene has also been detected in ambient air samples taken at remote locations. Toxaphene 
concentrations of <0.04-1.6 ng/m3 in ambient air samples taken over the western North Atlantic Ocean 
from 1973 to 1974 have been reported (Bidleman and Olney 1975). Mean concentrations in ambient air 
samples from Bermuda were 0.81 ng/m3 (±0.45 ng/m3 standard deviation [SD]) and 0.72 ng/m3 
(±0.09 ng/m3 SD).
In an ambient air monitoring study conducted at four urban sites (Baltimore, Maryland; Fresno, 
California; Riverside, California; and Salt Lake City, Utah) and at five rural sites (Buffalo, New York; 
Dothan, Alabama; Iowa City, Iowa; Orlando, Florida; and Stoneville, Mississippi) in the United States in 
1967-1968, toxaphene was detected only in samples taken from the three agricultural areas in southern 
states. Maximum concentrations detected were 68 ng/m3 (detected in 11 of 90 samples), 2,520 ng/m3 
(9 of 99 samples), and 1,340 ng/m3 (55 of 98 samples) in Dothan, Alabama; Orlando, Florida; and 
Stoneville, Mississippi, respectively (Stanley et al. 1971). Toxaphene was included in the ambient air 
sampling of agricultural and urban areas conducted in 14-16 states as part of the National Air Pesticide 
Monitoring Program. For the years 1970-1972, toxaphene was detected in 3.5% of the 2,479 samples 
collected at mean and maximum concentrations of 17 and 8,700 ng/m3, respectively; the mean of the 
positive samples was 1,890 ng/m3 (Kutz et al. 1976). In 1981, toxaphene was detected at maximum 
concentrations of 9.05, 1.73, 0.44, and 0.14 ng/m3 in Greenville, Mississippi; Saint Louis, Missouri; 
Bridgeman, Michigan; and Beaver Island, Michigan, respectively (EPA 1984b; Rice et al. 1986).
Concentrations of chlorobornanes measured in air samples from Columbia, South Caroline during 1994­
1995 ranged from 39 to 183 pg/m3 (Bidleman et al. 1998). Air samples collected at a height of 40 cm 
above the soil at farms in Alabama, Louisiana, and Texas during June 1999 and June 2000 contained total 
toxaphene at concentrations ranging from 0.47 to 42.1 ng/m3 (Bidleman and Leone 2004).
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The average gas-phase concentrations of toxaphene were 1,600, 280, 34, and 10 pg/m3 in air samples 
collected during 2000-2001 in Rohwer, Arkansas; Lubbock, Texas; Bloomington, Indiana; and Sleeping 
Bear Dunes, Michigan (Lake Michigan), respectively (James and Hites 2002). The average gas-phase 
concentrations of toxaphene were 61, 1,400, 60, and 23 pg/m3 in air samples collected during 2002-2003 
in Cocodrie, Louisiana; Rohwer, Arkansas; Bloomington, Indiana; and Sleeping Bear Dunes, Michigan 
(Lake Michigan), respectively (Hoh and Hites 2004). Based on these concentrations and analysis of air 
trajectories, the authors of these studies concluded that toxaphene detected in air from Indiana and the 
Great Lakes region originates in the southern United States (Hoh and Hites 2004; James and Hites 2002). 
Mean concentrations of total toxaphene and the congeners p-26 and p-50 measured in the air at locations 
over Lake Superior, Lake Huron, and Lake Erie were 28, 2.2, and 1.9 pg/L, respectively, in August 1996 
and 12, 0.32, and 0.26 pg/L, respectively, in May 1997 (Jantunen and Bidleman 2003).
A seasonal variation in toxaphene concentrations in ambient air samples collected in Stoneville, 
Mississippi, from 1972 to 1974 was noted in a study by Arthur et al. (1976). The highest concentrations 
were observed in summer months, corresponding to the growing season, and the lowest in winter months. 
The sampling site was located in the middle of the most intensive cotton-growing area in Mississippi.
The maximum concentration detected in weekly air samples was 1,747 ng/m3. Average monthly levels 
were 258, 82, and 160 ng/m3 for 1972, 1973, and 1974, respectively. A similar seasonal variation was 
found in atmospheric toxaphene concentrations in southern Ontario, which was attributed to increased 
volatilization of PCCs during the warmer summer months (Hoff et al. 1993b). During this 1988-1989 
study, average monthly concentrations ranged from 0.08 pg/m3 in February to 110 pg/m3 in July; the 
overall maximum and mean concentrations (n=114) were 580 and 26 pg/m3, respectively. Shoeib et al. 
(1999) measured total toxaphene concentrations ranging from 0.9 to 10.1 pg/m3 in the air at Point Petre, 
Ontario sampled during 1992 and from 1995 to 1997. The summer-to-winter concentration ratio was 
reported to be about 6. Glassmeyer et al. (1998) reported vapor-phase toxaphene concentrations ranging 
from 1.0 to 42 pg/m3 measured in the air at Eagle Harbor, Michigan (Lake Superior) during 1996 and 
1997.
Toxaphene has been identified in air samples collected at 3 of the 68 NPL hazardous waste sites where it 
was detected in some environmental media (HazDat 2007).
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6.4.2 W ater
Toxaphene has been detected very rarely in drinking water supplies. Toxaphene concentrations ranged 
from 5 to 410 ppt (0.005-0.410 ppb) in drinking water samples collected in Flint Creek, Alabama, 
between 1959 and 1963 (Faust and Suffet 1966). In an extensive water quality monitoring program 
conducted by the California Department of Health Services, toxaphene was detected (detection limit not 
specified) in only 2 of 5,279 public drinking water sources sampled from 1984 to 1992, at mean and 
maximum concentrations of 0.30 and 0.50 ppb, respectively (Storm 1994). Concentrations did not exceed 
the Maximum Contaminant Level (MCL) of 5.0 ppb.
The median toxaphene concentration detected in ambient surface waters in the United States in 1980­
1982, according to analyses of EPA's STORET water quality database, was 0.05 ppb (Staples et al. 1985). 
The mixture was detected in 32% of the 7,325 samples collected over that period. Toxaphene was 
detected in only 3.4% of the 708 effluent samples taken during 1980-1983 at a median concentration of 
<0.2 ppb.
In a study of toxaphene concentrations in surface water and runoff from the Bear Creek, Mississippi, 
watershed conducted in 1976-1979, toxaphene concentrations in surface water were found to be 
measurable only after major runoff events (Cooper et al. 1987). At other times, only trace amounts of the 
compound (<0.01-1.07 ppb) were detected. However, runoff from two fields historically cultivated in 
cotton and soybeans contained toxaphene residues of 0.04-4.18 ppb and 289-2,964 ppm in the aqueous 
and particulate fractions, respectively. Petty et al. (1995) conducted studies using semipermeable 
membrane devices to determine bioavailable organochlorine pesticide residues in streams receiving 
irrigation drainwater from agricultural activity in the Lugert Altus Watershed in southwestern Oklahoma. 
Among the pesticides monitored, toxaphene was predominant, with calculated bioavailable (dissolved) 
water concentrations at six sampling sites ranging from 0.3 to 7 ^g/L (ppb). In general, concentrations 
were higher in summer than in spring. The authors noted that the Kow used in these calculations was an 
average for the toxaphene mixture and that, because Kow values for individual congeners may vary by an 
order of magnitude, water concentrations of toxaphene congeners could range from 0.9 to 9 ppb. There is 
an additional uncertainty in these estimates because they were derived from the dialysate data using 
models and preliminary data on uptake kinetics. The results do indicate, however, that significant 
concentrations of bioavailable toxaphene may still be present in this aquatic ecosystem several years after 
discontinuation of its use.
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In contrast to agricultural areas, municipal areas do not show evidence of toxaphene in water samples. 
Toxaphene was not detected in 86 samples of municipal runoff collected from 15 cities in the United 
States in 1982 as part of the Nationwide Urban Runoff Program (Cole et al. 1984). Toxaphene was not 
detected (detection limits 0.06-0.2 ppb) in surface water samples collected in 1990-1993 from 13 sites in 
the Potomac River and Upper Chesapeake Bay areas (Hall et al. 1993, 1995). Sampling sites included 
both clean reference areas and suspected polluted areas.
Swackhamer et al. (1999) reported mean dissolved toxaphene concentrations of 1.12 ng/m3 in Lake 
Superior surface water collected in 1996 and 0.38 ng/m3 in Lake Michigan surface water collected in 
1994-1995. Surface water concentrations were estimated to be <0.5 ng/m3 in Lakes Huron, Erie, and 
Ontario. The higher levels in Lake Superior were attributed to colder temperatures (lower volatilization 
rate) and lower sedimentation rates (James et al. 2001; Swackhamer et al. 1999). The mean concentration 
of total toxaphene and the congeners p-26 and p-50 measured in surface water collected at locations 
across Lake Superior in 1996 and 1997 were 918, 3.5, and 13 pg/L, respectively (Jantunen and Bidleman 
2003).
Toxaphene has also been detected at hazardous waste sites in surface water, groundwater, and leachates. 
Toxaphene was detected at a maximum concentration of 17 ppb in surface water samples taken from two 
of nine disposal ponds at a Superfund site (EPA 1986a). In a study of the chemical composition of 
leachates within existing landfills, toxaphene was not detected in any of the municipal landfill leachates 
examined (Brown and Donnelly 1988). However, the mixture was detected in industrial landfill leachates 
at a concentration of <10 ppb. In a review of groundwater monitoring data collected in 1981-1984 from 
more than 500 wells at 334 hazardous waste disposal sites (RCRA and CERCLA sites) located in all 
10 EPA regions and 42 states, Plumb (1987) reported that toxaphene was detected at 0.2% frequency at 
the 178 CERCLA sites examined and at 1.1% frequency at the 156 RCRA sites examined. Concentration 
data were not provided. Toxaphene has been identified in surface water and groundwater samples 
collected at 14 and 27 of the 68 NPL hazardous waste sites, respectively, where it was detected in some 
environmental media (HazDat 2007).
Toxaphene has been detected in rainwater samples taken in southern France near the Mediterranean Sea 
at mean concentrations of 7.2 ppt (range: not detected to 53 ppt) and 25.2 ppt (range: not detected to 
81 ppt) in solution and sorbed to particulates, respectively (Villeneuve and Cattini 1986). Burniston et al.
(2005) reported annual average toxaphene concentrations of 0.68-0.85 ng/L (38-47 ppt) measured in 
Lake Ontario precipitation samples collected continuously from November 1994 through December 1998.
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No additional information was found in the literature for concentrations of toxaphene in rainwater 
samples collected in the United States.
6.4.3 Sediment and Soil
Toxaphene has been detected in some samples of urban and agricultural soils from throughout the United 
States. Wiersma et al. (1972a) detected the mixture in concentrations that ranged from 0.11 to 52.7 ppm 
in samples of surface soils from three of eight U.S. cities in 1969. In another study of 14 cities conducted 
in 1970, toxaphene was detected at 3 of 28 sites (10.7%) at mean and geometric mean concentrations of 
1.94 and 0.012 ppm, respectively; concentrations in the positive samples ranged from 7.73 to 33.4 ppm.
In Sikeston, Missouri, toxaphene was detected at 1 of 27 sites at a concentration of 0.6 ppm. Carey et al. 
(1979a) monitored soils in five U.S. cities in 1971 and found toxaphene only in 11 of 43 samples (25.6%) 
taken from Macon, Georgia, at a mean concentration of 0.24 ppm (range, 0.23-4.95 ppm; geometric 
mean, 0.02 ppm). Toxaphene residues in domestic cropland soils were surveyed in the National Soils 
Monitoring Program (Carey et al. 1978, 1979b; Wiersma et al. 1972b). Toxaphene was found in 73 of 
1,729 soil samples collected in 43 states during 1969 with a mean concentration of 0.07 ppm and a range 
of 0.10-11.72 ppm (Wiersma et al. 1972b). Toxaphene was found in 76 of 1,483 soil samples collected 
in 37 states during 1972 with a mean concentration of 0.24 ppm and a range of 0.22-46.58 ppm (Carey et 
al. 1979b).
Toxaphene was detected in 38 of 39 agricultural soil samples collected at locations across the state of 
Alabama (Hamer et al. 1999). The geometric mean concentration of toxaphene in these samples was 
84 ng/g dry weight and the maximum concentration was 2,423 ng/g dry weight. The concentrations of 
toxaphene measured in soil samples collected from 32 cotton fields in southern South Carolina and 
eastern Georgia ranged from 3.3 to 2,500 ng/g dry weight (Kannan et al. 2003). The median of the 
reported concentrations was 85.3 ng/g dry weight for the South Carolina soils and 67.25 for the Georgia 
soils. Soil samples collected at farms in Alabama, Louisiana, and Texas during June 1999 and June 2000 
contained total toxaphene at concentrations ranging from 3.2 to 6,520 ng/g dry weight (Bidleman and 
Leone 2004).
Toxaphene levels were measured in soil samples collected during 2000-2001 from three schools and one 
field ballpark in Brunswick, Georgia (Agency for Toxic Substances and Disease Registry 2005). These 
sites are all located within 0.5 miles of the Hercules, Incorporated industrial facility, which manufactured
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toxaphene from the mid 1940s until 1982. Maximum toxaphene levels measured in the soil from the 
sampling locations were <0.010, 0.180, 0.030, and 0.380 ppm, respectively.
Rapaport and Eisenreich (1986) found toxaphene in samples of peat from bogs located in remote regions 
of the northern United States and Canada at concentrations ranging from <1 ppb (detection limit) to 
30 ppb. Toxaphene was not detected (detection limit 0.5 ppm wet weight) in surface core samples (0­
15 cm depth) of soils derived from dredged materials from nine confined disposal facilities in the Great 
Lakes region (Beyer and Stafford 1993).
Toxaphene has also been detected in sediment samples throughout the United States. Toxaphene was 
detected in 2.2% of 548 sediment samples collected in the lower Mississippi River and its tributaries in 
1964 and from 1966 to 1967. Concentrations in the positive samples ranged from 0.1 to 13.18 ppm, the 
mean concentration was 6.5 ppm (Barthel et al. 1969). In southern Florida, toxaphene was detected, but 
not quantified, in 3.2% of 126 sediment samples collected from 1969 to 1972 (Mattraw 1975).
Toxaphene was not detected in 27 sediment samples collected in Delaware and in the Raritan Canal, New 
Jersey, from 1979 to 1980 (Granstrom et al. 1984), or in sediment samples collected in Casco Bay,
Maine, in 1991 (Kennicutt et al. 1994). At a site 1.4 miles from the outfall of a toxaphene plant on Terry 
Creek in Brunswick, Georgia, toxaphene was found at a concentration of 5.27 ppm in a 70-80-cm deep 
sediment sample collected in 1971 (IARC 1979). According to analyses of EPA's STORET water quality 
database, the median toxaphene concentration in sediment was 2.0 ppb; the compound was detected in 
25% of the 1,603 samples taken during 1980-1983 (Staples et al. 1985).
During an investigation of organochlorine pesticides in soil sediments in the upper Steele Bayou 
watershed of Mississippi, toxaphene was found in 41% of 56 samples collected at two depths (2.54­
7.62 and 25.4-30.48 cm) along eight different drainages (Ford and Hill 1991). The geometric mean and 
maximum wet weight toxaphene concentrations were 0.12 and 2.80 ppm for the shallow samples, and 
0.07 and 4.60 ppm for the deeper samples, respectively. There was no significant difference in toxaphene 
concentrations between corresponding shallow and deep samples. Raff and Hites (2004) measured 
toxaphene levels ranging from 0.4 to 39 ng/g in suspended sediment samples collected from 32 locations 
along the Mississippi River during 2002-2003. The concentrations of toxaphene in the sediments were 
found to increase rapidly as the river passes through the cotton-growing regions of the southern United 
States. Studies in agricultural areas of the Mississippi Delta have provided indications of the persistence 
of toxaphene in soils and sediments under what might be construed as a worst case scenario. Results of 
investigations at Moon Lake and sites within its watershed just to the east of the main levees on the
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Mississippi River in Coahoma County, Mississippi, have been reported (Cooper 1991). In soils, which 
provide a generally aerobic redox environment, the average total toxaphene level based on 69 samples 
collected in the period 1983-1984 was 734 ppb. The toxaphene concentration in lake sediments averaged
12.4 ppb. In core samples from wetland flats displaying marked signs of anaerobic conditions, there was 
no detectable toxaphene. These findings underscore the fact that it is only in media providing appreciable 
residence times in biologically active anoxic conditions that one can expect significant biodegradation of 
toxaphene. In even moderately aerobic environments, and especially in soil or sediments rich in clay 
colloids, the pesticide agent is persistent for many years.
Shanks et al. (1999) reported toxaphene concentrations of 1.4-9.0 ng/g dry weight measured in sediment 
from rivers near pulp and paper mills near Lakes Michigan and Superior. These authors also measured 
toxaphene concentrations of 6.0-43 ng/g dry weight in sediments from rivers near sites where this 
pesticide was previously used. Maximum toxaphene concentrations measured in sediment cores collected 
from Lake Michigan, Lake Superior, and Lake Ontario during the early 1990s were 48, 42, and 29 ng/g, 
respectively (Pearson et al. 1997). Surficial accumulation rates of 0.097-1.01 ng/cm2-year were 
determined (Pearson et al. 1997). Analysis of sediment cores showed that in most cases, toxaphene 
accumulations peaked in the early 1970s to early 1980s and then declined in following years (Pearson et 
al. 1997; Schneider et al. 2001). Howdeshell and Hites (1996) observed similar trends in eight Lake 
Ontario sediment cores collected in 1993 and cited contaminated flow from the Niagara River in addition 
to atmospheric deposition as sources of toxaphene in the lake. Analysis of sediment cores from two lakes 
in Canada that were treated with toxaphene during 1961-1962 revealed maximum toxaphene 
concentrations of 500 and 1,602 ng/g dry weight at depths corresponding to the time of treatment 
(Miskimmin et al. 1995). Surface concentrations in these lakes were 53 and 112 ng/g dry weight. 
Toxaphene was not detected in untreated lake sediments. Toxaphene sediment concentrations from five 
Canadian lakes previously treated with this pesticide ranged from 2.6 to 110 ^g/kg dry weight (Donald et 
al. 1998). Toxaphene was also detected at 0.2 ^g/kg dry weight in an oligotrophic glacial fed lake that 
had no record of treatment.
Toxaphene has also been found in soils and sediments at hazardous waste disposal sites. Mirsatari et al. 
(1987) reported that toxaphene has been found as a contaminant at pesticide disposal sites at 
concentrations in soils or sediment approaching or exceeding 100 ppm. Toxaphene was also detected at a 
maximum concentration of 2,900 ppb (2.9 ppm) in sediment samples taken from two of nine disposal 
ponds at a Superfund site (EPA 1986a). Toxaphene was found at concentrations ranging from 18 to
1,505 mg/kg (ppm) in pesticide contaminated soils at four other Superfund sites in Litchfield, Arizona;
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Albany, Georgia; Marrianna, Florida; and Malone, Florida (Troxler et al. 1993). More recently, 
toxaphene has been identified in soil and sediment samples collected at 40 and 22 of the 68 NPL 
hazardous waste sites, respectively, where it was detected in some environmental media (HazDat 2007).
6.4.4 O ther Environm ental Media
Several studies conducted to determine the levels of toxaphene in food indicate that this substance is 
found only infrequently in the U.S. food supply, generally at very low residue concentrations, which have 
decreased significantly since the restriction of its use in 1982 (EPA 1982a) and its total ban in 1990 (EPA 
1990b). Except for fish and wild game animals from some areas of the United States (Agency for Toxic 
Substances and Disease Registry 2009; Ford and Hill 1990; Xia et al. 2009), the current U.S. food supply 
does not appear to contain levels of toxaphene that are of concern for human health.
Levels of toxaphene in food have been determined as part of the Food and Drug Administration’s (FDA) 
Total Diet Studies. In a 1980-1982 survey of pesticides, toxaphene was detected in samples of food 
groups that comprised typical infant and toddler diets. Concentrations of 0.1-0.2 ppm (number positive 
samples, 3) and 0.7-0.12 ppm (number positive samples, 6) were found in the oils and fats food groups of 
infants' and toddlers' diets, respectively. The samples were collected in 13 U.S. cities. Toxaphene was 
not detected in drinking water or the other foods examined in the diet of either group. Other food groups 
examined included: whole milk; other dairy and dairy substitutes; meat, fish, and poultry; grain and 
cereal products; potatoes; vegetables; fruit and fruit juices; sugar and adjuncts; and beverages (Gartrell et 
al. 1986a, 1986b). In a summary of data from 1985 to 1991 FDA Total Diet Studies on pesticide residues 
in infant foods and adult foods eaten by infants and children, toxaphene was found only in peanut butter 
at a maximum concentration of 0.16 ppm (number of positive samples, 27 of 27) (Yess et al. 1993).
Toxaphene was detected each year in regulatory monitoring of domestic and imported foods conducted by 
the FDA from 1988 to 1994 as part of its Pesticide Residue Monitoring Program (FDA 1989, 1990, 1991, 
1992, 1993, 1994c, 1995). Concentrations were not reported; however, <1% of the surveillance samples 
had any pesticide residue levels that were above established tolerances. Toxaphene was also detected in 
the FDA Total Diet Studies in 1987, 1988, 1989, 1990, and 1991 (FDA 1988, 1990, 1991, 1992). From 
1987 to 1990, it was listed among the most commonly found pesticides, with frequencies of detection of 
1-2% (FDA 1988, 1989, 1990, 1991). Reports of 1992-1994 FDA Total Diet Studies indicated that the 
types of pesticide residues found and their frequencies of occurrence were consistent with those in 
previous years; however, there was no explicit statement that toxaphene was detected in the years 1992-
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1994 (FDA 1993, 1994c, 1995). Concentrations of toxaphene found in the FDA Total Diet Studies were 
not reported. However, in an overall summary for the 5-year period 1986-1991, average dietary intakes 
of toxaphene, in ^g/kg body weight/day, for eight age/sex groups were reported to range from 
0.0057 (25-30-year-old females) to 0.0224 (2-year-old children) (FDA 1993).
Overall, in 234 ready-to-eat foods tested 37 times each from 1982 to 1991 as part of the FDA Total Diet 
Studies, toxaphene was found 138 times at an average concentration of 0.04 ^g/g (ppm) in 18 different 
foods: cantaloupe, raw carrots, boiled collards, corn chips, cucumbers, cooked frankfurters, dry-roasted 
peanuts, creamy peanut butter, dill pickles, cured ham, potato chips, radishes, boiled spinach, boiled 
summer squash, boiled winter squash, strawberries, tomato sauce, and cooked veal cutlet (KAN-DO 
Office and Pesticides Team 1995). Concentrations ranged from 0.0050 ^g/g (ppm) (strawberries) to 
0.12 ^g/g (ppm) (dry-roasted peanuts). During the period 1989-1991, estimated toxaphene intakes were 
<0.01 ^g/kg body weight/day for 6-11-month-old infants, 14-16-year-old males, and 60-65-year-old 
females, with a noticeable downward trend in all age categories (FDA 1990, 1991, 1992). (See 
Section 6.5 for more detailed information on estimated daily toxaphene intakes.) While progressive 
improvements in analytical technologies complicate comparisons of older values with more recent 
collections, the FDA Total Diet Studies clearly suggest that toxaphene residue levels in food and general 
population intake levels have fallen dramatically over the last decade.
Other studies further indicate that the occurrence of toxaphene in the U.S. food supply is very low. 
Toxaphene was not detected as a violative residue in a 1992-1993 statistically based FDA study of 
pesticide residues in more than 3,000 samples of domestic and imported pears and tomatoes (Roy et al.
1995). A regional food basket study conducted in San Antonio, Texas, in the period from 1989 to 1991 
screened 6,970 produce items for a suite of 111 pesticide analytes. Toxaphene was not detected in any 
produce items at levels above FDA violation thresholds (Schattenberg and Hsu 1992). A summary of 
results from the FOODCONTAM database (Minyard and Roberts 1991) for the period 1988-1989 
showed no detectable toxaphene residues in food samples. This database involves 10 states that follow 
quality assurance/quality control (QA/QC) protocols consistent with those of such federal counterpart 
agencies as the USDA, EPA, and the FDA.
Toxaphene has been found in fish and shellfish in some areas of the United States at levels of concern for 
human health and, at present, there are fourteen fish consumption advisories in effect for this compound 
(see Section 6.7) (EPA 2010d).
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Toxaphene is of particular concern as a major contaminant of Great Lakes fish. Xia et al. (2009) detected 
the toxaphene congeners, p-26, TMX-1, p-38, p-40, p-41, p-44, p-50, and p-62, in fish composites from 
Lake Michigan, Lake Superior, Lake Huron, Lake Ontario, and Lake Erie collected during 2004.
Reported total toxaphene concentrations were 39 ng/g wet weight in Lake Erie walleye, 155 ng/g wet 
weight in Lake Huron lake trout, 243 ng/g wet weight in Lake Michigan lake trout, 113 ng/g wet weight 
in Lake Ontario lake trout, 398 ng/g in Lake Superior lake trout, and 846 ng/g wet weight in a Lake 
Superior lake trout Standard Reference Material labeled SRM 1946. Congeners p-26, p-50, and p-62 
were reported to be the dominant peaks, together accounting for 2-44% of the amount of total toxaphene 
in the fish samples.
Swackhamer et al. (1998) measured toxaphene in plankton from Lake Michigan and fish from Lake 
Superior. Reported mean toxaphene concentrations were 51.3 ng/g dry weight in phytoplankton,
243 ng/g dry weight in zooplankton, 92.4 ng/g dry weight in mysis, 162 ng/g dry weight in bythotrephes, 
411 ng/g dry weight in diporeia, 225 ng/g dry weight in sculpin, and 2,373 ng/g dry weight in lake trout. 
Mean total toxaphene concentrations of 92 and 198 ng/g wet weight were measured in bloater chub and 
alewife samples, respectively, collected from Grand Traverse Bay, Lake Michigan during 1997 and 1998 
(Stapleton et al. 2002). Kucklick and Baker (1998) reported toxaphene concentrations of 99-210 ng/g 
wet weight in smelt, 560-720 ng/g wet weight in herring, 840-1,360 ng/g wet weight in bloater, 260­
460 ng/g wet weight in sculpins, 21-40 ng/g in mysis, 110-180 ng/g wet weight in limnocatanus,
100 ng/g wet weight in amphipod, and 250-540 ng/g wet weight in lake trout collected from Lake 
Superior during the summer of 1994.
Whittle et al. (2000) reported toxaphene concentrations of 0.081-1.926 ^g/g wet weight in lake trout, 
1.024 ^g/g wet weight in herring, 0.245-0.546 ^g/g wet weight in sculpin, 0.016-0.291 ^g/g wet weight 
in smelt, 0.049-0.139 ^g/g wet weight in alewife, 0.029-0.197 ^g/g wet weight in diporeia, 0.020­
0.091 ^g/g wet weight in mysis, and <0.015-0.062 ^g/g wet weight in plankton collected from Lake 
Superior, Lake Huron, Lake Erie, and Lake Ontario. Results of this study are summarized in Table 6-2. 
Levels in Lake Superior samples were consistently higher than levels in samples from the other lakes. 
Henry et al. (1998) measured toxaphene in smallmouth bass collected from Fumee Lake in the Upper 
Peninsula of Michigan. Mean toxaphene concentrations were 137 ng/g wet weight in 0-20 cm length 
fish, 255 ng/g wet weight in 20-30 cm length fish, and 312 ng/g wet weight in >30 cm length fish.
Glassmeyer et al. (1997) measured toxaphene in lake trout, walleye, and smelt archival samples collected 
in 1982 and 1992/1994 from the Great Lakes. Reported 1982 toxaphene levels were 4.5-5.2 ^g/g wet
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weight in lake trout, 0.25 ^g/g wet weight in walleye, and 0.16-0.83 ^g/g wet weight in smelt. Reported 
1992/1994 levels were 0.54-6.7 ^g/g wet weight in lake trout, 0.13 ^g/g wet weight in walleye, and 
0.059-0.16 ^g/g wet weight in smelt. While concentrations in the Lake Superior samples were not 
significantly different between the 2 years, the results showed a decline in toxaphene concentrations in the 
fish from the other Great Lakes from 1982 to 1992.
Residues of toxaphene and other pesticides in fish were examined as part of the NCBP, formerly a part of 
the National Pesticide Monitoring Program conducted in 1984. Composite samples (n=321) of 
bottom-feeding and predatory fish were taken from 112 stations located along the major domestic rivers 
and in the Great Lakes. Toxaphene residues were detected in fish tissue samples collected at 69% of the 
stations. In earlier sampling periods, the percentages of stations where detectable residues were present 
were approximately 60% (1976-1977 and 1978-1979) and 88% (1980-1981). The maximum and 
geometric mean wet weight concentrations of the mixture in the 1984 samples were 8.2 and 0.14 ppm, 
respectively, the lowest values found in any NCBP sampling period. Maximum and geometric mean wet 
weight concentration data for earlier sampling periods were 12.7 and 0.34 ppm (1976-1977), 18.7 and 
0.28 ppm (1978-1979), and 21.0 and 0.28 ppm (1980-1981), respectively (Schmitt et al. 1985, 1990).
Fillets of Great Lakes coho salmon collected from the five lakes in 1980 had mean concentrations of 
0.19-1.53 ppm of "apparent toxaphene" (Clark et al. 1984). Lake trout collected from Lake Michigan 
have been found to contain residues of toxicant congeners A (p-42a and p-42b) and B (p-32) that were 
approximately one-tenth or less of the estimated total toxaphene residues (Gooch and Matsumura 1985, 
1987). The percentages of toxicant A and toxicant B in the fish residues were, however, similar to those 
in the technical toxaphene, indicating that in the environment, the rates of degradation of these congeners 
are roughly the same as those of other toxaphene components.
Toxaphene concentrations in nearshore fish collected from the mouths of rivers and embayments around 
Lake Michigan in 1983 were determined in a study conducted by Camanzo et al. (1987). In 28 composite 
whole-fish samples collected from 14 sites, toxaphene was detected at a mean concentration of 0.04­
3.46 ppm in samples of rock bass, northern pike, common carp, smallmouth bass, lake trout, bowfin, 
pumpkinseed, channel catfish, and largemouth bass. The investigators noted that bottom-feeding species 
(e.g., common carp, channel catfish) had higher residue levels than top predatory fish (e.g., northern 
pike), possibly as a result of the bottom-feeders being older, having more fat tissue, and living in 
proximity to contaminated sediments. Most of the residues differed from the GLC peaks for the 
toxaphene standard, indicating that some metabolism/transformation of the compound had taken place. In
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1982, toxaphene (reported as a toxaphene-like compound) was detected (detection limit 1 mg/kg [ppm] 
wet weight) in all of 10 samples of lake trout collected in Lake Michigan (mean concentration 
4.70.5 ppm), and in 9 of 10 samples of lake trout collected in Lake Superior (mean concentration 
1.6±0.2 ppm) (Miller 1993). In this same study, toxaphene was detected in all of 10 samples of chinook 
salmon collected in Lake Michigan in 1982 (mean concentration 2.0±0.2 ppm), and in 4 of 8 samples of 
chinook salmon collected in Lake Michigan in 1983 (mean concentration 1.0±0.0 ppm ). Fish fillet 
samples from 11 species of Great Lakes fish were found to have toxaphene levels ranging from not 
detected (detection limit 10 ppb [0.01 ppm] wet weight) in bass and bullhead to 936 ppb (0.936 ppm) wet 
weight in trout (Andrews et al. 1993; Newsome and Andrews 1993). The levels appeared to be species 
specific, with higher levels found in fish having higher fat content (trout, herring) than in fish having 
lower fat content (bass, bullhead, perch, pickerel, smelt, menominee).
Levels of toxaphene in fish to which consumers are actually exposed are dependent on the type of sample 
and the method of preparation, with higher concentrations generally found in the higher fat content skin- 
on fillets. Zabik et al. (1995a, 1995b) investigated the levels of pesticides in Great Lakes fish and the 
effects of processing and selected cooking methods on residue levels. Toxaphene was not detected 
(detection limit 0.050 ppm wet weight) in skin-on or skin-off fillets of carp from Lake Huron and Lake 
Michigan (Zabik et al. 1995a); however, in skin-on fillets of walleye and white bass from these lakes, 
concentrations ranged from not detected to 0.09 ppm (Zabik et al. 1995b). In chinook salmon, toxaphene 
was found in skin-on fillets at average concentrations of 0.41 and 0.34 ppm in Lake Huron and Lake 
Michigan, respectively; corresponding concentrations in skin-off fillets were 0.23 and 0.22 ppm (Zabik et 
al. 1995a). Baking and charbroiling significantly reduced toxaphene concentrations in both skin-on and 
skin-off fillets of salmon (38-56% reduction), while canning skin-off fillets resulted in a 77% reduction 
of toxaphene concentration. Toxaphene was not found in any samples from Lake Erie (Zabik et al.
1995a, 1995b).
The mean concentrations of toxaphene measured in largemouth bass at five different locations in the 
Mobile River basin in Alabama ranged from 13 to 104 ng/g in 2004 (Hinck et al. 2009). Maruya and Lee 
(1998) reported toxaphene concentrations of 0.5-1 ^g/g lipid in fish collected from the Turtle/Brunswick 
River Estuary near Brunswick, Georgia. Toxaphene was found at maximum concentrations of 11 ppm in 
shellfish samples from California (4 positives in 85 samples) and 54 ppm in shellfish samples from 
Georgia (128 positives in 211 samples) in a National Pesticide Monitoring Program survey of estuarine 
molluscs conducted from 1965 to 1972, a period when toxaphene was heavily used (Butler 1973). 
Toxaphene was detected at concentrations <0.10 ppm wet weight in eggs, ovary, liver, and muscle tissue
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of three pallid sturgeon (Scaphirnyncus albus) samples from the Missouri River in North Dakota and 
Nebraska (Ruelle and Keenlyne 1993).
The concentrations of total toxaphene measured in 19 fish samples collected from different locations in 
the Yukon, Canada ranged from 42 to 242 ng/g with a mean of 107 ng/g (Chan and Yeboah 2000). The 
sum of the concentrations of the three congeners, p-26, p-50, and p-62, ranged from 10 to 55 ng/g.
Donald et al. (1998) reported higher chlorobornane concentrations in fish (75.7-303 ^g/kg wet weight) 
from untreated oligotrophic lakes at higher elevations than in fish (3.3-82 ^g/kg wet weight) from treated 
trophic lakes at lower elevations in western Canada. Toxaphene concentrations of 1.1 ppm on a wet 
weight basis (24 ppm fat weight basis) in cod liver samples and 0.4-1.0 ppm wet weight basis (4.4­
12 ppm fat weight basis) in herring fillets collected from the east coast of Canada were reported by 
Musial and Uthe (1983). Toxaphene was not detected in samples of deep sea scallops.
Tuerk et al. (2005) reported total toxaphene concentrations of 13.0-10.7 ^g/g wet mass measured in the 
blubber of Atlantic white-sided dolphins and 1.49-3.33 ^g/g wet mass measured in the blubber of rough­
toothed dolphins. The relative proportions of the toxaphene congeners, p-50, p-26, and p-62, in the 
blubber samples were approximately 50, 35, and 15%, respectively. Mean concentrations of total 
toxaphene were 11.7 and 1.03 ^g/g lipid in the blubber of bottlenose dolphins from the Turtle/Brunswick 
River Estuary and the Savannah Area Estuary, respectively, along the coast of Georgia (Pulster et al. 
2009). Fourteen toxaphene congeners were identified in the blubber samples. Congener p-42a, which is 
one of the most abundant congeners in technical toxaphene, was present in the highest concentrations 
(maximum of 3,950 ^g/g lipid). Toxaphene congeners, p-25, p-40, p-50, Hx-Sed, and Hp-Sed, were 
frequently detected at concentrations ranging from 100 to 1,000 ng/g lipid.
Gouteux et al. (2003) measured toxaphene congeners in blubber samples of 26 male and 26 female beluga 
whales from the St. Lawrence Estuary. The mean concentrations of the toxaphene congeners p-26 and 
p-50 were 710 and 1,510 ng/g wet weight, respectively, in the males and 280 and 520 ng/g wet weight, 
respectively, in the females. Maximum concentrations of these congeners were 1,240 and 3,060 ng wet 
weight, respectively, in the males and 1,110 and 1,690 ng/g wet weight, respectively, in the females. The 
authors stated that on average, toxaphene concentrations decreased by a factor of two between 1988 and 
1999. Gouteux et al. (2005) measured chlorobornanes in blubber samples from six seal species in the St. 
Lawrence marine ecosystem. Toxaphene congeners, p-26, p-40/41, p-44, p-50, and p-62, were all 
detected, with p-26 and p-50 comprising 50-80% of the total chlorobornanes in each sample. The mean 
concentrations of total chlorobornanes were 49 ng/g lipid weight in gray seals, 80 ng/g lipid weight in
6. POTENTIAL FOR HUMAN EXPOSURE
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE 153
harbor seals, 18 ng/g lipid weight in ringed seals, 370 ng/g lipid weight in harp seals, and 680 ng/g lipid 
weight in hooded seals.
Vetter et al. (2001) detected eight toxaphene congeners in the blubber of seals from the Baltic Sea, the 
North Sea, and the Antarctic. Congeners p-26, p-50, B8-1412, p-44, and p-62 were detected in the 
greatest concentrations, followed by B7-1453, p-40, and p-41. Total toxaphene concentrations ranged 
from 5 ^g/kg wet weight in an Antarctic elephant seal to 1,457 ^g/kg wet weight in a harp seal from the 
North Sea. Concentrations in three Weddell seals in Antarctica ranged from 161 to 489 ^g/kg wet 
weight. Total toxaphene concentrations were 68-303 ^g/kg in cod liver samples, 1,194 ^g/kg in cod liver 
oil, and 4-98 ^g/g in two penguins.
Alder et al. (1997) measured the levels of the three toxaphene congeners, p-26, p-50, and p-62, in 
>100 samples of fish species that are consumed in Germany. Reported mean concentrations for the sum 
of these congeners were 12.1 ^g/kg wet weight in herring, 0.2 ^g/kg wet weight in Alaska Pollock,
0.8 ^g/kg wet weight in saithe, 15.1 ^g/kg wet weight in redfish, 0.1 ^g/kg wet weight in hake, 7.9 ^g/kg 
wet weight in mackerel, 1.1 ^g/kg wet weight in cod, 2.2 ^g/kg wet weight in sardine, and 36.7 ^g/kg wet 
weight in halibut. Mean concentrations of congeners p-26, p-50, and p-62 were 5.87, 8.70, and 
1.59 ^g/kg fresh weight, respectively, in salmon collected along the Swedish east coast of the Baltic Sea 
(Atuma et al. 2000).
The chief regions where bioaccumulation or biomagnification in fish or wildlife might pose a serious 
public health concern are in high latitude areas outside the contiguous United States. Studies on marine 
mammals in eastern Canada (Muir et al. 1992) suggest risks to native Inuit groups that eat blubber or 
visceral tissues such as liver. While no comparable work has been done in Alaska, this is an area of the 
United States where there could be genuine concern for Native American Inuit groups that hunt and 
consume marine mammals.
Within the contiguous United States, there is concern for populations that regularly consume meat from 
omnivores or carnivores, such as raccoons. Studies reported in Ford and Hill (1990) on the Upper Steele 
Bayou near the Yazoo National Wildlife Refuge in Mississippi show wildlife still displaying toxaphene 
residues in adipose tissues in collections made in 1988. The residues were most pronounced for raccoons, 
where adipose concentrations of total toxaphene up to 31 ppm (weight mass basis) were observed. The 
Upper Steel Bayou region in Washington County was close to another area on the Big Sunflower River 
previously studied in 1980. Due to radical changes in the GC methods for analyzing toxaphene,
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researchers are hesitant to make quantitative comparisons (Ford and Hill 1990). Nevertheless, in the late 
1970s, the U.S. Fish and Wildlife Service was concerned enough to issue advisories on human 
consumption of wildlife in the Mississippi Delta region. Many members of this region's rural 
subsistence-level population eat significant amounts of game meat, including raccoons.
Toxaphene was also reported to be a contaminant of tobacco crops and products. Gibson et al. (1974) 
reported that toxaphene was a sporadic contaminant of Kentucky Burley tobacco crops during the period 
1963-1972. Toxaphene was detected in about 4% of the samples at maximum concentrations exceeding 
100 ppm. Toxaphene was also detected in six brands of cigar tobacco sampled in 1972 at an average 
concentration of 0.92 ppm; four of the six samples had toxaphene concentrations of <0.5 ppm. McDonald 
and Hites (2003) measured the concentrations of toxaphene in 46 tree bark samples collected in the 
United States and Canada. Higher concentrations (>20 ng/g bark) were found in samples collected from 
the South and Southeastern United States, between 40 and 32 degrees latitude, where toxaphene was used 
heavily in the past. Two samples had toxaphene concentrations as high as 250 and 300 ng/g bark. 
Toxaphene concentrations generally ranged from 1 to 11 ng/g bark in samples collected at locations 
further north or south.
Toxaphene has also been found as a contaminant in anhydrous lanolin, which is used as a moisturizer in 
cosmetics and as a vehicle compound in pharmaceutical preparations (Heikes and Craun 1992).
Toxaphene was detected (detection limit not reported) in 2 of 10 samples of anhydrous lanolin analyzed 
in 1989 at concentrations of 2.8 and 5.8 mg/kg (ppm), but not in any of 10 samples analyzed in 1991.
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Current human exposure to toxaphene in the United States appears to be very limited. Members of the 
general population may be exposed to low levels of the mixture through ingestion of contaminated 
foodstuffs and possibly through inhalation of ambient air (Kutz et al. 1991). Populations consuming large 
quantities of fish and shellfish potentially contaminated with toxaphene may be exposed to higher levels 
than the general public. Exposure to higher concentrations of toxaphene may also result from contact 
with contaminated media in the vicinity of waste disposal sites containing toxaphene-contaminated 
wastes. No information was found in the available literature regarding the size of the human population 
potentially exposed to toxaphene in the vicinity of hazardous waste sites.
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Based on the toxaphene levels in their 1980-1982 food survey, the FDA estimated average dietary 
intakes, in ^g/kg body weight/day of 0.080, 0.036, and 0.023 for infants, toddlers, and adults, respectively 
(Gartrell et al. 1986a, 1986b). However, actual intakes must be lower than the estimates because other 
reported average dietary intakes were based on the mean concentration of the positive samples.
Toxaphene intakes, in ^g/kg body weight/day, estimated for the total diet analyses were 0.0059, 0.0087, 
and 0.0046 in 1989 (FDA 1990); 0.0071, 0.0085, and 0.0093 in 1990 (FDA 1991); and 0.0033, 0.0059, 
and 0.0024 in 1991 (FDA 1992) for 6-11-month-old infants, 14-16-year-old males, and 60-65-year-old 
females, respectively. An overall summary for the 5-year period 1986-1991 of average dietary intakes of 
toxaphene, in ^g/kg body weight/day, by eight age/sex groups was reported: 6-11-month-old infants, 
0.0071; 2-year-old children, 0.0224; 14-16-year-old females, 0.0062; 14-16-year-old males, 0.0089; 25­
30-year-old females, 0.0057; 25-30-year-old males, 0.0067; 60-65-year-old females, 0.0078; and 60­
65-year-old males, 0.0077 (FDA 1993; Gunderson 1995). These dietary intake estimates suggest a 
decreasing trend following the cancellation of most registered uses of toxaphene as an agricultural 
pesticide in the United States in 1982 (EPA 1982a) and a cancellation of all registered uses in 1990 (EPA 
1990b).
Toxaphene has been detected at a concentration of 0.1 mg/kg on a milk fat basis in pooled human breast 
milk samples collected in Uppsala, Sweden (Vaz and Blomkvist 1985), and at an average concentration 
(n=16) of 2 mg/kg lipid weight in human breast milk samples from Nicaragua, where toxaphene is still 
being produced and used (de Boer and Wester 1993). Mean concentrations of total toxaphene and the 
toxaphene congeners p-26 and p-50 were 0.8, 0.4, and 0.6 ng/g fat, respectively, in 10 pools of human 
milk collected during 2002-2003 from 238 primiparous women living in Hong Kong and south China 
(Hedley et al. 2010). The toxaphene congener p-62 was not detected in any of the samples. Newsome 
and Ryan (1999) measured toxaphene levels in human milk samples collected from women living in 
northern and southern Canada. These authors found that toxaphene concentrations in the northern 
samples were approximately 10-fold higher than those measured in the southern samples and stated that 
this disparity may be due to differences in types of food consumed. Mean concentrations of total 
toxaphene, congener 26, and congener 50 were 6.03, 1.32, and 2.35 ng/g lipid, respectively, in samples 
collected across southern Canada in 1992 (n=58); 7.28, 1.32, and 1.15 ng/g lipid, respectively, in samples 
collected in the Great Lakes basin in 1992 (n=24); 12.1, 2.83, and 4.37 ng/g lipid, respectively, in samples 
collected across southern Canada in 1986 (n=30); and 67.7, 24.9, and 33.1 ng/g lipid, respectively, in 
samples collected in Keewatin, Northwest Territories in 1997 (n=12). Toxaphene was measured in 
pooled human milk samples collected from individuals living in sub-arctic and arctic locations in 
northwestern Russia (Polder et al. 2003). Concentrations of the toxaphene congeners p-26, p-50, and
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p-62 measured in these samples were 2.34-4.33, 3.70-5.75, and 1.32-1.67 ^g/kg milk fat, respectively. 
Polder et al. (2008) reported a mean concentration of 11 ng/g lipid weight measured in 10 human milk 
samples collected during 2000-2001 from primipara mothers living in the town of Tromso in northern 
Norway. Skopp et al. (2002b) found the sum of congeners p-26, p-41, p-44, and p-50 to range from 7 to 
24 ^g/kg milk fat in breast milk samples from women in an area of northern Germany. Levels of 
toxaphene in human milk from U.S. populations are not available.
Barr et al. (2004) measured the levels of two toxaphene congeners, p-26 and p-50, in old serum pools 
originally collected in Atlanta, Georgia in 1987, Chicago, Illinois in 1992, and Cincinnati, Ohio in 1994. 
Reported concentrations in these samples were 14.3, 3.5, and 28.9 pg/mL, respectively, for p-26 and 10.5, 
10.0, and 25.2 pg/mL, respectively, for p-50. Patel et al. (2004) measured toxaphene levels in pools of 
108 serum samples collected from pregnant women in Barrow and Bethel, Alaska. p-26 and p-50 were 
detected in >50% of the samples with geometric mean concentrations of 1.10 and 1.61 ng/g lipid-weight, 
respectively.
When toxaphene was being manufactured and used as an insecticide, occupational exposure to toxaphene, 
particularly via the dermal and inhalation routes, may have been significant. Dermal exposures of 
22.72 and 16.56 ^g/hour were reported by Munn et al. (1985) for adults and youths, respectively, 
harvesting a toxaphene-treated onion crop in the Platte River Valley of Colorado in 1982. Any farmers, 
farm workers, or pesticide applicators who formerly used the mixture to control insects on livestock and 
crops may have been exposed to relatively high concentrations via these exposure routes.
6.6 EXPOSURES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans. Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults.
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults. A child’s 
behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths,
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sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Children may be exposed to toxaphene by breathing contaminated air, drinking contaminated water, 
eating contaminated soil, or eating contaminated fish or animals. Children living near areas where 
toxaphene was used heavily or near hazardous waste sites contaminated with toxaphene may have higher 
exposure to this substance. Based on the maximum concentration (0.380 ppm) of toxaphene measured in 
soil from school grounds and a park located near a former production facility in Brunswick, Georgia, an 
exposure dose of 0.000015 mg/kg/day was estimated for a child if exposure through pica is excluded 
(Agency for Toxic Substances and Disease Registry 2005). The estimated exposure dose for a child rose 
to 0.0006 mg/kg/day if exposure through pica was included. Both of these values were below the 
intermediate-duration oral MRL of 0.002 mg/kg/day derived for toxaphene.
Witt and Niessen (2000) measured levels of toxaphenes in the adipose tissue of 48 children living in 
Germany, Russia, and Kazakhstan. Median and maximum concentrations at the different sampling 
locations were 0.37-1.97 and 0.69-6.02 ^g/kg, respectively, for congener p-26 and 0.65-2.36 and 1.22­
6.12 ^g/kg, respectively, for congener p-50. Levels of toxaphene measured in neonatal blood, cord blood, 
meconium fluid, or the blood or urine of children were not located.
Nursing infants may be at risk for potentially high exposure to toxaphene; however, no data on levels of 
toxaphene congeners in breast milk from U.S. women could be located in the available literature. There 
are several documented cases of toxaphene congeners in fats from human breast milk (Hedley et al. 2010; 
Mussalo-Rauhamaa et al. 1988; Newsome and Ryan 1999; Polder et al. 1998, 2003, 2008; Skopp et al. 
2002b; Vaz and Blomkvist 1985). Toxaphene congeners were also found in the fats in human breast milk 
in Nicaragua, while toxaphene was still being produced and used (de Boer and Wester 1993). The high 
concentrations found, and the lack of correlation between the number of children a woman had and the 
toxaphene concentration in her breast milk, were cited as evidence that elimination of toxaphene via 
transfer to the infant was fully compensated for by a regular intake of toxaphene. Consequently, nursing 
infants of mothers who incur regular and potentially high exposures to toxaphene (e.g., from the 
consumption of contaminated fish or game) may be at a potentially high risk for exposure to toxaphene.
An additional subpopulation that could experience slightly higher levels of exposure are infants and 
young children who receive vitamin supplements from cod liver oil. This is of some concern in Europe 
where fish oil products may involve catches taken in polluted areas (Walter and Ballschmiter 1991).
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Oetjen and Karl (1998) measured levels of three toxaphene indicator congeners in fish oils from Europe 
ranging from 13 ^g/kg fat in sand eel oil to 206 ^g/kg fat in cod oil. While no recent literature was 
identified on fish oil products entering U.S. markets, studies conducted in the early 1980s did detect 
toxaphene residues in food products that would be part of typical toddler and infant diets (Gartrell et al. 
1986a, 1986b). Cod liver samples taken from the east coast of Canada have also shown measurable 
concentrations of toxaphene (Musial and Uthe 1983).
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
Members of the general population currently having potentially higher intakes of toxaphene include 
residents living near NPL sites and other hazardous waste sites contaminated with toxaphene; populations 
that consume large quantities of fish and shellfish from waterbodies where fish consumption advisories 
for toxaphene contamination are in effect; and Native American and subsistence hunter groups that 
consume large quantities of wild game animals in their diet. No information was found in the available 
literature regarding the size of these populations. The concentrations of toxaphene in all of the 
contaminated media to which these populations might be exposed have not been adequately characterized.
In September 2010, toxaphene was cited as the causative pollutant in three fish consumption advisories in 
Arizona (Gila River, Hassayampa River, and Salt River), two in Delaware (Army Creek and Army Pond), 
five in Georgia (Back River, Back River from Causeway to St. Simons Sound, Coastal Georgia, Middle 
and South Georgia, Terry And Dupree Creeks), one in Louisiana (Tensas River), two in Mississippi 
(Delta Region and Roebuck Lake), and one in Oklahoma (Bitter Creek) (EPA 2010d).
EPA has identified toxaphene as a target analyte and recommended that this chemical be monitored in 
fish and shellfish tissue samples collected as part of state toxics monitoring programs. Residue data 
obtained from these monitoring programs should be used by states to conduct risk assessments to 
determine the need for issuing fish and shellfish consumption advisories (EPA 2010d).
In much of the contiguous United States where toxaphene was once used as a pesticide agent, the 
incidence of toxaphene residues in freshwater fish appears to be declining. While changes in GC analysis 
technologies make it very hard to compare post-1980 records with analyses conducted in the 1970s, 
results from two sampling periods in the 1980s from the U.S. Fish and Wildlife Service NCBP show that 
the number of sites with detectable levels of total toxaphene in fish tissue samples dropped from 88% in
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1980-1981 to 69% in samples collected in 1984 (Schmitt et al. 1990). There may still be the potential for 
localized contamination of fish in the vicinity of hazardous waste sites and in the Great Lakes.
As noted in Section 6.4.4, there could also be risks of high exposures for three U.S. subpopulations that 
consume large amounts of marine mammals or game animals. The first includes Native American groups 
in Alaska, although any quantification of the risks would have to be based on data collected from such 
groups as the Inuit in the Baffin Bay area of Canada (Muir et al. 1992). The second includes people such 
as recreational or subsistence hunters in rural areas of the Southeast where historically heavy use of 
toxaphene as a pesticide agent occurred. People in this area who eat large amounts of wild game animals, 
particularly such species as raccoons, could be at risk of higher exposures (Ford and Hill 1990). The third 
includes individuals who regularly consume sport fish caught from the Great Lakes (ATSDR 2009).
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of toxaphene is available. Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of toxaphene.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
6.8.1 Identification o f Data Needs
Physical and Chemical Properties. In general, physical and chemical properties of toxaphene 
have been sufficiently well characterized to permit estimation of its potential environmental fate 
(Bidleman et al. 1981; Budavari et al. 1989; EPA 1981a; NIOSH/OSHA 1978; Worthing 1979). Since 
toxaphene is a complex mixture, the environmental fates of specific congeners in original product 
formulations will vary. Information on the physical and chemical properties of specific congeners is 
needed for more reliable prediction of environmental fate and transport processes for toxaphene mixtures.
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This information, in combination with additional information on the toxicities of toxaphene congeners 
and their degradation products, is necessary to permit more quantitative estimation of exposure risks and 
analysis of environmental exposures to toxaphene.
Production, Im port/Export, Use, Release, and Disposal. According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA. The TRI, which contains this 
information for 2008, became available in February of 2010. This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
Recent U.S. production data for toxaphene are not available; however, it is assumed that this substance is 
no longer being produced for use as a pesticide in the United State since all registered uses were canceled 
in 1990 (EPA 1990b; USDA 1995). The most recent estimate of U.S. production levels was in 1982, the 
year that EPA first restricted the use of toxaphene (EPA 1982a). Production levels that year were less 
than 2 million kg (EPA 1987a), substantially lower than in 1972 (21 million kg) when toxaphene was the 
most widely manufactured pesticide in the United States (Grayson 1981). The TRI lists one facility in 
Idaho and one facility in Texas that were involved in toxaphene production during 2008 (TRI08 2010). 
No other information regarding recent production of toxaphene in the United States was found.
In other parts of the world, toxaphene use continues at very high levels (Bidleman et al. 1989; Stern et al. 
1993). Although reliable information on use levels outside western European countries is almost 
impossible to obtain, many researchers feel that global use levels are quite substantial (Lahaniatis et al. 
1992; Stern et al. 1993). It has been estimated that total global usage of toxaphene from 1950 to 1993 
exceeded 1.3 million tons (Voldner and Li 1993); however, this may be a significant underestimation 
(Swackhamer et al. 1993). Since toxaphene, once volatilized, can be transported atmospherically over 
very long distances, all terrestrial and aquatic ecosystems, including those in the United States, are still 
subject to low levels of exposure. Especially in terms of atmospheric inputs, the best available 
monitoring information shows no demonstrable downward trends (Bidleman et al. 1992). More reliable 
information on global usage and atmospheric emissions of toxaphene would be useful in estimating 
potential human exposures in the United States. Additional information on the amounts of PCCs released 
to the environment as by-products of the chlorinated pulp processes involving pine oils (pinene) (Rantio 
et al. 1993; Swackhamer et al. 1993) would also be useful in developing estimates of global production 
and emissions for toxaphene.
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The TRI lists four states containing facilities that were involved with the import of toxaphene into the 
United States during 2008 (TRI08 2010). Export of toxaphene to foreign nations for use as a pesticide is 
not expected since nations around the globe have adopted similar bans under the Stockholm Convention. 
No other information was found regarding the import of toxaphene into or the export of toxaphene from 
the United States.
In 1982, the use of toxaphene was restricted by EPA to its use as a pesticide on livestock; to control 
grasshopper and army worm infestation on cotton, corn, and small grains (in emergency situations only); 
and on banana and pineapple crops in Puerto Rico and the Virgin Islands (EPA 1982a). After July 1990, 
the pesticide registrations for all toxaphene formulations were canceled in the United States and in all 
U.S. territories (EPA 1990b). Because of its historic use as a pesticide, toxaphene has been widely 
distributed in the air, soil, surface water and sediments, aquatic organisms, and foodstuffs. Information 
on the current distributional patterns, which may involve localized hotspots, would be helpful in 
estimating human exposure.
Incineration in a pesticide incinerator is the preferred method of disposal for toxaphene (EPA 1989a). 
Additional information on the amount of toxaphene disposed of by this method, as well as the amount of 
toxaphene disposed of or abandoned at hazardous waste sites, would be helpful for estimating the 
potential for human exposure.
Environm ental Fate. Information on the environmental fate of toxaphene congeners (as a chemical 
group) is only sufficient to permit a general understanding of the partitioning and widespread transport, of 
toxaphene mixtures in the environment. The composition of toxaphene mixtures varies among producers 
(Walter and Ballschmiter 1991; Worthing and Walker 1987), and only limited data are available on the 
transport and transformation of individual toxaphene congeners in these mixtures. Additional information 
on the identity, physical/chemical properties, and environmental fate of toxic fractions of toxaphene 
mixtures would be useful. However, the sampling and analytical methodology limitations that have 
contributed to the lack of availability of this type of data in the past have not been completely overcome 
(Andrews et al. 1993; Bidleman et al. 1993; Bruns and Birkholz 1993; de Boer and Wester 1993; EPA 
2010e; Lamb et al. 2008; Muir and de Boer 1995; Vetter et al. 1993; Zhu et al. 1994). Therefore, the 
development of this information may be difficult. More information on the rates of biotransformation and 
abiotic reduction of toxaphene in soils and sediments under anaerobic conditions would improve the 
current understanding of toxaphene’s environmental fate. The role of biotic transformations in aerobic 
environments following initial reductive dechlorination needs to be clarified. Toxaphene metabolites
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such as Hp-Sed and Hx-Sed have been identified (Buser et al. 2000; EPA 2010e). Further information 
regarding the identity, toxicity, and environmental fate of the major toxaphene transformation products 
will be useful in making a more critical assessment of potential human exposure.
B ioava ilab ility  from  Environm ental Media. Animal studies and case reports of human exposure 
indicate that toxaphene is absorbed following inhalation, oral, and dermal exposure (Kutz et al. 1991; 
Munn et al. 1985). Pharmacokinetics data indicate that toxaphene present in water or food is extensively 
absorbed; however, the degree to which toxaphene is absorbed as a result of inhalation of contaminated 
air or dermal contact with contaminated environmental media has not been well studied. The high K,c for 
toxaphene indicates that it is adsorbed relatively strongly to soil, but it is not possible to estimate the 
extent to which toxaphene present on ingested soil would be absorbed from the gastrointestinal tract. 
Toxaphene is not expected to be available to humans via ingestion of plants unless they have been 
recently treated with the mixture. Since all registered uses of toxaphene as a pesticide were canceled in 
the United States and U.S. Territories in July 1990, ingestion of domestically grown agricultural 
commodities should no longer be a source for toxaphene. More information on the extent of absorption 
of components of the mixture following contact with contaminated air, water, or soil would be helpful in 
determining the potential health effects resulting from human exposure.
Food Chain B ioaccum ulation. Laboratory bioassay and field monitoring data clearly indicate that 
toxaphene components are bioconcentrated by aquatic organisms. Available model ecosystem and field 
monitoring studies of aquatic food chains are sufficient to indicate that toxaphene bioaccumulates in 
aquatic organisms (Lowe et al. 1971; Sanborn et al. 1976; Schimmel et al. 1977; Swackhamer and Hites 
1988; Whittle et al. 2000). However, as the result of metabolism, toxaphene is not biomagnified to the 
same degree as other chlorinated compounds, such as DDT and PCBs (Evans et al. 1991; Ford and Hill 
1991; Niethammer et al. 1984; Stapleton et al. 2001). While several studies show that toxaphene is 
biomagnified in some ecosystems, several other studies show that little or no biomagnification of 
toxaphene occurs in other ecosystems because of effective metabolism of toxaphene by higher trophic 
level mammalian species (Andersson et al. 1988; Muir et al. 1988a, 1988b, 1992). Further congener- 
specific information on the bioaccumulation and biomagnification potential of toxaphene in both 
terrestrial and aquatic food chains would be desirable to resolve differences observed in different 
ecosystems. These data will be helpful in assessing the potential for human exposure as a result of 
ingestion of contaminated food.
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Exposure Levels in Environm ental Media. Reliable monitoring data for the levels of toxaphene 
in contaminated media at hazardous waste sites are needed so that the information obtained on levels of 
toxaphene in the environment can be used in combination with the known body burden of toxaphene to 
assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste 
sites.
Although a large amount of monitoring data is available for toxaphene, most of the data were collected 
20-30 years ago when the mixture was widely used as a pesticide (Cole et al. 1984; Cooper et al. 1987; 
EPA 1984b; Faust and Suffet 1966; Kutz et al. 1976; Plumb 1987; Stanley et al. 1971; Staples et al.
1985). Some recent monitoring data are available for air (Bidleman and Leone 2004; Hoh and Hites 
2004; James and Hites 2002; Jantunen and Bidleman 2003), surface water (Jantunen and Bidleman 2003), 
soil (Agency for Toxic Substances and Disease Registry 2005; Bidleman and Leone 2004; Hamer et al. 
1999; Kannan et al. 2003), and sediment (Raff and Hites 2004; Schneider et al. 2001). Additional 
information on current levels in environmental media would be helpful in characterizing current 
concentrations to which humans could be exposed. This is particularly important for concentrations of 
toxaphene in air, soils, and surface waters in the vicinity of hazardous waste sites. The data currently 
available are too limited to be useful in estimating the exposure of populations coming into contact with 
the mixture through inhalation of contaminated air, consumption of contaminated surface water, 
groundwater, or foodstuffs, and/or contact with contaminated soil. Reliable information is needed on 
current exposure levels in all environmental matrices and food sources (fish, shellfish, and terrestrial 
wildlife) in the vicinity of hazardous waste sites. Additional biomonitoring studies of both aquatic and 
terrestrial wildlife populations near hazardous waste sites, near water bodies where fish consumption 
advisories are currently in place (EPA 2010d), and in areas where toxaphene was historically used in 
agriculture applications (Ford and Hill 1991) are needed. This information on levels of toxaphene in the 
environment would be useful in assessing the potential risk of adverse health effects in populations living 
in these areas.
Exposure Levels in Humans. Exposure levels for the populations with either short- or long-term 
contact with hazardous waste sites are unknown. These levels currently cannot be estimated because of 
the lack of toxaphene concentration data for contaminated media in the vicinity of hazardous waste sites. 
Exposure of the general population has been estimated from levels in foodstuffs (FDA 1990, 1991, 1992,
1993). Estimates of average dietary intakes for several age/sex categories are based on data obtained 
subsequent to the restriction of most uses of toxaphene in 1982 (EPA 1982a) and appear to be adequate. 
Inhalation is not expected to be a major exposure route for the general public; consequently, additional
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data are not necessary. Pharmacokinetic data indicate that toxaphene rapidly redistributes to body fat and 
toxaphene has been identified in human breast milk fat from non-U.S. nursing mothers (de Boer and 
Wester 1993; Hedley et al. 2010; Mussalo-Rauhamaa et al. 1988; Newsome and Ryan 1999; Polder et al. 
2008; Vaz and Blomkvist 1985). Levels of toxaphene have been measured in serum (Barr et al. 2004; 
Patel et al. 2004). Tissue levels have not been obtained from persons exposed to toxaphene as a result of 
contact with a hazardous waste site. This information would be useful in assessing the risk to human 
health for populations living in the vicinity of hazardous waste sites.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures o f Children. Limited data are available regarding the exposures of children to toxaphene. 
Agency for Toxic Substances and Disease Registry (2005) assessed the potential for toxaphene exposure 
of children attending school near a former production facility. The estimated exposure dose for these 
children was calculated as 0.000015-0.0006 mg/kg/day. A few foreign studies are available that report 
toxaphene levels measured in human milk and adipose tissue of children (Hedley et al. 2010; Mussalo- 
Rauhamaa et al. 1988; Newsome and Ryan 1999; Polder et al. 2003, 2008; Vaz and Blomkvist 1985; Witt 
and Niessen 2000). Levels of toxaphene in human milk, amniotic fluid, meconium, umbilical cord blood, 
neonatal blood, childhood serum, or childhood adipose tissue of individuals living in the United States 
were not located.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for toxaphene were located. This substance is not 
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry. The substance will be considered in the future when chemical selection is made for sub­
registries to be established. The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance.
6.8.2 Ongoing Studies
No ongoing studies were located regarding the potential for human exposure to toxaphene.
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring toxaphene, its metabolites, and other biomarkers of exposure and effect to 
toxaphene. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is 
to identify well-established methods that are used as the standard methods of analysis. Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision.
This chapter summarizes the methods available for the analysis of toxaphene in biological and 
environmental media. In designing a study and choosing a method, it is very important that adequate 
attention be paid to the extent of validation and field applicability. Some of the EPA methods have been 
validated, while some of the literature methods have not. It is the analyst’s responsibility to determine the 
data quality needed before initiating the application of a particular method.
The analytical methods used to quantify toxaphene in biological and environmental samples are 
summarized below.
7.1 BIOLOGICAL MATERIALS
Table 7-1 lists the applicable analytical methods for determining toxaphene in biological samples. The 
analysis and chemical characterization of toxaphene is difficult because of the extreme complexity of the 
compound. Commercial toxaphene is a complex mixture of chlorinated camphene derivatives containing 
more than 670 components (Jansson and Wideqvist 1983). Furthermore, widespread contamination from 
ubiquitous PCBs, 1,1-dichloro-2-2-bis (chlorphenyl)-ethane (DDE), and other organochlorine pesticides, 
which are also complex multi-isomeric chemicals, often interferes with toxaphene's analysis. Hence, 
identification of toxaphene in biological and environmental samples almost invariably involves rigorous 
sample preparation and clean-up procedures prior to chromatographic analysis (de Geus et al. 1999; 
Gooch and Matsumura 1985; Matsumura et al. 1975; Nelson and Matsumura 1975).
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Table 7-1. Analytical Methods for Determining Toxaphene in Biological Samples
Sample
matrix Preparation method
Analytical
method
Sample
detection
limit
Percent
recovery Reference
TLCHuman Maceration of tissue into a fine slurry; 
tissues addition of anhydrous Na2SO4 and 
(toxaphene acetone; filtration of solution and 
and some addition of water and saturated Na2SO4 
metabolites) solution to extract; extraction with 
chloroform; addition of 5% KOH to 
chloroform extract; extraction with 
water; water removal (Na2SO4); 
evaporation and dissolution of residue 
in acetone
Tissues Grinding of sample (20 g, wet weight) GC/NCIMS 
containing internal standards anhydrous 
sodium sulfate followed by extraction 
with 1:1 dichloromethane:hexane, 
volume reduction; cleanup using GPC 
and Florisil
Human Centrifugation of milk sample; freeze- GC/ECD and 
breast milk drying of fat concentrate; dissolution in GC/NCIMS 
acetone and cooling to -60 °C; re­
dissolution of residue in hexane and 
shaking with concentrated H2SO4 ; 
cleanup using silica gel column
Human Homogenization and extraction with GC/ECD 
breast fat petroleum ether; removal of water from 
extract with anhydrous Na2SO4 ; volume 
reduction
Stomach Filtration of sample and wash of residue TLC 
washings with water; addition of saturated solution 
and urine of Na2SO4 and extraction with hexane;
(toxaphene filtration of extract through anhydrous 
and some Na2SO4 and evaporation to dryness; 
metabolites) dissolution of residue in acetone
Human Addition of 60% H2SO4 to blood sample; GC/ECDGC/ 
blood extraction with hexane:acetone (9:1); MC
centrifugation and evaporation to 
dryness; dissolution of residue in 
hexane
1 pg/sample 94 Tewari and
Sharma
1977
~10 ppb 77-107 
at 40­
50 ppb
Fowler et al. 
1993
100 ng/g No data Vaz and
Blomkvist
1985
No data No data Head and 
Burse 1987
1 pg/sample 94
No data 10- 100
40 ppb 100
Tewari and
Sharma
1977
Griffith and
Blanke
1974
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Table 7-1. Analytical Methods for Determining Toxaphene in Biological Samples
Sample
matrix
Analytical
Preparation method method
Sample
detection
limit
Percent
recovery Reference
Human
blood
Addition of sample to a solution of dilute TLC 
H2SO4 and 10% sodium tungstate; 
filtration of solution and wash of residue 
with water; water removal with (Na2SO4) 
and extraction with hexane; filtration of 
extract through anhydrous Na2SO4 and 
evaporation to dryness; dissolution of 
residue in acetone
1 ^g/sample 94 Tewari and
Sharma
1977
ECD = electron capture detection; GC = gas chromatography; GPC = gel permeation chromatography;
MC = microcoulometry; NCIMS = negative chemical ionization mass spectrometry; TLC = thin-layer chromatography
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Cautions regarding potential transformations of toxaphene components during sample clean-up operations 
are described below in Section 7.2. The determination of trace amounts of toxaphene in human tissues 
and fluids has been restricted to a limited number of analytical techniques. These include gas 
chromatography equipped with either an electron capture detector (GC/ECD), or a microcoulometric 
detector (GC/MC), or negative ion chemical ionization mass spectrometry (GC/NCIMS), and thin-layer 
chromatography (TLC).
The most prevalent analytical technique employed to determine trace amounts of toxaphene in biological 
and environmental samples is GC/NCIMS because it has shown the greatest sensitivity to these types of 
chlorinated compounds (Lau et al. 1996; Xia et al. 2009). Vaz and Blomkvist (1985) developed a 
GC/NCIMS method to quantitatively and selectively detect components of toxaphene at ppb (ng/g) levels 
in human breast milk. These authors demonstrated that several mass (M) fragments containing mainly 
(M-35)-ions can be identified, thereby giving relatively simple mass spectra. More important, however, 
fragmented ions from contamination by other organochlorine compounds were not detected because they 
gave weak NCIMS spectra. One disadvantage of GC/NCIMS is the potential for obtaining false negative 
results for certain congeners (Lau et al. 1996; Santos et al. 1997; Xia et al. 2009).
An alternative method is gas chromatography/electron impact/mass spectrometry (GC/EI/MS) (Lau et al.
1996). This method is less sensitive than GC/NCIMS; however, it is better at overcoming interferences 
(Lau et al. 1996; Xia et al. 2009). In efforts to improve sensitivity, methods using high resolution GC/EI 
coupled with tandem MS/MS have been developed (Chan et al. 1998; Gouteux et al. 2002; Skopp et al. 
2002a; Xia et al. 2009).
GC/ECD has also been widely used as a low-cost and sensitive method for toxaphene analysis. Griffith 
and Blanke (1974) and Head and Burse (1987) employed GC/ECD for analysis of toxaphene in human 
blood and breast fat, respectively. MS detection techniques have been favored over ECD since ECD has 
lower selectivity and higher risk for the coelution of congeners (Bordajandi et al. 2006; de Geus et al. 
1999; Fowler 2000; Lau et al. 1996). A number of studies have explored multidimensional gas 
chromatography (MDGC) or similar techniques coupled with ECD as a way to increase selectivity 
(Bordajandi et al. 2006; De Boer et al. 1997; Korytar et al. 2003; Shoeib et al. 2000). Enantiomeric 
determination of chiral toxaphene congeners has been achieved using MDGC/ECD (Bordajandi et al. 
2006).
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Detection of the individual toxaphene congener enantiomers, referred to as enantioselective 
determination, has been demonstrated using both GC/NCIMS and MDGC/ECD (Bordajandi et al. 2006; 
de Geus et al. 1999; Vetter and Luckas 1995, 2000). Enantiomers tend to show differences in biological 
behavior due to chiral-specific interactions despite their identical physical properties (Vetter and Luckas 
2000). The enantiomers of a single congener may be biodegraded or metabolized at different rates and 
they may show differences in toxicity. Therefore, analysis of the enantiomeric ratios of the congeners 
found in biological and environmental samples may provide further insight into the environmental fate 
and toxicity of toxaphene.
Identification of low ppb levels of toxaphene in human blood was achieved by GC/MC (Griffith and 
Blanke 1974). The advantages of GC/MC are that the system is linear and more specific, and a lower 
temperature is generally required to vaporize the compound in the GC column.
A radioreceptor assay has been described for the determination of toxaphene in whole blood (Saleh and 
Blancato 1993). The method is based on the ability of toxaphene to displace 35S tertiary butylbicyclo- 
phosphorothioate from the chloride channel of isolated gamma-aminobutyric acid receptor ionophore 
complexes. Unlike chromatographic methods, this approach requires no sample clean-up, needs only 
0.1 mL of blood, and is sensitive to toxaphene concentrations in blood of 2 ppb. An advantage of this 
method is that it assays those toxaphene isomers that are toxic to the nervous system by exploiting the 
known receptor-based mechanism of that toxicity.
In addition to direct measurement of toxaphene in biological media, it is also possible to determine the 
level of metabolites in biological tissues and fluids. Tewari and Sharma (1977) developed a TLC method 
for determination of toxaphene and its metabolites (dechlorinated and dehydrochlorinated toxaphene) in 
urine, stomach washings, and blood. A detection limit of 1x10-6 g of toxaphene per sample was achieved. 
The authors employed a series of solvent systems and chromogenic reagents on silica gel plates 
impregnated with silver reagents and copper sulfate for separation of the pesticides. The TLC technique 
is, however, laborious and time consuming.
Despite the availability of advanced instrumental methods, the accurate quantitative determination of the 
level of toxaphene is difficult because of inherent differences between the GC fingerprint pattern of the 
technical toxaphene standard and the pattern found in human fluid extracts containing toxaphene. These 
differences reflect changes caused by metabolism and degradation of the original compound (Lamb et al. 
2008).
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Table 7-2 lists the methods used for determining toxaphene in environmental samples. Residues of 
toxaphene are detectable in the environment because of its use as a piscicide and its use as a pesticide on 
field crops, fruits, vegetables, and uncultivated lands. The identification and quantification of toxaphene 
in environmental samples is complicated by changes in the numbers and relative sizes of constituent 
peaks (components) due to the difference in their rates of degradation, sorption, and volatilization in the 
environment. In addition, quantitative analysis can be further hindered by the lack of purified, individual 
congeners, although improvements in this area are being made (Foreid et al. 2000; Gill et al. 1996; Muir 
and de Boer 1993; Vetter et al. 2000). This is important because of the differing detector response factors 
of the different congeners, a problem of particular relevance to mass spectrometric detection methods (Xu 
et al. 1994). Most recently, the focus of analytical toxaphene research has been to develop methods 
capable of sensitive, selective, and accurate determination of the many different individual toxaphene 
congeners present in samples (Bordajandi et al. 2006; EPA 2010e; Gill et al. 1996; MacEachen and Cocks 
2002; Vander Pol et al. 2010; Vetter et al. 2005; Xia et al. 2009).
Since the formerly used commercial form of toxaphene, called technical toxaphene, undergoes 
"weathering" through environmental transformation and degradation processes, methods that are strictly 
based on technical toxaphene analysis may not give the most accurate picture regarding the form that 
humans may be exposed to in the environment. Therefore, recent efforts have also been made to 
differentiate between the congener profiles for technical toxaphene and weathered toxaphene (EPA 
2010e).
A number of potential problems in the procedures used to isolate toxaphene components (chlorobornanes) 
have been noted and compiled after a workshop on the analytical chemistry of toxaphene (Muir and de 
Boer 1993). Extraction/clean-up procedures that include treatments with sulfuric or nitric acid modify the 
toxaphene peak profile. Gel permeation chromatography (GPC) or column chromatography on alumina 
were judged suitable for the isolation of lipids from toxaphene and related organochlorines. The use of 
base hydrolysis for the removal of lipids would degrade chlorobornanes and is not recommended. It has 
also been reported that oxygen in the chemical ionization (CI) source during mass spectrometric detection 
can produce fragment ions from PCBs that appear to be derived from chlorobornanes and this can lead to 
errors in quantitation (Andrews et al. 1993; Muir and de Boer 1993). Other researchers claim that the
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Table 7-2. Analytical Methods for Determining Toxaphene in Environmental
Samples
Sample matrix Preparation method
Analytical Sample Percent
method detection limit recovery Reference
Air
Air
Air
Ambient air
Drinking water
Drinking water
Trapping on chromasorb 102; 
extraction with hexane
Collection of air sample in an 
air sampling train equipped 
with prefilter and ethylene 
glycol; dilution of ethylene 
glycol with water and 
extraction with hexane; 
extraction of prefilter with 
hexane; pooling of extracts 
before drying and 
concentration
Adsorption onto PUF using a 
high volume sampling pump; 
extraction with hexane and 
volume reduction
High volume sampler 
consisting of glass fiber filter 
with PUF backup adsorbent 
and flow rate approximately 
200-280 L/minute for 
24 hours; extraction of filter 
and PUF in soxhlet with 
5% ether in hexane; cleanup 
using alumina column 
chromatography and 
concentration using K-D (EPA 
Method TO4)
Extraction of sample with 
15% dichloromethane in 
hexane; water removal using 
anhydrous Na2SO4; extract 
volume reduction
GC/ECD
GC/ECD
GC/ECD;
GC/MS
Extraction of sample with GC/ECD
dichloromethane, water (capillary
removal and solvent exchange column) 
to methyl-t-butyl ether (EPA 
Method 508)
0.234­
0.926 ng/m3
0.10 pg/m3 
(10,000 m3 
sample)
GC/ECD (EPA 
Method 608)
Generally 
>1 ng/m3
GC/ECD or 
GC/MC or 
GC/electrolytic 
conductivity 
and GC/MS
100
1-10 ng/m No data
Thomas
and
Nishioka
1985
Kutz et al. 
1976
No data Barrie et 
al. 1993
No data EPA 1984a
0.001­
0.01 pg/L 
(single 
component 
pesticide 
sample) 0.050­
1.0 pg/L 
(multiple 
component 
pesticide 
sample)
No data
No data EPA 1987a
No data EPA 1989
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Table 7-2. Analytical Methods for Determining Toxaphene in Environmental
Samples
Sample matrix Preparation method
Analytical Sample Percent
method detection limit recovery Reference
Drinking water, 
groundwater, 
soil, sludges, 
wastes
Drinking water
Tap water, 
groundwater, 
river water
Waste water 
Waste water
Waste water
Municipal and 
industrial 
discharge water
Municipal and
industrial
discharges
Extraction of sample with GC/ECD 
organic solvent and cleanup 
using Florisil column
Extraction of sample with GC/ECD and
acetone on a water sampling GC/MS
apparatus equipped with
porous polyurethane plugs;
elution of extract through
activated Florisil column with
diethyl ether in petroleum
ether
Isolation of compounds from GC/ion trap
water using C1 8  SPE followed MS
by recovery of adsorbed
analytes with supercritical
carbon dioxide containing
acetone
Extraction with Tandem MS
dichloromethane
Extraction with GC/ECD
dichloromethane, solvent (packed
exchange to hexane; Florisil column) 
cleanup
Extraction with 15% dichloro- GC/ECD 
methane in hexane followed 
by water removal with sodium 
sulfate and concentration with 
K-D; additional cleanup, if 
needed, by partition with 
acetonitrile to remove fats and 
oils or fractionation using a 
Florisil column
Adjustment to pH=11 and GC/MS
extraction with
dichloromethane;
concentration using K-D after
drying
Extraction with GC/ECD
dichloromethane (no pH 
adjustment) and solvent 
exchange to hexane during 
concentration; magnesia-silica 
gel cleanup and concentration
0.24 pg/L No data
(drinking water) 
to 24 mg/L 
(non-water 
miscible waste)
0.01 ng/L 100
EPA 1986f
EPA 1976b
7.4 pg/L (ppb, 105 (18% Ho et al. 
w:v) RSD) at 1995
25 pg/L
5 pg/sample 
0.24 pg/L 96
No data 96
Hunt et al. 
1985
EPA 1984c
EPA 1992c
No data No data
0.24 pg/L 80
APHA
1998a
APHA
1998b
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Table 7-2. Analytical Methods for Determining Toxaphene in Environmental
Samples
Sample matrix Preparation method
Analytical Sample Percent
method detection limit recovery Reference
Municipal and 
industrial waste 
water, sludges
Primary sludge
Soil, water
Soil, water
Soil
(1) If solids <1%, extraction GC with ECD, 
with dichloromethane. (2) For MC, or 
nonsludges with solids 1-30%, electrolytic 
dilution to 1% and extraction conductivity 
with methylene chloride. If 
solids >30%, sonication with 
methylene chloride/acetone.
(3) For sludges: if solids 
<30%, treatment as in 
#2 above. If solids >30%, 
sonication with acetonitrile 
then methylene chloride. Back 
extraction with 2% sodium 
sulfate. Water removal with 
sodium sulfate, concentration 
using K-D, purification using 
GPC, Florisil, and/or SPE
Extraction of sample with GC/ECD and
hexane: dichloromethane: GC/MS
acetone (83:15:2); extract 
concentration and cleanup on 
Florisil column and elution with 
20% acetone in hexane
Extraction of sample with GC/ECD or
organic solvent or mixture of GC/ELCD
organic solvents, depending (EPA Method
on the sample matrix, followed 8081B)
by open-column, 
chromatographic cleanup
Extraction of sample with GC/NIMS
organic solvent or mixture of (EPA Method
organic solvents, depending 8276)
on the sample matrix, followed 
by open-column, chromato­
graphic cleanup
910 ng/L (lower 76-122 at EPA 1992d 
if many 5,000
interferences) ng/L is 
accept­
able
No data 85-93 EPA 1982b
No data No data EPA 2007a
No data No data EPA 2010e
Addition of water and extract 
with methanol:toluene (1:1); 
loading of extract onto 
chromaflex column containing 
Florisil; concentration of 
sample; addition of 43% 
methanolic KOH solution and 
refluxing followed by extraction 
with hexane and Florisil 
column cleanup
GC/MS and 
HPLC
0.05 |jg/g 76-91 Crist et al. 
1980
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Table 7-2. Analytical Methods for Determining Toxaphene in Environmental
Samples
Sample matrix Preparation method
Analytical Sample Percent
method detection limit recovery Reference
Soil
Soil
Soil
Sediment, and 
mussel tissue
Pesticide
formulation
Pesticide
formulation
Pesticide
formulation
Pesticide
formulation
Cotton leaves
GC/EC-NIMS 100 |jg/kg
HPLC followed <1 ng/g 
by GC/FID or 
GC/ECD
Soxhlet extraction using 
methylene chloride or 
sonication with methylene 
chloride:acetone (1:1, v/v);
GPC or SPE cleanup
Extraction of sample (1 g) with GC/NCIMS 
dichloromethane:acetone (1:1) 
using sonication; removal of 
water with a sodium sulfate 
column; solvent exchange to 
isooctane; Florisil cleanup
Extraction of soil; introduction Colorimetric 
of extract with enzyme- immunoassay
toxaphene conjugate into tube 
containing immobilized 
toxaphene antibody
Extraction of sample with 
hexane; elution from alumina 
column and concentration of 
eluent
Extraction of sample using 
50% methanolic KOH; elution 
with ether from Florisil
Removal of solvent (xylene) 
from pesticide sample by 
reduced pressure; extraction 
with hexane
Extraction of sample with 
hexane
Dissolution of sample in 
hexane and loading onto 
alumina column; elution with 
hexane, then 20% methylene 
chloride in benzene and finally 
100% methanol
Extraction of sample with TLC followed
water and petroleum ether; by GC/ECD
addition of methanolic KOH 
and heat treatment; 
concentration of extract
No data
50 jg/kg (ppb, 
w:w)
0.5 jg/g 
(0.5 ppm)
90-109 
(10% 
RSD)
118% 
>0.25- 
5.0 jg/g
95-100
GC/ECD
Open tubular 
GC column 
and GC/TLC
TLC
GC/ECD or 
GC/FID
1 ng/sample No data
No data No data
1 pg/sample No data
No data No data
0.16­
0.45 jg/cm2
No data
Brumley et 
al. 1993
Onuska et 
al. 1994
EPA 1996
Petrick et 
al. 1988
Gomes
1977
Saleh and
Casida
1977
Ismail and
Bonner
1974
Seiber et 
al. 1975
Bigley et 
al. 1981
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7. ANALYTICAL METHODS
Table 7-2. Analytical Methods for Determining Toxaphene in Environmental
Samples
Sample matrix Preparation method
Analytical Sample Percent
method detection limit recovery Reference
Non-fatty foods
Various produce
Fruits and 
vegetables
Cucumber
Fortified extracts 
(various foods)
Molasses
Fatty foods
Extraction of homogenized 
sample with solvent (acetone, 
acetonitrile, or acetonitrile/ 
water, depending on moisture 
and sugan content) followed 
by water removal and Florisil 
cleanup
50 g homogenized sample 
extracted with acetonitrile, 
filtered, and salt added to 
affect phase separation; 
evaporation to near dryness 
and reconstitution in benzene
Extraction with acetone in 
blender; filtration and 
extraction with petroleum 
ether/di-chloromethane; 
solvent evaporation and 
dissolution of residue in 
minimum amount of acetone
Blending of sample with 
acetone folloed by extraction 
with petroleum ether and 
dichloromethane (1:1); water 
removal (Na2SO4) and 
concentration followed by 
Florisil column cleanup
Preparation of sample solution 
with acetone or hexane; 
addition of diphenylamine and 
zinc chloride solution and 
evaporation to dryness; 
heating of residue (250 °C) for 
a few minutes and dissolution 
of residue complex in acetone
Dilution of sample with water; 
extraction with hexane: 
isopropanol
Extraction of fats and residues 
from homogenized sample by 
dissolution in an organic 
solvent followed by isolation of 
the residues from the fat using 
Florisil
GC/ECD
(PAM1
methods 302, 
303)
GC/ECD
<0.2 ppm >80 FDA 1994a
2 ppm No data Hsu et al. 
1991
GC/ECD No data No data WHO 1984
GC/ECD or 
FID
4.34 ppm 113 Luke et al. 
1975
Spectro­
photometer 
(absorbance at 
640 nm)
<1 ppm 69-100 Graupner 
and Dunn 
1960
GC/ECD
GC/ECD
0.03 mg/kg No data WHO 1984
<0.2 ppm >80 FDA 1994b
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7. ANALYTICAL METHODS
Table 7-2. Analytical Methods for Determining Toxaphene in Environmental
Samples
Sample matrix Preparation method
Analytical Sample Percent
method detection limit recovery Reference
Meat
Bovine 
defibrinated 
whole blood
Bovine 
defibrinated 
whole blood
Bovine 
defibrinated 
whole blood
Lard
Poultry fat
Milk fat
Milk and butter
Blending with ethyl acetate 
followed by drying (Na2SO4) 
and filtration; treatment of 
extract with KOH and heat; 
extraction with hexane; Florisil 
column cleanup
Dilution of blood with water 
and exatraction with hexane
Addition of sample to 88% 
formic acid and shaking on a 
vortex mixer; extraction with 
hexane and extraction of 
hexane with 5% potassium 
carbonate; extract volume 
reduction
Addition of sample to 88% 
formic acid followed by mixing 
and loading onto Florisil 
column; elution with 6% diethyl 
ether in petroleum ether; 
volume reduction and washing 
with hexane
Extraction with petroleum 
ether; centrifugation; removal 
of water from extract with 
anhydrous Na2SO4; volume 
reduction
Rendering of fat followed by 
direct analysis
Centrifugation and 
fractionation using Florisil 
column
GC/ECD No data 76-79
GC/ECD
GC/ECD
0.58 |jg/mL 73.4
0.465 jg/mL 71.7
GC/ECD 0.026 jg/mL 103.4
GC/ECD 1.37 jg/g 46.5­
107.3
Boshoff
and
Pretorius
1979
Maiorino et 
al. 1980
Maiorino et 
al. 1980
Maiorino et 
al. 1980
Head and
Burse
1987
GC/ECD
GC/ECD and 
GC/MS
0.475­
0.908 ppm
92.6-96.9 Ault and 
Spurgeon 
1984
<10 ppb (ECD) No data Cairns et 
7 ppb (MS) al. 1981
Addition of sample to KOH GC/ECD 
followed by heat treatment and 
extraction with hexane; 
centrifugation and cleanup 
using Florisil
No data 78-88 Boshoff
and
Pretorius
1979
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7. ANALYTICAL METHODS
Table 7-2. Analytical Methods for Determining Toxaphene in Environmental
Samples
Sample matrix Preparation method
Analytical Sample Percent
method detection limit recovery Reference
Human breast 
milk
Fish (whole)
Fish tissues
Fish tissue
Fish
Centrifugation of milk sample; GC/ECD and 
freeze-drying of fat GC/NCIMS
concentrate; dissolution in 
acetone and cooling to -60 °C; 
re-dissolution of residue in 
hexane and shaking with 
concentrated H2SO4; cleanup 
using silica gel column
Blending of frozen sample with GC/NCIMS 
dry ice and anhydrous 
Na2SO4 ; extraction in a column 
with hexane: acetone (1:1), 
followed by methanol
Extraction of tissues with a GC/NCIMS
mixture of hexane and acetone 
followed by a second 
extraction with hexane and 
diethyl ether; evaporation and 
dissolution of lipid extract in 
hexane; shaking of extract with 
H2SO4 to remove lipid
Homogenization of 10 g GC/NCIMS
sample with hexane:acetone 
(1:2.5) under acid condition, 
extraction twice more with 
10% diethyl ether in hexane.
Treatment with 98% H2SO4 
and cleanup using GPC and 
silica gel chromatography
Homogenization of 20 g GC/HRMS
sample followed by extraction (SIM) 
with hexane/acetone, addition 
of internal standards 
(13C-PCBs), and cleanup using 
GPC and Florisil
100 ng/g No data Vaz and
Blomkvist
1985
75 pg/sample 98 Swack- 
hamer et 
al. 1987
No data No data Jansson 
and
Wideqvist
1983
No data 94 (RSD= Jansson et 
11%) at al. 1991
19 ng/g
10 ppb (wet 
weight)
No data Andrews et 
al. 1993
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7. ANALYTICAL METHODS
Table 7-2. Analytical Methods for Determining Toxaphene in Environmental
Samples
Sample matrix Preparation method
Analytical
method
Sample Percent 
detection limit recovery Reference
Fish tissue Pulverization of tissue with 
anhydrous sodium sulfate and 
extraction with acetone; 
solvent exchange to hexane 
and volume reduction; cleanup 
using dry-packed Florisil, wet- 
packed Florisil and silica gel
GC/MS (SIM) 0.1 ng/g 90 (RSD= 
7%) at 
100 ng
Jarnuzi
and
Wakimoto
1991
ECD = electron capture detector; ELCD = electrolytic conductivity detector; FID = flame ionization detector;
FTIR = Fourier transform infrared spectroscopy; GC = gas chromatograph; GPC = gel permeation chromatography; 
HPLC = high performance liquid chromatography; HRMS = high resolution mass spectrometry; K-D = Kuderna- 
Danish concentration; MC = microcoulometry; MS = m ass spectrometry; NCIMS = negative ion chemical ionization 
m ass spectrometry; PCBs = polychlorinated biphenyls; PUF = polyurethane foam; SIM = selected ion monitoring; 
RSD = relative standard deviation; SIM = selected ion monitoring; SPE = solid phase extraction; TLC = thin-layer 
chromatography; v/v = volume/volume; wt/wt = weight/weight
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problem of residual oxygen in the ion source does not present a major problem (Fowler et al. 1993). In 
order to minimize problems with interferences during analysis, it is recommended that toxaphene 
components be isolated as completely as possible from PCBs and that the presence of oxygen in the ion 
source be minimized.
GC/ECD, sometimes in combination with GC/MS, is the most frequently used analytical method for 
characterization and quantification of toxaphene in air, drinking water, fish, and other environmental 
samples (Boshoff and Pretorius 1979; Cairns et al. 1981; EPA 1976c, 1985c, 2007a; Kutz et al. 1976; 
Luke et al. 1975; Thomas and Nishioka 1985; WHO 1984; Wideqvist et al. 1984). Analysis of the sample 
includes extraction in organic solvent; a Florisil silica, gel permeation, or TLC clean-up step; and 
detection by GC (Atuma et al. 1986; Ault and Spurgeon 1984; EPA 1976b; Head and Burse 1987; Ismail 
and Bonner 1974; Maiorino et al. 1980; Saleh and Casida 1977; Seiber et al. 1975). A typical gas 
chromatogram contains a series of hills and valleys with three main peaks (EPA 1982b; Gomes 1977). 
Detection limits of toxaphene residues in fish and drinking water were 50 ng of toxaphene per g of sample 
and 1 ng of toxaphene per g of sample, respectively (EPA 1976c, 1987a). GC/ECD is the standardized 
method used by EPA (method 8081B) for determining toxaphene in water and soil samples (EPA 2007a). 
EPA method 8270c (GC/MS, electron impact ionization) is not recommended for toxaphene because of 
limitations in sensitivity arising from the multicomponent nature of toxaphene (EPA 2007b). More 
recently, EPA Method 8276 has been developed to detect congeners typically found in weathered 
toxaphene such as p-26, p-40, p-41, p-44, p-50, p-62, Hx-Sed, and Hp-Sed (EPA 2010e). This method 
uses fused-silica, open tubular capillary columns with negative ion mass spectrometry (NIMS) and is 
considered an appropriate alternative to EPA Method 8081.
Archer and Crosby (1966) developed a confirmatory method for toxaphene analysis in environmental 
samples that involved dehydrohalogenating (in 50% methanolic potassium hydroxide) the residue extract 
prior to GC analysis. The gas chromatogram indicated one main peak and several minor peaks. Also, the 
detector response was doubled, thereby increasing the sensitivity of this procedure. While this method 
was also rapid, its main application was in samples where toxaphene was the major residue. In samples 
with multiple organochlorine pesticide residues, it would be difficult to measure accurately all of the 
residues and quantify the amount of toxaphene (Archer and Crosby 1966; Bigley et al. 1981; Crist et 
al. 1980; Gomes 1977). Recoveries from various samples are generally good with detection limits at 
levels of <1 ppm.
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The tandem MS method has been used as an alternative to GC/MS. This method employs the technique 
of collision-activated dissociation on a triple quadruple mass spectrometer. This facilitates direct and 
rapid qualitative and semiquantitative analysis of toxaphene samples in both liquid and solid 
environmental matrices at the 10-100 ppb level (Hunt et al. 1985). Additional features of tandem MS 
include the elimination of most wet chemical and chromatographic separation steps, detection of both 
known and unknown compounds by molecular weight and functional group, and a total analysis time per 
sample of <30 minutes. A disadvantage is that tandem MS is somewhat less specific than GC/MS in the 
identification of some isomeric compounds.
Techniques developed by Jansson and Wideqvist (1983) and modified by Swackhamer et al. (1987) 
indicated that toxaphene can be detected at 75 pg per sample (approximately 1.2 ng/g) in fish using 
methane NCIMS. The authors noted that the NCIMS technique is more specific and 100 times more 
sensitive than EI or chemical ionization (CI) mass spectrometry and GC/ECD. In combination with a 
selected ion monitoring program, specific fragment ions can be monitored without any preseparation 
column chromatography to eliminate other organochlorine pesticides that coelute with toxaphene 
(Swackhamer et al. 1987). Furthermore, NCIMS spectra are less complex than EI or CIMS spectra and 
contain higher mass ions due to successive losses of chloride and hydrochloride from the molecular ion. 
Jansson et al. (1991) reported a GC/NCIMS method for toxaphene in fish that allowed detection of levels 
below 19 ng/g. Methods based on GC/NCIMS generally give lower limits of detection than GC/ECD 
methods and thus, are recommended for the best sensitivity (Muir and de Boer 1993).
Shafer et al. (1981) reported that the combined data of a gas chromatograph coupled to a Fourier­
transform infrared spectrometer (GC/FT-IR) and GC/MS provide complementary information that leads 
to a better understanding and identification of the EPA's priority pollutants (including toxaphene) in air. 
Both GC/FT-IR and GC/MS separations were performed quickly and efficiently on wall-coated open 
tubular capillary columns.
A semi-specific spectrophotometric method for toxaphene analysis in fortified extracts of various foods 
was developed by Graupner and Dunn (1960). It was based on measuring the absorbance at 640 nm of a 
greenish-blue diphenylamine-toxaphene complex that was formed by reacting a sample extract with 
diphenylamine in the presence of zinc chloride. Several other organochlorine pesticides also reacted 
under these conditions, but only a few formed complexes that absorbed appreciably at 640 nm, thereby 
causing some interference with toxaphene analysis. A detection limit of <1 ppm of toxaphene was 
reported (Graupner and Dunn 1960).
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Petrick et al. (1988) employed high-performance liquid chromatography (HPLC) as a clean-up technique 
prior to GC analysis. Petrick and co-workers efficiently separated toxaphene residues from other 
organochlorinated compounds in fat-rich samples with quantitative recovery. A detection limit of less 
than 1 ng of toxaphene per gram of sample was achieved by GC/ECD. The authors noted that the HPLC 
technique is highly efficient and reproducible and has a low consumption of solvents and high sample 
loading capacity.
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of toxaphene is available. Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of toxaphene.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification o f Data Needs
Methods fo r Determ ining B iom arkers o f Exposure and Effect.
Exposure. Methods are available for detecting and quantifying levels of toxaphene in the blood and milk 
fat of humans. The precision, accuracy, reliability, and specificity of these methods have been reported. 
These methods are sufficiently sensitive to determine background levels of toxaphene in the general 
population and levels at which adverse health effects would begin to occur. Pharmacokinetic data 
indicate that toxaphene rapidly redistributes to fat; therefore, blood levels would be useful for identifying 
very recent exposures to toxaphene. Levels in milk fat are retained somewhat longer, but these levels 
decrease within weeks of cessation of exposure.
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A highly sensitive and specific NCIMS technique has been employed to detect components of toxaphene 
at ppb levels in breast milk without the interference of other organochlorine pesticides (Vaz and 
Blomkvist 1985). GC/ECD and GC/MS can also detect trace amounts of toxaphene in human tissues and 
fluids following an efficient sample preparation and rigorous clean-up procedures. TLC has been used for 
analysis of toxaphene metabolites (Tewari and Sharma 1977). There is a growing need for research and 
development of highly sensitive and quantitative methods for determination of toxaphene metabolites. 
These methods would be useful, since they would allow investigators to assess the risks and health effects 
of long-term, low-level exposure to toxaphene.
Currently, no methods are available to quantitatively correlate monitored levels of toxaphene in tissues or 
fluids with exposure levels or toxic effects in humans. If methods were available, they would provide 
valuable information on systemic effects following exposure to trace levels of toxaphene.
Effect. No specific biomarkers of effect have been clearly associated with toxaphene poisoning. Some 
biological parameters have been tentatively linked with toxaphene exposure, but insufficient data exist to 
adequately assess the analytical methods associated with measurement of these potential biomarkers.
Methods fo r Determ ining Parent Com pounds and Degradation Products in Environm ental 
Media. Human exposure to toxaphene occurs primarily by inhalation of ambient air, ingestion of 
contaminated foodstuffs, and contact with contaminated soil and surface water. Reliable analytical 
methods are available to detect background levels of toxaphene in a wide range of environmental 
matrices. Toxaphene levels of 75 pg/sample (approximately 1.2 ng/g) can be detected in fish using the 
NCIMS technique (Swackhamer et al. 1987). However, there is a need to implement more refined 
software to process efficiently the data generated by the NCIMS technique. GC/ECD is the standardized 
analytical method used by EPA (2007a) to determine toxaphene in soil and water samples at ppb levels.
A newer EPA method (8276) has been developed as an alternative to method 8081, which uses GC/NIMS 
(EPA 2010e). GC/ECD, GC/MS, and tandem MS can detect and quantify toxaphene in air, soil, plant 
material, fish, water, milk, fat, and meat at ppb levels. The MRL for intermediate oral exposure to 
toxaphene is 0.002 mg/kg/day. Assuming a 70-kg individual and oral intakes of either 2 L/day of water 
or 2 kg/day of food, analytical methods would need to have sensitivities below 70 ppb (70 ^g/L or 
70 ^g/kg) in either medium. The methods reported for drinking water have limits of detection far below 
this value (EPA 1976b, 1987a, 1989, 1986f; Ho et al. 1995). The needed sensitivities can be achieved for 
produce (Hsu et al. 1991; Luke et al. 1975), molasses (WHO 1984), and fish (Andrews et al. 1993;
Jarnuzi and Wakimoto 1991; Swackhamer et al. 1987). Limits of detection in FDA methods are reported
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as “<0.2 ppm” and are thus inadequate for these MRLs. Additional analytical methods for detecting low 
levels of toxaphene are needed for foods other than produce.
Little is known about the toxic properties of toxaphene congener metabolites in the environment 
(Bidleman et al. 1993). Additional analytical methods specifically targeted at toxaphene metabolites and 
degradation products are needed to support such investigations.
7.3.2 Ongoing Studies
No ongoing studies concerning techniques for measuring and determining toxaphene in biological and 
environmental samples were reported.
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T h i s  p a g e  i s  i n t e n t i o n a l l y  b l a n k .
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites.
An MRL of 0.05 mg/kg/day has been derived for acute-duration oral exposure (<14 days) to toxaphene. 
The MRL is based on a NOAEL of 5 mg/kg/day and a serious LOAEL of 10 mg/kg/day for neurological 
effects (convulsions, salivation, and vomiting) in male and female beagle dogs (Chu et al. 1986). The 
NOAEL of 5 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolation from animals to 
humans and 10 for human variability).
An MRL of 0.002 mg/kg/day has been derived for intermediate-duration oral exposure (15-364 days) to 
toxaphene based on decreased anti-SRBC (IgM) titers as an indicator of depressed humoral immunity in 
monkeys. Benchmark dose (BMD) modeling was conducted using mean anti-SRBC (IgM) titre data 
collected from female cynomolgus monkeys that received toxaphene from the diet for 44 weeks prior to 
primary immunization with SRBC (Tryphonas et al. 2001). The resulting BMDLiSD of 0.22 mg/kg/day 
was divided by an uncertainty factor of 100 (10 for interspecies extrapolation and 10 for sensitive 
individuals).
EPA (IRIS 2010) has not established an oral reference dose (RfD) or inhalation reference concentration 
(RfC) for toxaphene.
The International Agency for Research on Cancer (IARC) has classified toxaphene as a Group 2B 
carcinogen (possibly carcinogenic to humans) (IARC 2009). The National Toxicology Program (NTP) 
has determined that toxaphene is reasonably anticipated to be a human carcinogen (NTP 2005), and EPA 
has classified toxaphene as a B2 carcinogen (probable human carcinogen) (IRIS 2010). The American 
Conference of Governmental Industrial Hygienists (ACGIH) has classified toxaphene as an 
A3 carcinogen (confirmed animal carcinogen with unknown relevance to humans) (ACGIH 2009).
OSHA has required employers of workers who are occupationally exposed to toxaphene to institute 
engineering controls and work practices to reduce and maintain employee exposure at or below 
permissible exposure limits (PELs) (OSHA 2009). The employer must use engineering and work practice 
controls to reduce toxaphene exposures to or below 0.5 mg/m3 at any time (ceiling) (OSHA 2009).
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EPA has designated toxaphene as a hazardous air pollutant (HAP) under the Clean Air Act (CAA) 
(EPA 2006b). Toxaphene is on the list of chemicals appearing in “Toxic Chemicals Subject to Section 
313 of the Emergency Planning and Community Right-to-Know Act of 1986" and has been assigned a 
reportable quantity (RQ) limit of 1 pound (EPA 2009e). The RQ represents the amount of a designated 
hazardous substance which, when released to the environment, must be reported to the appropriate 
authority.
The international and national regulations, advisories, and guidelines regarding toxaphene in air, water, 
and other media are summarized in Table 8-1.
8. REGULATIONS AND ADVISORIES
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8. REGULATIONS AND ADVISORIES
Table 8-1. Regulations and Guidelines Applicable to Toxaphene
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC
WHO
NATIONAL
Regulations and 
Guidelines:
a. Air
ACGIH
AIHA
DOE
EPA
NIOSH
OSHA
b. Water 
EPA
Carcinogenicity classification 
Air quality guidelines 
Drinking water quality guidelines
TLV (8-hour TWA)
STEL (15-minute TWA)
TLV-basis (critical effect)
ERPG values 
TEELs 
TEEL-0d 
PAC-1e 
PAC-2f 
PAC-3g 
AEGL values 
Hazardous air pollutant
Regulated toxic substances and 
threshold quantities for accidental 
release prevention
Second AEGL Chemical Priority List
REL (10-hour TWA)
IDLH
Potential Occupational Carcinogen 
Target organs
Group 2Ba
No
Nob
Category of Pesticide 
PEL (8-hour TWA) for general industry 0.5 mg/m
Designated as hazardous substances in Yes 
accordance with Section 311(b)(2)(A) of 
the Clean Water Act
0.5 mg/m3 c
1 mg/m3 c
Central nervous 
system convulsions; 
liver damage
No
0.5 mg/m3 
1 mg/m3
20 mg/m3 
200 mg/m3 
No 
Yes
No
Yesh
No'
200 mg/m3 
Yes
Central nervous 
system, skin
Group Ij
3  i
IARC 2009 
WHO 2000 
WHO 2006
ACGIH 2009
AIHA 2010 
DOE 2010
EPA 2010b
EPA 2006b 
42 USC 7412
EPA 2009h 
40 CFR 68.130
EPA 2008 
NIOSH 2005
NIOSH 1992
OSHA 2009 
29 CFR 1910.1000, 
Table Z-1
EPA 2009b 
40 CFR 116.4
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Table 8-1. Regulations and Guidelines Applicable to Toxaphene
Agency Description Information Reference
NATIONAL (cont.) 
EPA
c. Food 
FDA
Drinking water standards and health 
advisories
1-Day health advisory for a 10-kg 
child
10-Day health advisory for a 10-kg 
child
DWEL
Lifetime
10-4 Cancer risk
Drinking water contaminants list
National primary drinking water 
regulations
MCL
Potential health effects from 
exposure above the MCL
Common sources of toxaphene in 
drinking water
Public health goal
National recommended water quality 
criteria
Freshwater
CMC (acute)
CCC (chronic)
Saltwater
CMC (acute)
CCC (chronic)
Human health for the consumption 
of:
Water + organism
Organism only
Reportable quantities of hazardous 
substances designated pursuant to 
Section 311 of the Clean Water Act
Groundwater Monitoring List
Bottled drinking water
0.004 mg/L
0.004 mg/L
0.01 mg/L 
No
0.003 mg/L 
Yes
0.73 |jg/L 
0.0002 jg /L k
0.21 jg /L  
0.0002 jg /L k
0.00028 jg /L  
0.00028 jg /L  
1 pound
Yes
0.003 mg/L
l , m
l , m
EPA 2009c
EPA 2010c 
EPA 2009d
0.003 mg/L
Kidney, liver, or thyroid 
problems; increased 
risk of cancer
Runoff/leaching from 
insecticide used on 
cotton and cattle
Zero
Yes EPA 2006a
EPA 2009i 
40 CFR 117.3
EPA 2009a 
40 CFR 264, 
Appendix IX
FDA 2010a
21 CFR 165.110
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8. REGULATIONS AND ADVISORIES
Table 8-1. Regulations and Guidelines Applicable to Toxaphene
Agency Description Information Reference
NATIONAL (cont.)
FDA
d. Other 
ACGIH
EPA
NTP
EAFUSn No
Carcinogenicity classification A3o
Biological exposure indices (end of shift No 
at end of workweek)
Carcinogenicity classification
Oral slope factor
Drinking water unit risk
Inhalation unit risk
RfC
RfD
Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous 
substance
Reportable quantity
Effective date of toxic chemical 
release reporting
Extremely hazardous substances 
and its threshold planning quantity
Carcinogenicity classification
B2p
1.1 (mg/kg-day)-1 
3.2x10-5 (pg/L)-1 
3.2x10-4 (pg/m3)-1 
No 
No
Yesq
1 pound 
01/01/1987
No
Toxic pollutants designated pursuant to Yes 
Section 307(a)(1) of the Clean Water 
Act
Reasonably 
anticipated to be a 
human carcinogen1"
FDA 2010b 
ACGIH 2009
IRIS 2010
EPA 2009a 
40 CFR 302.4
EPA 2009g 
40 CFR 372.65
EPA 2009f 
40 CFR 355, 
Appendix A
EPA 2009j 
40 CFR 401.15
NTP 2005
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8. REGULATIONS AND ADVISORIES
Table 8-1. Regulations and Guidelines Applicable to Toxaphene
Agency Description Information Reference
aGroup 2B: possibly carcinogenic to humans.
bChemical is excluded from guideline value derivation because  of determination that toxaphene is unlikely to occur in 
drinking water.
cSkin notation: refers to the potential significant contribution to the overall exposure by the cutaneous route, including 
mucous membranes and the eyes, and by contact with vapors, liquids, and solids.
dTEEL-0 is the threshold concentration below which most people will experience no adverse health effects. 
ePAC-1 is the airborne concentration (expressed as  or mg/m3) of a substance above which it is predicted that the 
general population, including susceptible individuals, could experience discomfort, irritation, or certain asymptomatic, 
nonsensory effects. However, these  effects are not disabling and are transient and reversible upon cessation of 
exposure.
fPAC-2 is the airborne concentration (expressed as mg/m3) of a substance above which it is predicted that the 
general population, including susceptible individuals, could experience irreversible or other serious, long-lasting, 
adverse health effects or an impaired ability to escape.
gPAC-3 is the airborne concentration (expressed as  mg/m3) of a substance above which it is predicted that the 
general population, including susceptible individuals, could experience life-threatening health effects or death. 
hCampheclor is included on the list of 371 priority chemicals that are acutely toxic and represent the selection of 
chemicals for AEGL development by the NAC/AEGL committee during the next several years.
Skin designation: indicates the potential for dermal absorption.
jGroup I pesticides pose a significant risk of adverse acute health effects at low concentrations, or carcinogenic, 
teratogenic, neurotoxic, or reproductive effects.
kThis criterion is based on a 304(a) aquatic life criterion issued in 1980 or 1986, and was issued in toxaphene (EPA 
440/5-86-006). This CCC is currently based on the FRV procedure. Since the publication of the Great Lakes Aquatic 
Life Criteria Guidelines in 1995 (60 FR 15393-15399, March 23, 1995), the Agency no longer uses the Final Residue 
Value procedure for deriving CCCs for new or revised 304(a) aquatic life criteria. Therefore, the Agency anticipates 
that future revisions of this CCC will not be based on the FRV procedure (EPA 2006b).
This criterion has been revised to reflect The EPA's q1* or RfD, as  contained in IRIS as  of May 17, 2002. The fish 
tissue bioconcentration factor from the 1980 Ambient Water Quality Criteria document was retained in each case  
(EPA 2006b).
mThis criterion is based on carcinogenicity of 10-6 risk.
nThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as  food 
additives or listed or affirmed as  GRAS.
oA3: confirmed animal carcinogen with unknown relevance to humans.
pB2: probable human carcinogen; based on increased incidence of hepatocellular tumors in mice and thyroid tumors 
in rats and supported by mutagenicity in Salmonella.
qDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act, section 307(a) of 
the Clean Water Act, Section 112 of the Clean Air Act, and Section 3001 of RCRA. 
rBased on sufficient evidence of carcinogenicity in experimental animals.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response, 
Compensation, and Liability Act; CFR = Code of Federal Regulations; CCC = criterion continuous concentration;
CMC = criterion maximum concentration; DOE = U.S. Department of Energy; DWEL = drinking water equivalent level; 
EAFUS = Everything Added to Food in the United States; EPA = U.S. Environmental Protection Agency;
ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; FRV = final residue value; 
GRAS = generally recognized as  safe; IARC = International Agency for Research on Cancer; IDLH = immediately 
dangerous to life or health; IRIS = Integrated Risk Information System; MCL = maximum contaminant level; MTL = 
Master Testing List; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology 
Program; OSHA = Occupational Safety and Health Administration; PAC = protective action criteria; PEL = permissible 
exposure limit; RCRA = Resource Conservation and Recovery Act; REL = recommended exposure limit;
RfC = inhalation reference concentration; RfD = oral reference dose; STEL = short-term expsoure limit; TEEL = 
temporary emergency exposure limit; TLV = threshold limit values; TSCA = Toxic Substances Control Act;
Tw A = time-weighted average; USC = United States Code; WHO = World Health Organization
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response. For example, a BMDJ0 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%. The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period.
Biomarkers— Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome. At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point 
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information. A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals.
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Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period.
Intermediate Exposure—Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration^ )  (LClo)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration^ ) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function.
Maximum Contaminant Level (MCL) —The highest level of a contaminant that is allowed in drinking 
water.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
10. GLOSSARY
Immunological Effects—Functional changes in the immune response.
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Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control. Effects may be produced at this dose, but they are not 
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Parlar—A system (after Dr. H. Parlar, a pioneer in toxaphene analytical chemistry) for naming 
toxaphene congeners, numbered in the order in which the chemical is detected by laboratory equipment 
(elution order).
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based 
and physiologically-based. A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
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Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose- 
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows. These models require a 
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time.
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study. A group is followed over time.
qi*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually ^g/L for water, mg/kg/day for food, and 
^g/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. 
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical. The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior,
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fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
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Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest- 
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99­
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance. During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level 
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public. They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-62, Atlanta, Georgia 30333.
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APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 
CAS Numbers: 
Date:
Profile Status: 
Route:
Duration:
Graph Key: 
Species:
Toxaphene
8001-35-2 
September 2010 
Final Draft for Public Comment 
[ ] Inhalation [X] Oral 
[X] Acute [ ] Intermediate [ ] Chronic 
26 
Dog
Minimal Risk Level: 0.05 [X] mg/kg/day [ ] ppm
Reference: Chu I, Villeneuve DC, Sun CW, et al. 1986. Toxicity of toxaphene in the rat and beagle dog. 
Fundam Appl Toxicol 7:406-418.
Experimental design: (human study details or strain, number of animals per exposure/control group, sex, 
dose administration details): Groups of male and female beagle dogs (6/sex/group) were given gelatin 
capsules containing toxaphene at 0, 0.2, 2.0, or 5.0 mg/kg daily for 13 weeks. During the first 2 treatment 
days, the high-dose group received toxaphene at 10 mg/kg/day. This dose was reduced to 5 mg/kg/day on 
treatment day 3 because the 10 mg/kg/day dose level elicited convulsions, salivation, and vomiting in 
1/6 males and 2/6 females. These clinical signs were not observed in any of the toxaphene-treated dogs 
throughout the remainder of the scheduled 13-week treatment period.
Effect noted in study and corresponding doses: Serious neurological effects (convulsions, salivation, and 
vomiting in 1/6 males and 2/6 females) were elicited during the first 2 days of oral treatment at 10 mg/kg/ 
day. These effects were not elicited after the highest dose was reduced to 5 mg/kg/day on treatment day 3 
and maintained at that level throughout the remainder of the scheduled 13-week treatment period.
Dose and end point used for MRL derivation: NOAEL of 5 mg/kg/day for neurological effects; the 
LOAEL was 10 mg/kg/day for clinical signs (convulsions, salivation, and vomiting in 1/6 males and 
2/6 females).
[X] NOAEL [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? No.
Other additional studies or pertinent information that lend support to this MRL: Lackey (1949) reported 
convulsions in 4/5 fasted dogs administered toxaphene (in corn oil) once by capsule at 10 mg/kg. Higher 
single dose levels (15-50 mg/kg) resulted in convulsions and mortalities; there were no signs of
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convulsions in three dogs dosed at 5 mg/kg. Seriously depressed maternal weight gain in pregnant rats 
and mice have been observed at toxaphene doses in the range of 15-32 mg/kg/day (Chernoff and Carver 
1976; Chernoff et al. 1990). The dose necessary to induce nonfatal convulsions in humans has been 
estimated to be approximately 10 mg/kg (CDC 1963).
Agency Contacts (Chemical Managers): Nickolette Roney, MPH
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APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 
CAS Numbers: 
Date:
Profile Status: 
Route:
Duration:
Graph Key: 
Species:
Toxaphene
8001-35-2
September 2010
Final Draft for Public Comment
[ ] Inhalation [X] Oral
[ ] Acute [X] Intermediate [ ] Chronic
47
Monkey
Minimal Risk Level: 0.002 [X] mg/kg/day [ ] ppm
Reference: Tryphonas H, Arnold DL, Bryce F, et al. 2001. Effects of toxaphene on the immune system 
of cynomolgus (Macaca fascicularis) monkeys. Food Chem Toxicol 39:947-958.
Experimental design: (human study details or strain, number of animals per exposure/control group, sex, 
dose administration details): Groups of 10 female cynomolgus monkeys/dose group were administered 
toxaphene by oral capsules at 0, 0.1, 0.4, or 0.8 mg/kg/day for up to 75 weeks. Groups of five males were 
similarly dosed at 0 or 0.8 mg/kg/day. Testing for immune effects was initiated on week 33 and included 
flow cytometry, lymphocyte transformation, natural killer cell activity, and determination of serum 
cortisol during weeks 33-46 and immunizations with SRBC at treatment week 44 a primary response and 
week 48 for a secondary response (observations made through treatment week 52).
Effect noted in study and corresponding doses: Treatment with toxaphene at 0.4 mg/kg/day resulted in 
significant (p<0.05) reductions in mean primary anti-SRBC IgM responses at weeks 1 and 4 following 
primary immunization (27 and 35% lower than that of controls) and secondary anti-SRBC IgM responses 
at week 1 following secondary immunization (10% lower than that of controls). The dose level of
0.8 mg/kg/day resulted in significantly reduced mean primary anti-SRBC IgM responses at weeks 1-4 
following primary immunization, significantly reduced mean secondary anti SRBC IgM response at 
weeks 1 and 4 following secondary immunization, and significantly reduced primary anti-SRBC IgG 
responses at weeks 2 and 3 following primary immunization (51 and 43% lower than that of controls). In 
males, 0.8 mg/kg/day toxaphene induced a significant reduction in mean primary anti-SRBC IgM 
response at weeks 1-3 following primary immunization. Flow cytometry tests showed that the only 
effect on leukocyte and lymphocyte subsets was a reduction in absolute B lymphocytes (CD20) in
0.8 mg/kg/day females (62% lower than controls). There were no detectable treatment-related effects on 
natural killer cell activity, lymphoproliferative response to mitogens, or serum cortisol levels. Table A-1 
shows the results of primary anti-SRBC IgM responses.
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Table A-1. Mean Anti-SRBC (IgM) Titres at 1-4 Weeks Post-Immunization in 
Female Cynomolgus Monkeys Administered Toxaphene in Gelatin Capsule 
Daily for 75 Weeks Including 44 Weeks Prior to Immunization
Weeks post-immunization (mean log2 titres ± standard error)3
dose (mg/kg/day) 1 2  3 4
0 7.10±0.35 6.40±0.31 5.30±0.34 4.90±0.41
0.1 6.40±0.54 5.20±0.73 4.50±0.64 4.00±0.61
0.4 5.20±0.79b 4.60±0.78 3.80±0.85 3.20±0.63b
0.8 3.70±0.83b 3.00±0.88b 3.00±0.75b 2.80±0.61b
aMean values calculated from 10 animals per treatment group. 
bp<0.05.
Source: Tryphonas et al. 2001
All continuous variable models in the EPA Benchmark Dose Software (Version 2.1.1) were fit to the 
mean anti-SRBC (IgM) titre data at week 1 post-immunization; standard error values were converted to 
standard deviation values prior to running the models. A default benchmark response (BMR) of 
1 standard deviation (1 SD) from the control mean was selected in the absence of a toxicological rationale 
for selecting an alternative BMR. Model results for the mean anti-SRBC (IgM) titre data are shown in 
Table A-2. The linear model was initially fit to the data using constant variance, but failed to meet 
conventional goodness-of-fit criteria for modeled variance (p=0.04395). Adequate fit for modeled 
variance was obtained, however, when fit to the data using non-constant variance. Therefore, non­
constant variance was selected to fit the remaining continuous variable models to the data. The Hill 
model failed the test for mean fit (degrees of freedom <0) and was not considered further. Using non- 
homogeneous variance, the polynomial (2- and 3-degree), and power models converged on the linear 
model and provided identical predictions of the BMD1SD (0.34 mg/kg/day) and the 95% lower confidence 
limit on the BMDiSD (BMDLiSD; 0.22 mg/kg/day). The fit of the linear model to the malformation data is 
presented in Figure A-1. This figure is identical to those generated from the polynomial (2- and 
3-degree), and power models.
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Table A-2. Model Predictions for Mean Anti-SRBC (IgM) Titre Data at 
Week 1 Post-Immunization from Female Cynomolgus Monkeys 
Administered Toxaphene in Gelatin Capsule Daily for 
75 Weeks Including 44 Weeks Prior to Immunization
Model
Variance
p-valuea
Means
p-valuea
Scaled 
residual of 
interestb AIC
BMD1SD BMDL1SD 
(mg/kg/day) (mg/kg/day)
Constant variance
Linearc 0.04395 0.9335 -0.15 100.43 - -
Nonconstant variance
Linearc 0.48 0.41 -0.16 97.45 0.34 0.22
Polynomial (2-degree)c 0.48 0.41 -0.16 97.45 0.34 0.22
Polynomial (3-degree)c 0.48 0.41 -0.16 97.45 0.34 0.22
Powerd 0.48 0.41 -0.16 97.45 0.34 0.22
Hillc 0.48 NAe 0.26 99.68 0.14 0.04
aValues <0.10 fail to meet conventional goodness-of-fit criteria. 
bScaled residual at measured response closest to the benchmark response. 
cCoefficients restricted to be negative. 
dPower restricted to >1.
eDegrees of freedom for test of mean fit are less than or equal to 0; the %2 test for fit is not valid.
AIC = Akaike's Information Criterion; BMD = maximum likelihood estimate of the dose/concentration associated with 
the selected benchmark response; BMDL = 95% lower confidence limit on the BMD; SD = standard deviation
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Figure A-1. Predicted and Observed Mean Anti-SRBC (IgM) Titres from Female 
Cynomolgus Monkeys Administered Toxaphene in Gelatin Capsule Daily for 
75 Weeks Including 44 Weeks Prior to Immunization*
Linear Model with 0.95 C onfidence Level
d o se
12:15 06/09 2010
*BMD and BMDL associated with a 10% extra risk increase over control are shown; doses  given in units of 
mg/kg/day.
Dose and end point used for MRL derivation: A BMDL1sd of 0.22 mg/kg/day for decreased anti-SRBC 
(IgM) titers as an indicator of decreased humoral immunity.
[ ] NOAEL [ ] LOAEL [X] BMD
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? No.
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Other additional studies or pertinent information that lend support to this MRL: In an enzyme-linked 
immunosorbent assay (ELISA) performed on female mice that received toxaphene from the diet at doses 
>19 mg/kg/day for up to 8 weeks, Allen et al. (1983) reported suppressed antibody production, indicating 
depressed humoral immunity; the study identified a NOAEL of 2 mg/kg/day for the effect. Koller et al. 
(1983) reported a 46% decrease in the IgG primary antibody response in male rats receiving toxaphene 
from the diet at 2.6 mg/kg/day for up to 9 weeks and challenged twice (after 8 and 15 days on test) with 
keyhole limpet hemocyanin (KLH).
Agency Contacts (Chemical Managers): Nickolette Roney, MPH
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APPENDIX B. USER'S GUIDE
Chapter 1 
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release. If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2 
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight- 
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human 
data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). 
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer 
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. 
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure.
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance. Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects. If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In 
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables.
Chapter 3 
Health Effects 
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures. Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends 
correspond to the numbers in the example table and figure.
APPENDIX B
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LEGEND
See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document. 
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15­
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. 
In this example, an inhalation study of intermediate exposure duration is reported. For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7) System. This column further defines the systemic effects. These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems. In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
APPENDIX B
***DRAFT FOR PUBLIC COMMENT***
TOXAPHENE B-4
APPENDIX B
(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose. A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from 
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies. CELs are always considered serious effects. The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases.
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND 
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in
the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond
symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the
LSE table.
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(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper- 
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (qi*).
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
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Table 3-1. Levels of Significant Exposure to [Chemical x] -  Inhalation
Exposure
Key to frequency/
figure3 Species duration
LOAEL (effect)
NOAEL 
System (ppm)
Less serious 
(ppm)
Serious (ppm)
Reference
INTERMEDIATE EXPOSURE
18 Rat 13 wk
5 d/wk
6 hr/d
CHRONIC EXPOSURE 
Cancer
38
39
40
Rat
Rat
Mouse
7 8
i i
Resp 3b 10 (hyperplasia)
11
18 mo 
5 d/wk 
7 hr/d
89-104 wk
5 d/wk
6 hr/d
79-103 wk
5 d/wk
6 hr/d
i
20
10
10
10
Nitschke et al. 1981
(CEL, multiple 
organs)
(CEL, lung tumors, 
nasal tumors)
(CEL, lung tumors, 
hemangiosarcomas)
Wong et al. 1982
NTP 1982
NTP 1982
12 ^  a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
2
5 6 9
i i i i
4
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDx dose that produces a X% change in response rate of an adverse effect
BMDLx 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software
BMF biomagnification factor
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CCC criterion continuous concentration
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CMC criterion maximum concentration
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
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DOD 
DOE 
DOL 
DOT
DOT/UN/
NA/IMDG 
DWEL 
ECD
ECG/EKG 
EEG 
EEGL 
EPA 
F
APPENDIX C
Fi first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LClo lethal concentration, low
LD50 lethal dose, 50% kill
LDLo lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
Department of Defense
Department of Energy
Department of Labor
Department of Transportation
Department of Transportation/United Nations/
North America/Intergovernmental Maritime Dangerous Goods Code 
drinking water exposure level 
electron capture detection 
electrocardiogram 
electroencephalogram 
Emergency Exposure Guidance Level 
Environmental Protection Agency 
Fahrenheit
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MA trans, trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor
MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data Syst
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
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OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic
PCBs polychlorinated biphenyls
PCCs polychlorinated camphenes
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
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VOC volatile organic compound
WBC white blood cell
WHO World Health Organization
> greater than
> greater than or equal to
= equal to
< less than
< less than or equal to
% percent
a alpha
P beta
Y gamma
5 delta
^m micrometer
microgram
qi* cancer slope factor
- negative
+ positive
(+) weakly positive result
(-) weakly negative result
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APPENDIX D. INDEX
absorbed dose....................................................................................................................................... 19, 93
adipose tissue......................................................................................  70, 71, 73, 93, 98, 119, 153, 157, 164
adrenal gland............................................................................................................................ 24, 51, 74, 96
adsorbed.................................................................................................................................7, 119, 162, 172
adsorption................................................................................................................................................... 136
aerobic..................................................................................................  77, 78, 119, 136, 137, 138, 146, 161
ambient air...............................................................................  121, 124, 126, 127, 138, 140, 141, 154, 182
anaerobic......................................................................................  77, 78, 119, 125, 136, 137, 138, 146, 161
antiestrogenic ..............................................................................................................................................  90
bioaccumulation................................................................................................................................. 153, 162
bioavailability .............................................................................................................................................  69
bioconcentration factor..........................................................................................................7, 119, 131, 190
biodegradation................................................................................................................... 107, 136, 137, 146
biomarkers........................................................................................... 71, 73, 92, 93, 94, 105, 106, 165, 182
body weight effects................................................................................................................ 23, 51, 60, 103
breast milk..............................................  3, 7, 17, 83, 93, 121, 134, 155, 156, 157, 164, 166, 168, 177, 182
cancer........................................................................... 4, 10, 18, 23, 24, 26, 49, 58, 59, 60, 90, 92, 103, 188
carcinogen.............................................................................................................................. 4, 10, 185, 190
carcinogenic........................................................................................................... 4, 9, 10, 17, 18, 185, 190
carcinogenicity...............................................................................................................  54, 59, 89, 103, 190
carcinomas ..................................................................................................................................................  59
cardiovascular................................................................................................................................ 19, 46, 60
cardiovascular effects...................................................................................................................................46
chromosomal aberrations..................................................................................................................... 64, 103
clearance .....................................................................................................................................................  87
congener.....................................................................................  17, 134, 137, 155, 157, 162, 169, 170, 183
death............................................................................ 8, 9, 17, 18, 19, 25, 26, 55, 64, 68, 99, 102, 103, 190
deoxyribonucleic acid (see DNA)................................................................................................................64
dermal effects................................................................................................................................. 23, 51, 63
developmental effects.................................................................................... 4, 23, 55, 56, 58, 64, 104, 108
DNA (see deoxyribonucleic acid).................................................................. 64, 65, 66, 67, 68, 89, 93, 103
elimination rate.......................................................................................................................................... 107
endocrine..................................................................................................................  8, 11, 13, 19, 50, 60, 89
endocrine effects.......................................................................................................................................... 50
erythema......................................................................................................................................................  63
estrogen receptor.........................................................................................................................................  90
estrogenic..................................................................................................................................................... 90
fetal tissue.................................................................................................................................................... 74
fetus.......................................................................................................................................................  73, 91
gastrointestinal effects ..........................................................................................................................  46, 62
general population..............................................................................  7, 8, 95, 148, 154, 158, 163, 181, 190
genotoxic................................................................................................................................  17, 68, 89, 103
genotoxicity.......................................................................................................... 9, 64, 66, 68, 89, 103, 104
groundwater.............................................................................................  119, 125, 129, 138, 143, 163, 172
half-life.........................................................................................................  79, 93, 119, 127, 136, 137, 138
hematological effects .....................................................................................................................  20, 47, 62
hepatic effects ..............................................................................................................  20, 47, 48, 62, 68, 94
hydrolysis................................................................................................................................................... 170
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hydroxyl radical................................................................................................................................119, 136
immune system.................................................................................................... 3, 16, 92, 95, 97, 106, 108
immunological........................................................................ 8, 11, 14, 16, 17, 24, 52, 53, 57, 63, 102, 103
immunological effects.................................................................................................................. 16, 52, 103
Kow.................................................................................................................................................... 111, 142
LD50..................................................................................................................................... 25, 26, 60, 94, 99
leukemia............................................................................................................................................  9, 23, 24
lymphoreticular..................................................................................................................................... 53, 63
menstrual..................................................................................................................................................... 56
milk..........................................  7, 17, 69, 81, 82, 83, 96, 105, 106, 147, 155, 157, 164, 166, 177, 181, 182
mucociliary ................................................................................................................................................. 98
musculoskeletal effects ............................................................................................................................... 26
neonatal............................................................................................................................................. 157, 164
neoplastic .................................................................................................................................................... 59
neurobehavioral........................................................................................................................................... 90
neurodevelopmental.................................................................................................................................... 55
neurological effects................................................................. 8, 13, 23, 54, 55, 63, 87, 89, 94, 97, 105, 185
neurotransmitter .......................................................................................................................................... 88
non-Hodgkin’s lymphoma.......................................................................................................................9, 23
nuclear........................................................................................................................................................... 8
ocular effects.................................................................................................................................. 19, 51, 63
odds ratio.....................................................................................................................................................  23
pesticide........................................................  3, 7, 8, 17, 19, 20, 23, 49, 73, 87, 95, 98, 102, 106, 113, 114,
117, 121, 122, 125, 126, 129, 133, 134, 139, 142, 146, 147, 
148, 155, 156, 158, 159, 160, 161, 162, 163, 170, 171, 174, 179
pharmacodynamic........................................................................................................................................84
pharmacokinetic...........................................................................................................  83, 84, 85, 86, 87, 91
photolysis................................................................................................................................................. 136
placenta .......................................................................................................................................................  73
renal effects....................................................................................................................................  23, 49, 62
reproductive effects.................................................................................................... 9, 23, 56, 64, 104, 190
respiratory effects........................................................................................................................... 20, 26, 60
retention.......................................................................................................................................................77
salivation........................................................................................................................................ 13, 54, 185
serum glutamic oxaloacetic transaminase................................................................................................... 47
solubility........................................................................................................................................... 116, 130
systemic effects..........................................................................................................  19, 26, 60, 68, 89, 182
T3............................................................................................................................................. 21, 27, 50, 61
T4.................................................................................................................................................................50
technical toxaphene...............................................................7, 8, 17, 66, 90, 109, 110, 113, 121, 125, 133,
134, 136, 137, 138, 140, 150, 152, 169, 170
thyroid.......................................................................................... 4, 9, 12, 14, 50, 51, 59, 96, 103, 188, 190
toxicokinetic................................................................................................................................... 17, 89, 107
tremors........................................................................................................................................... 12, 54, 99
tumors........................................................................................................................ 9, 59, 60, 94, 103, 190
vapor phase.............................................................................................................................................. 136
volatility................................................................................................................................................... 119
volatilization....................................................................................  119, 122, 124, 127, 128, 141, 143, 170
weanling...................................................................................................................................................... 56
weathered toxaphene...................................................................................... 7, 17, 105, 121, 134, 170, 179
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